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Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder 
characterized by a progressive loss of cognition. Histopathologically, AD is defined by 
the presence of two lesions, senile plaques (SP) and neurofibrillary tangles (NFT), which 
result from the accumulation and deposition of the amyloid-β peptide (Aβ) and the 
aggregation of hyperphosphorylated tau protein, respectively. Aβ is formed upon 
sequential cleavage of the amyloid precursor protein (APP) by β- and γ-secretases and 
is secreted extracellularly. The accumulation of extracellular Aβ is thought to initiate a 
pathogenic cascade resulting in synaptic dysfunction in neurons, followed by the their 
eventual demise through apoptosis. However, while Aβ has been shown to be 
increased in AD patients’ brains, little is known about how the cleavage of APP and the 
subsequent generation of Aβ is influenced or if the cleavage process changes over 
time. Moreover, while the effects of Aβ on neurons are known, the exact mechanism 
remains unclear. Many have postulated that Aβ exerts its effects by binding a putative 
receptor, but the search for an Aβ receptor has so far remained inconclusive. 
Interestingly, one of the proposed potential receptor for Aβ is APP itself. In this model, 
soluble oligomeric Aβ binds cell-surface APP, inducing its dimerization leading to all the 
downstream effects of Aβ in cells -- e.g. cell death and/or synaptic dysfunction. 
Moreover, it has been proposed that Aβ can promote its own production in neurons, 
thereby initiating a pathogenic loop. However, isolating Aβ-induced APP signaling has 
remained challenging due to the promiscuous nature of Aβ binding. To work around this 
problem, we used an antibody-mediated approach to artificially trigger the dimerization 
of cell-surface APP in cells. We found that dimerization of APP could recapitulate all of 
the effects of oligomeric Aβ in hippocampal neurons, triggering neuronal death at high 
concentrations and interfering with normal synaptic functions low concentrations. We 
also found that dimerization of APP is sufficient to promote the amyloidogenic pathway, 
by increasing levels of the β-secretase BACE1, resulting in increased Aβ production. 
Finally, we found that dimerization of APP triggered caspase-dependent cleavage of 
APP and the formation of a second neurotoxic fragment, termed C31, which also 
mimics the effects of Aβ in hippocampal neurons. Taken together, our data provides 
support for the occurrence of a positive pathogenic feedback loop involving Aβ, APP 
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CHAPTER 1: GENERAL INTRODUCTION
1.1 Neuropathology of Alzheimer’s disease (AD)
1.1.1	 Historical perspective
In 1901, German psychiatrist and neuropathologist Alois Alzheimer was presented with 
the case of a 51-year old woman named Auguste Deter at the Frankfurt Asylum. The 
patient exhibited a peculiar cluster of behavioral symptoms. He described her as being 
cognitively impaired and suffering from auditory hallucinations, delusions, paranoia and 
a near complete loss of short-term memory and comprehension. Alzheimer continued 
to follow Auguste Deter until her death on April 8th 1906. Shortly after, he requested 
that her records and brain be sent to Munich, where he undertook a series of studies on 
the neuropathological features of her illness. In his description of the histopathological 
findings of the disease he noted the following: “In the center of an otherwise almost 
normal cell there stands out one or several fibrils due to their characteristic thickness 
and peculiar impregnability.” He also chronicled the presence of abundant plaque-like 
features: “Numerous small miliary foci are found in the superior layers. They are 
determined by the storage of a peculiar material in the cortex” (Alzheimer, 1906). What 
Alzheimer described in his findings are what are now commonly referred to as 
neurofibrillary tangles (NFT) and senile plaques (SP), which are the hallmark brain 
lesions in the disease that would eventually bear his name, Alzheimer’s disease (AD) 
(reviewed by Maurer et al., 1997).
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1.1.2	 Epidemiology
Today, over a century after it was first described, AD represents one of the most serious 
and costly health issues not only in the United States, but worldwide. It is the most 
common type of dementia, accounting for an estimated 60-80% of all dementia cases 
(Maslow, 2010). In 2007, according to the national statistics from the Aging, 
Demographics and Memory Study (ADAMS; Plassman et al., 2007), there were well over 
2 million people over the age of 71 afflicted with the disease (Table 1-1), a number that 
is projected to reach 7.7 million people by 2030 and to increase to as many as 16 
million people by 2050 by some estimates (Hebert et al., 2003). Across gender, 7% and 
11.5% of men and women respectively over the age of 71 have the disease (Figure 1-1). 
In terms of mortality, AD was the fifth leading cause of death in the United States in 
2006 for those older than 65 years old (Heron et al., 2009). In fact, while other major 
causes of death have been on a steady decline over the past few years, those for AD 
have continued to rise (Figure 1-2).

















95% CI in parentheses
Table 1-1. National estimates of the number of individuals with dementia or 
AD by age categories 
National statistics from the Aging, Demographics, and Memory Study (ADAMS). 
(Created from data from Plassman et al., 2007)
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Unfortunately, it is unlikely that these numbers will reverse course in the near future. 
Current therapeutic approaches have yielded modest results at best. One possible 
reason for the lack of success may be due to the fact that reliably diagnosing AD 
continues to pose a significant challenge, especially in its early stages. Consequently, it 
is possible that by the time a patient is diagnosed with AD, it may be too late to reverse 
or even slow down the tremendous damage already inflicted on a patient’s brain and 
cognitive functions over several years of living with the disease. Hopefully, a thorough 
understanding of the neuropathological features of AD may help in the development of 














Figure 1-1. Estimated percentage of Americans aged 71+ with dementia by gender
National statistics from the Aging, Demographics, and Memory Study (ADAMS, 2002). 
(Created from data from Plassman et al., 2007)
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Figure 1-2. Percentage changes in selected causes of death between 2000a and 2006b
National Center for Health Statistics; Deaths: Final Data for 2000 a(Minino et al., 2002) and 2006 b(Heron et al., 






















1.1.3	 Clinical features of AD
The nature of the trigger(s) that kick-starts the Alzheimer’s disease process has so far 
remained poorly understood. It is believed however, that the damage to the brain may 
begin several years before any overt cognitive problems. As the damage becomes more 
pronounced, the disease slowly progresses through various stages, as outlined in 
Figure 1-3 (reviewed by Forstl and Kurz, 1999), typically reflective of the underlying 
neuropathology (discussed later). Memory problems are usually the first noticeable 
symptoms, developing from seemingly simple forgetfulness to a more pervasive loss of 
recent memory. A meticulous neuropsychological evaluation at this pre-clinical stage 
may reveal that these individuals suffer from with a condition called amnestic mild 
cognitive impairment (MCI). Sufferers of MCI have noticeably more memory problems 
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than normal people of the same age, but their symptoms are not as severe as those 
with AD. Most, but not all people with MCI, eventually enter the mild dementia stages, 
where they experience a significant impairment in learning and memory, sometimes 
accompanied by some aphasic or visuoconstructional deficits. As a result, these 
patients may have difficulties in communicating, as their vocabulary and word fluency 
diminishes and may even experience some spatial disorientation. They may also 
experience a reduced ability to plan, judge and organize, especially in complex tasks. 
Usually, patients in the mild stages are able to survive on their own without much 
supervision. Over time, their symptoms worsen as they enter the moderate stages of 
AD. 
Logical reasoning, planning and organizing abilities significantly deteriorate during this 
stage, as do their language, reading and writing skills. Patients may lose their ability to 
recognize familiar faces and some may even experience visual hallucinations. 
Behavioral changes, such as sudden violent physical and verbal outbursts, or excessive 
passivity are also common in these patients. At this stage, they usually cannot function 
properly without close supervision and will require even closer attention as they 
progress into the advanced stages of AD.
In the advanced stages of AD, most cognitive functions are severely impaired. Early 
biographical memories are often lost and language skills are typically reduced to simple 
phrases or even single words, leaving patients unable to articulate even their simplest 
needs. Restlessness and aggressive reactions become more frequent, as they often 
misinterpret or misunderstand their caregiver’s interventions. They can also experience 
other motor disturbances, leading to rigidity or displays of primitive reflexes, such as 
snouting and grasping reactions. Eventually, patients experience a deterioration of their 
musculature and mobility, forcing them to become bedridden and unable to feed 
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themselves. Pneumonia, followed by myocardial infarction and septicemia are the most 
frequent terminal events in AD.
1.1.4	 Macroscopic changes in AD brain
Upon examination at the autopsy table, the brain from an AD patient reveals numerous 
clues that could be considered useful for diagnostic purposes. However, most gross 
visible changes are usually non-specific, as there is a significant overlap with those 
seen in specimens taken from cognitively normal older individuals during the course of 
Figure 1-3. Progression of AD, from MCI to the advanced stages and a 
description of the typical symptoms associated with each stage
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normal aging (reviewed by Perl, 2010). In most AD patients, a close examination of the 
brain reveals variable degrees of frontal and temporal cortical and sub-cortical atrophy 
(Figure 1-4B), reflected by severe thinning of the cortical gyri and widening of the sulci 
(Figure 1-4C). In most cases, primary motor, sensory and visual areas of the brain are 
usually spared from such atrophy. Although atrophy and loss of overall brain weight is 
usually associated with normal aging (Figure 1-4A), there may be an additive effect in 
AD patients compared to aged-matched controls. However, the degree of brain weight 
loss overlaps significantly among both groups (Terry, 1986), making it almost impossible 
to use brain weight and cortical thickness as a determinants of AD. It should be noted 
that when examining early-onset or familial cases of AD (onset before the age of 65), a 
clear and obvious difference emerges when comparing the degree of atrophy and loss 
of brain weight observed in those patients with their aged-matched cognitively normal 
counterparts (Ridha et al., 2006; Schott et al., 2003).
Finally, AD cases almost always present with significant atrophy of the amygdala (Unger 
et al., 1991) and of the entorhinal cortex and hippocampus, with an associated dilation 
of the adjacent temporal horn of the lateral ventricle (Frisoni et al., 1999). In fact, both of 
these regions are thought to be the first ones affected in the early stages of AD (Braak 
and Braak, 1985, 1991). Such findings in an autopsy, when accompanied with clinical 
data and with sufficient microscopic evidence (e.g. amyloid deposits and neurofibrillary 
tangles), usually provide a strong indication of an AD case. Alternatively, the lack of 
these microscopic findings is an indication that other factors are at the root of the 
dementia.
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Figure 1-4. Gross macroscopic brain changes in AD
(A) 79-year-old cognitively normal patient’s brain showing a moderate amount of cortical atrophy. (B) An 89-year-old 
AD patient’s brain showing an unusually high level of cortical atrophy. (C) AD brain showing severe atrophy of the 
frontal, temporal and parietal lobes atrophy, widening of the sulci and narrowing of the gyri. (Images courtesy of Dr. 
Jean-Paul Vonsattel; Columbia University, NY)
1.1.5	 Microscopic changes in AD brain
Relying on gross visual changes in the brain is often a misleading means to characterize 
AD. Not only are these changes seen in several other types of dementia, they can also 
be observed in cognitively normal elderly individuals. It is only upon the histological 
examination of a brain specimen and the identification of two key morphological 
abnormalities that AD fully reveals itself: neurofibrillary tangles (NFT) and senile plaques 
(SP).
1.1.5.1		 Intracellular neurofibrillary tangles (NFT)
In his histological examination of Auguste Deter’s brain, Alois Alzheimer observed the 
presence of several abnormal microscopic fibrous lesions within the perikaryal 
cytoplasm of large pyramidal neurons (Figure 1-5A). He described them as such: “In the 
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center of an otherwise almost normal cell there stands out one or several fibrils due to 
their characteristic thickness and peculiar impregnability” (Alzheimer, 1906). These 
abnormal inclusions are referred to today as neurofibrillary tangles (NFT), and are 
considered to be one of two fundamental microscopic lesions not only associated with 
the disease, but required for making a definitive pathological diagnosis of AD. In fact, 
several studies have demonstrated a strong correlation between the extent and 
distribution of NFT and the severity and duration of the illness (Arriagada et al., 1992; 
Bierer et al., 1995). However, NFT lesions are not exclusive to AD, as they can be 
encountered in numerous other neurodegenerative diseases, termed tauopathies, 
including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), 
frontotemporal lobar degeneration (FTLD), and post-traumatic type dementias, as well 
as normal aging (Wisniewski et al., 1979).
As Alzheimer observed, NFT are located primarily in large pyramidal neurons of 
Ammon’s horn in the hippocampus and in the cerebral neocortex, although they can 
also be found in deeper structures, such as the midbrain and the hypothalamus in 
advanced cases (Braak et al., 1993). X-ray diffraction analysis of isolated NFT reveals a 
β-sheet like structural configuration (Kirschner et al., 1986), responsible for their 
argyrophilic and congophilic properties, and allowing them to be visualized by a variety 
of silver staining techniques, such as the modified Bielschowski (Figure 1-5B) or the 
Gallyas technique, or by fluorochrome dyes such as thioflavin S.
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Figure 1-5. Neurofibrillary tangles (NFT) in AD
(A) Original hand drawing by Alois Alzheimer of NFT from the brain of Auguste Deter. (adapted from Maurer et al., 
1997) (B) Photomicrograph of the hippocampus of a patient with AD (modified Bielschowsky silver stain; original 
magnification, 640x). Neurofibrillary tangles appear brown and have a distinct fibrillar morphology. The neuron at 
the top (right of center) shows granulovacuolar degeneration with characteristic argyrophilic core and surrounding 
clear halo. The major component of tangles are paired helical filaments containing polymerized 
hyperphosphorylated microtubule-associated protein Tau. (Image courtesy of Jean-Paul Vonsattel; Columbia 
University, NY)
Over the past several decades, much has been learned about the morphological 
features of NFTs. They are composed of several paired helical filaments (Kidd, 1963), 
comprised themselves of two axially opposed helical filaments measuring 10 nm in 
diameter. These are wound around each other in a helical configuration with a regular 
periodicity of 80 nm (Kidd, 1964; Terry et al., 1964; Wisniewski et al., 1976) --hence the 
name, paired helical filaments (PHF). The exact morphological features of each 
individual filament is not fully understood, but are thought to consist of two or more 
protofilaments (reviewed by Castellani et al., 2010). In terms of their biochemical 
constitution, it is widely accepted that the major proteinaceous component of NFT is 
the microtubule-associated protein tau (Grundke-Iqbal et al., 1986; Kosik et al., 1986; 
Wood et al., 1986). The tau protein found in NFT has been shown to be abnormally 
hyper-phosphorylated at several very specific sites, which may enhance its propensity 
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to aggregate (Garver et al., 1996; Lee et al., 1991). In addition to the tau protein, a wide 
variety of molecules have been shown to be associated with NFT (reviewed by 
Castellani et al., 2010; Smith, 1998). These include, but are not limited to: cytoskeletal 
proteins (e.g. vimentin and tropomyosin), protease-related elements (e.g. ubiquitin, α1-
antichymotrypsin and α1-antitrypsin, cathepsins B and D), proteoglycans (e.g. heparan 
and chondroitin), inflammatory proteins such as cytokines and complement molecules 
(reviewed by Kalaria, 1993), and even the β-amyloid protein (Hyman et al., 1989), which 
will be discussed later.
1.1.5.2		 Senile plaques (SP)
In addition to NFT, Alois Alzheimer noted the presence of another unusual lesion in 
Auguste Deter’s brain, which he described as “numerous small miliary foci” made up by 
“the storage of a peculiar material in the cortex” (Alzheimer, 1906). What Alzheimer 
described are the second characteristic lesions found in the brains of AD patients, 
senile plaques (SP), also known as neuritic plaques. Of note, the association between 
dementia in the elderly and SP was not a novel observation by Alzheimer. “Miliary foci” 
lesions had already been reported prior to Alzheimer, by Blocq and Marinesco, who are 
credited as having provided the first description of SP in an elderly epileptic patient 
(reviewed by Buda et al., 2009), and later by Beljahow and Redlich and later confirmed 
by Leri in association with senile dementia (reviewed by Castellani et al., 2008). 
However, the combination of both NFT and SP, as well as the early age of onset (51 
years old) gave a strong indication that Auguste Deter’s dementia was perhaps a novel 
disease modality.
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SP are complex extracellular sphere-like lesions ranging between 10 and 200 μM in 
diameter. They were originally identified and characterized through the use of the 
Bielschowski silver technique (Figure 1-6), due to the presence of a dense core 
accumulation of an “amyloid substance” which was confirmed by Divry in 1927 with 
Congo red staining (reviewed by Boller et al., 2007). However, the proteinaceous 
content of SP was not known for another 50 years, until Glenner and colleagues 
isolated and described the sequence of the peptide found in SP (Glenner et al., 1971a; 
Glenner et al., 1971b), which was found to be a 4-KD peptide with a β-sheet 
configuration, termed β-A4 (Beyreuther et al., 1986; Glenner and Wong, 1984; Masters 
et al., 1985a; Masters et al., 1985b; Wong et al., 1985), and later found to be a 
metabolic product of the amyloid precursor protein, APP (Kang et al., 1987), as we will 
discussed below.
Through the use of immunohistochemical techniques with antisera, we know today that 
several forms of SP can be encountered within the brains of elderly individuals, 
distributed predominantly within the cerebral cortex (Figure 1-6A) and hippocampus 
and within the grey matter of the neocortex. However, they can be classified into two 
main types, depending on their extent and severity (reviewed by Castellani et al., 2010; 
Perl, 2010). The classical senile or neuritic plaques have a dense core of β-A4 peptide 
and vary in size, between 10 and 50 μM in diameter. They are usually arranged in a 
radial fashion and are often surrounded by a corona of abnormally thickened neuronal 
processes (dystrophic neurites), which also stain with silver impregnation (Figure 1-6B, 
C). Often one or more microglial cells can be found in the periphery of SP, but whether 
or not they are merely reacting to the presence of SP or involved directly in a 
neuroinflammatory pathogenic cascade remains unclear (reviewed by Krause and 
Muller, 2010). Dense core senile plaques can also occur in the absence of any 
accompanying dystrophic neurites. It is often speculated that these types of plaques 
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are the remnants of previous neuritic plaques (Wisniewski et al., 1982), and are 
sometimes referred to as burned-out plaques or end-stage plaques. However, due to 
the cross-sectional nature of these observations, these interpretations remain 
speculative at best. The second type of plaques is made up of diffuse focal deposits of 
β-A4 in the cerebral cortex and occur in the absence of dystrophic neurites (Yamaguchi 
et al., 1989). Diffuse plaques tend to be more heterogeneous than neuritic plaques, with 
an average diameter of 20 μm, with larger plaques being far less common than their 
smaller counterparts (reviewed by Castellani et al., 2010). These plaques also stain with 
silver-based stains and are commonly found in the brains of cognitively normal elderly 
individuals, which raises the question as to whether or not they are a result of normal 
aging or indicative of an abnormal process. Nevertheless, they represent the earliest 
cerebral lesions found in AD and persist even in advanced AD cases, even making up 
the majority of β-A4-immunoreactive material found in these brains (Ikeda et al., 1989). 
It is not clear whether diffuse plaques evolve over time into neuritic plaques or whether 
they represent kinetically and thermodynamically different and distinct mechanisms.
Similar to NFT, amyloid deposits and SP are not exclusive to AD. In fact, several studies 
have failed to show a significant correlation between the extent of plaque pathology 
and the severity of the disease (Terry et al., 1991; Wisniewski et al., 1989). In addition, 
amyloid deposits can be found in several other conditions, including Down syndrome, 
dementia pugilistica, diffuse Lewy body disease and in acute traumatic brain injuries 
(Mann and Jones, 1990), making it difficult to establish how amyloid deposits contribute 
to AD or even if they are the major causative agent of neuronal degeneration.
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Figure 1-6. Different types of senile plaques in AD
(A) Temporal cortex of a patient with Alzheimer’s disease (immunohistochemical stain; original magnification, 100×): 
the microscopic appearance of an immunohistochemical preparation using an antibody directed against the 
components of beta- amyloid (4G8; a gift from Dr. Robakis). This antibody selectively decorates the numerous 
senile plaques present in this case of advanced Alzheimer’s disease and demonstrates the extent of amyloid 
accumulation that one may encounter in the terminal phases of the disease. (B) Senile plaque with neuritic 
components (Cerebral cortex; modified Bielschowsky silver stain). Many silver-positive (black), abnormally 
thickened,neuronal processes (dystrophic neurites) are arranged radially at the periphery of the senile plaque. The 
central amyloid core is brown and immediately surrounded by a clear zone. (Image courtesy of Jeau-Paul Vonsattel; 
Columbia University, NY). (C) Photomicrograph of the temporal cortex of a patient with Alzheimer’s disease 
(modified Bielschowski stain; original magnification, 400×). Two senile (neuritic) plaques with a neurofibrillary tangle 
between them are shown.
14
1.1.6	 Synaptic dysfunction in AD
Because of their prominence in AD, it was long speculated that NFT and SP played a 
causative role in the disease. Indeed, early studies hinted at a possible correlation 
between the severity of dementia and SP (Blessed et al., 1968) and NFT (Wilcock and 
Esiri, 1982). However, several subsequent studies have since failed to corroborate these 
findings and it is widely accepted today that there is only a weak correlation between 
the extent of plaque lesions and the severity of dementia. Alternatively, it appears that 
synapse loss and synaptic dysfunction may be more directly related to the severity of 
dementia than the lesions themselves (Delaere et al., 1989; Terry et al., 1991).
Ultrastructural and immunohistochemical studies from Masliah (Masliah et al., 1993; 
Masliah and Terry, 1993; Masliah et al., 1989; Terry et al., 1991) and Scheff (DeKosky et 
al., 1996; Scheff and Price, 1993, 1998; Scheff et al., 2001) have demonstrated a 
marked loss of synaptic elements, such as synaptophysin, SV2 and p65 in the brains of 
AD patients. They concluded that as much as 45% of synaptic boutons are lost in AD 
patients compared to normal controls, especially in the neocortex and hippocampus. 
They postulated that the loss of these critical elements, responsible for neuronal 
communication, constitute the principal morphological changes directly linked with 
cognitive impairment in AD. The exact mechanism(s) by which these changes occur 
have not been fully elucidated. However, there is ample evidence to suggest that the 
soluble forms of the β-amyloid peptide interferes directly with synaptic function 
(reviewed by Nimmrich and Ebert, 2009), leading to degeneration of the synapses and 
retraction of dendritic spines (discussed later).
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1.1.7	 Diagnosis of AD
Since Alzheimer’s original description of the disease, post-mortem brain examinations 
still remain the most accurate and definitive means by which AD is diagnosed. However, 
a probable diagnosis of AD upon neurologic examination can be made in most cases, 
especially if other potential underlying causes of the symptoms have been ruled out. 
The absence of reliable fluid-based biomarkers for AD have deflected the focus towards 
various brain imaging techniques, which can help visualize and identify changes in the 
structures in the brain that are associated with memory (Table 1-2). For example, 
computed tomography (CT) scans and magnetic resonance imaging (MRI) have been 
used as tools to visualize and measure brain atrophy in AD patients (Fox and 
Freeborough, 1997; Fox et al., 1996). Unfortunately, the specificity of these findings are 
sometime questionable since other conditions can also lead to atrophy of the brain. In 
addition, normal aging has also been shown to be associated with a certain degree of 
atrophy of the brain (reviewed by Scheltens and Korf, 2000).
Alternatively, imaging studies designed to address brain function and metabolism are 
revealing themselves to perhaps be better alternatives for diagnostic purposes. 
Functional magnetic resonance imaging (fMRI), positron emission tomography (PET) 
scans and single photon emission computed tomography (SPECT) have all been used 
to measure blood flow and glucose metabolism in the brain, which can be valuable in 
identifying potential functional abnormalities as early as the mild cognitive impairment 
(MCI) stages of AD (reviewed by Craig-Schapiro et al., 2009). More recently, the 
development and testing of various amyloid PET ligands have yielded promising results 
in the past several years. For example, one such agent, 11C-labelled Pittsburg 
compound B, or PIB has been shown to have an increased retention in the frontal, 
parietal, temporal, and occipital cortices and striatum in AD, leading to nearly all such 
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patients to test PIB-positive (Klunk et al., 2004; Pike et al., 2007; Rabinovici et al., 2007; 
Rowe et al., 2007). The goal of all of these techniques is to hopefully provide a suitable 
method not only for confirming an AD diagnosis in symptomatic cases but perhaps to 
pinpoint those individuals in the pre-clinical stages of the disease.
Select Candidate Fluid and Imaging Biomarkers of AD
Fluid-based markers
• Cerebral spinal fluid (CSF)
- Aβ42: decreased in AD; decreased in 
subjects with brain amyloid deposition; 
predictive of conversion from MCI to 
AD
- Aβ40: no difference in AD
- Aβ40/42 ration: discriminates AD from 
normal; predictive of conversion from 
MCI to AD
- Tau/pTau: increased in AD; pTau231 
predicts conversion from MCI to AD
- Tau/Aβ42 ratio: increased in AD; 
predictive of conversion from normal to 
MCI to AD
- Isoprostanes: increased in postmortem 
and antemortem AD CSF; predictive of 
conversion from normal to MCI to AD; 
increased in preclinical FAD mutation 
carriers
- α1-antichymotrypsin: mixed results
- Interleukin-6: mixed results
- various inflammation markers: mixed 
results
• Plasma/serum
- Aβ42: mixed results; increased in FAD
- Aβ40: mixed results; decreased in FAD
- Isoprostanes: mixed results
- α1-antichymotrypsin: mixed results; 
predictive of AD risk
- Interleukin-6: mixed results
• Urine
- Isoprostanes: mixed results
Imaging modalities
• CT and MRI: regional atrophy in AD; whole 
brain atrophy in AD; predictive of 
conversion from MCI to AD; predictive 
of conversion from normal to MCI
• fMRI: altered activation in AD; altered 
activation in MCI
• FDG-PET: regional hypometabolism in AD; 
predictive of conversion from MCI to 
AD
• H215O-PET: altered activation in AD
• SPECT: altered regional cerebral perfusion 
in AD; predictive of conversion from 
MCI to AD
• ASL-MRI/contrast-based MRI: regional 
hypoperfusion in AD
• FDDNP-PET: increased retention in AD and 
MCI brain
• PIB-PET: increased retention on AD brain; 
increased retention in a subset of 
cognitively normal controls; detects 
cerebral amyloid angiopathy
• Other PET amyloid imaging agents: 
increased retention in AD brain
• PET markers of microglial activation: 
increased retention in AD and MCI 
brain
Table 1-2. Select candidate fluid and imaging biomarkers of AD
(adapted from Craig-Schapiro et al., 2009)
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1.2	 The amyloid precursor protein (APP) family of genes
Over the years, there has been tremendous progress towards understanding the 
molecular pathways and signaling changes that occur in the pathology of AD. 
Unfortunately, the event(s) that trigger and alter these molecular pathways have 
remained, to a large extent, poorly understood. The discovery of the β-A4 peptide as 
the main constituent of amyloid plaques (Beyreuther et al., 1986; Masters et al., 1985a; 
Masters et al., 1985b; Wong et al., 1985) was an undeniably important leap forward in 
AD research. However, up to that point the provenance of the peptide remained a 
mystery. Two years later, its source would finally be revealed when the amyloid 
precursor protein (APP) was cloned for the first time (Kang et al., 1987). 
1.2.1	 Overview
Since it was originally cloned, the amyloid precursor protein, APP (Kang et al., 1987) 
has been found to be an evolutionary highly conserved gene family which, in addition to 
APP, includes the two homologous mammalian genes encoding the proteins APP-like 
protein-1, APLP1 (Wasco et al., 1992) and APP-like protein-2, APLP2 (Wasco et al., 
1993b), as well as the Drosophila melanogaster homologue, APPL (Rosen et al., 1989) 
and the Caenorhabditis elegans homologue APL-1 (Daigle and Li, 1993). The APP family 
proteins are intriguing due to their sequence and structure, which have lead to many 
proposed, but unclear, functions. However, it is becoming increasingly clear, as we’ll 
discuss in more detail below, that the APP gene family proteins have, at the very least, 
partly overlapping, if not redundant important functions.
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Of all the members of the gene family, APP has been the most well studied and 
characterized protein due to its role in AD. Much of what we will discuss below applies 
to APP; additional details will be provided for the other members when necessary.
1.2.2.	 Genetics
In humans, the gene for APP is located on chromosome 21 at 21q21.2 (Korenberg et 
al., 1989; Patterson et al., 1988; Robakis et al., 1987; Tanzi et al., 1987) and contains 19 
exons (Yoshikai et al., 1991), while APLP1 and APLP2 are found on chromosome 19 
(Wasco et al., 1993a) and chromosome 11 (von der Kammer et al., 1994) respectively. 
At least 8 different isoforms of APP can be generated by alternative splicing of exons 7, 
8 and 15 (Figure 1-7), all coding for part of the ectoplasmic portion of the molecule 
(reviewed by Menendez-Gonzalez et al., 2005). Although APP is ubiquitously expressed, 
some isoforms are preferentially expressed in different cell types. In non-neuronal cells, 
the longer isoforms containing exon 7 (APP751) or exons 7 and 8 (APP770) predominate, 
while neurons express primarily the shorter isoform lacking exons 7 and 8 (APP695) 
(Kang and Muller-Hill, 1990). APP isoforms devoid of exon 15 are typically not 
expressed in neurons, but can be found in many other cell types, where they function 
as the core protein for a proteoglycan called appican (Pangalos et al., 1995).
As for the other family members, APLP2 contains three exons that can be alternatively 
spliced in a manner very similar to APP (Sandbrink et al., 1994), while the APLP1 gene 
only produces a single transcript (Lenkkeri et al., 1998), as is the case for APPL and 
APL-1 (Daigle and Li, 1993). As for their expression profiles, APLP2 is ubiquitously 
expressed (Wasco et al., 1993b), but APLP1 is restricted to the nervous system (Lorent 
et al., 1995; Slunt et al., 1994). In C. elegans, APL-1 is expressed in multiple tissues 
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(Hornsten et al., 2007), whereas the Drosophila APPL protein is exclusively neuronal 
(Luo et al., 1990).
Figure 1-7. Exon-intron organization of the human APP (hAPP) gene
Boxes represent exons, colored boxes represent isoform-specific exons as shown. Horizontal lines indicate introns. 
The whole gene is approximately 400 kb in length (elements are not drawn to scale).
The overall extensive similarities in the amino acid sequences of APP and APLPs and 
their overlapping brain expression patterns strongly suggest that these proteins fulfill 
highly redundant biological roles in mammals.
1.2.3	 Protein structure
The APP family member proteins are all type I integral membrane proteins, which share 
the same basic domain structures (reviewed by Gralle and Ferreira, 2007): a single 
membrane-spanning domain, a large ectoplasmic N-terminal region and a shorter 
cytoplasmic C-terminal region. The ectoplasmic region of APP, which constitutes the 
major part of the protein is comprised of two distinct, largely independently-folding 
structural domains, E1 and E2 (Figure 1-8A). The former can be further subdivided into 
several sub-domains (Figure 1-8A, B), including a heparin-binding/growth factor-like 
domain (HBD/GFLD), a copper-binding domain (CuBD) and a zinc-binding domain 
(ZnBD). Similarly, the E2 domain contains an additional HBD/GFLD, as well as a random 
coil (RC) region. As mentioned above, the splicing of exon 15 in APP770 creates a 
chondroitin sulfate glycosaminoglycan (GS GAG) attachment site used in astrocytes but 
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not in neurons (Pangalos et al., 1995). The E1 and E2 domains are linked by an acidic 
region, rich in aspartic and glutamic acid residues and a Kunitz-type protease inhibitor 
domain (KPI) --only present in the longer isoforms APP751 and APP770-- thought to 
function in regulating cerebral thrombosis (Xu et al., 2005). The KPI domain is 
immediately followed by a seemingly random short stretch of 19 amino acids without 
significant homology to other known proteins and without a recognizable structure 
(Richards et al., 1995). This is followed by the transmembrane domain (TM), which 
includes part of the β-amyloid peptide (Aβ) sequence (Figure 1-8C; discussed below). 
Lastly, the cytoplasmic tail (IC) of APP contains a protein interaction motif, namely the 
YENPTY sequence (Lai et al., 1995) (including the NPXY internalization signal), 
conserved in all APP homologues.
Classical N- and O-glycosylation (Weidemann et al., 1989), as well as sulfation and 
phosphorylation of several tyrosine residues of APP occur on both sides of the 
membrane (Figure 1-6B) during trafficking through the endoplasmic reticulum (ER) and 
the Golgi apparatus (reviewed by Turner et al., 2003), increasing the structural 
complexity of APP and APLPs. While no clear role for APP glycosylation could be 
demonstrated in chinese-hamster ovary (CHO) cells (Pahlsson and Spitalnik, 1996), N- 
and O-glycosylation of the extracellular portion of APP has been suggested to be 
necessary for phosphorylation of a threonine residue (Thr668) in its cytoplasmic domain 
during neuronal differentiation (Ando et al., 1999).
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Figure 1-8. Domain structure and processing the amyloid precursor protein (APP)
(A) Overall structure of APP, showing the largely independently-folding structural domains that have been identified, 
including the soluble ectoplasmic region (sAPP), which is comprised of the E1 and E2 domains; a transmembrane 
domain (TM), which partially encompasses the β-amyloid peptide (Aβ) sequence and an intracellular domain (IC). 
(B) Relative positions of the heparin, metal-binding (Cu2+ and Zn2+) phosphorylation (P) and glycosylation sites 
(CHO) on APP. Two alternatively spliced variants containing a Kunitz-type protease inhibitor consensus sequence 
(KPI) or a chondroitin sulphate glycosaminoglycan attachment site (GS-GAG) are also indicated. (C) Schematic 
illustration of APP processing by the various secretases and amino acid sequence showing the precise location of 
each cleavage site. (Image adapted from De Strooper and Annaert, 2000)
1.3 Proteolytic processing of APP and formation of the β-amyloid peptide (Aβ)
In addition to the many post-translational modifications outlined above, APP is further 
modified through a series of cleavage processes, generating a wide variety of fragments 
including the Aβ peptide (reviewed by Walsh et al., 2007). Two related proteolytic 
22
pathways mediated by three distinct cleavage events have been identified.
1.3.1 α-Secretase and the non-amyloidogenic pathway
The first pathway, originally described by Esch et al. (Esch et al., 1990), is initiated by a 
protease referred to as α-secretase, which cleaves APP between lysine612 and 
leucine613 (APP695 numbering; Figure 1-8C), producing two fragments, the N-terminal 
ectodomain sAPPα and an 83-amino-acid-long C-terminal membrane-bound fragment 
C83 (Figure 1-9A). Since this cleavage occurs within the sequence of the Aβ domain 
itself (residues 16 and 17 of Aβ), this pathway is commonly referred to as the non-
amyloidogenic pathway for it precludes generation of the Aβ peptide.
Although this pathway has been known for some time, the complete picture of the 
processing events and the enzymes involved have not been fully unraveled. α-
Secretase candidates have been identified and characterized as being all zinc 
metalloproteinases, members of the ADAM (a disintegrin and metalloproteinase) family 
of proteases (reviewed by De Strooper and Annaert, 2000). These include TACE (tumor 
necrosis factor-α converting enzyme), also know as ADAM17 (Black et al., 1997; Moss 
et al., 1997), as well as ADAM10 (Lammich et al., 1999) and MDC-9, also known as 
meltrin-γ or ADAM9 (Koike et al., 1999).
Initially, it was thought that this cleavage may be physiological, thereby preventing the 
production of Aβ in AD (Esch et al., 1990; Sisodia et al., 1990). However, this view may 
be an oversimplification. Cleavage of APP by α-secretase occurs at the cell surface 
(Parvathy et al., 1999) and only a small percentage of APP (compared to the total 
cellular pool) is present at the cell surface (Kuentzel et al., 1993; Sambamurti et al., 
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1992) due to the rapid removal of cell-surface APP (Koo et al., 1996). Hence, only a 
small fraction of the total pool of APP is cleaved by α-secretase in most cell types, 
leaving most of APP available for the alternative amyloidogenic pathway, which we will 
outline below.
Figure 1-9. Proteolytic processing of APP
(A) APP undergoes two distinct cleavages within its juxtamembrane region. The predominant cleavage is mediated 
by α-secretase and results in the secretion of sAPPα and the generation of an 83-amino-acid-long membrane-
tethered fragment. The alternative, amyloidogenic, cleavage occurs just 16 residues N-terminal to the α-site and is 
brought about by BACE. β-Cleavage results in the secretion of sAPPβ and the production of the C99 fragment. C99 
and C83 undergo heterogeneous cleavage by γ-secretase leading to the secretion of Aβ and p3 and the release of 
ICD into the cytoplasm. (B) Aβ42 is prone to self-aggregate to form soluble globulomers consisting of 2-14 Aβ 
monomers, Staining of Aβ42 oligomers with an Aβ42 globulomer-specific antibody in a cortical section of a patient 
with AD (Barghorn et al., 2005).
1.3.2 β-Secretase and the amyloidogenic pathway
The second known proteolytic pathway leads to the production of Aβ, and is typically 
referred to as the amyloidogenic pathway. It is initiated by the protease β-secretase, 
which was identified through four independent approaches (Hussain et al., 1999; Sinha 
et al., 1999; Vassar et al., 1999; Yan et al., 1999), as BACE1 (β-site APP-cleaving 
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enzyme). Cleavage of APP by BACE1 (De Strooper and Annaert, 2000) occurs between 
methionine596 and aspartate597 of APP695 (Figure 1-8C), producing two fragments, the 
secreted N-terminal ectodomain sAPPβ and a remaining 99-amino-acid-long fragment 
C99 (Figure 1-9A), encompassing the Aβ peptide. Additionally, BACE1 can cleave APP 
at another site, between tyrosine606 and glutamate607 (Figure 1-8C), releasing a longer 
sAPPβ and an 89-amino-acid-long fragment C89. This results in a shorter form of the 
Aβ peptide previously detected in plaques (Masters et al., 1985b; Naslund et al., 1994) 
and in culture (Haass et al., 1992; Simons et al., 1996).
BACE1 is a type I integral membrane protein with a putative pro-domain and two DT/
SGT/S motifs on its extracellular domain (Hussain et al., 1999; Vassar et al., 1999), a 
classical signature of the catalytic domain of aspartyl proteinases. BACE1 is 
synthesized as a proenzyme, whose pro-domain is cleaved by furin-like protease as it is 
trafficked to the plasma membrane through the secretory pathway (reviewed by Tang, 
2009). BACE1 then cycles to the cell surface and endosomes, and at steady-state is 
found primarily in the late Golgi-TGN compartments and endosomes (Huse et al., 2000). 
Additionally, the C-terminus of BACE1 contains an acidic dileucine motif 
(495DDISLLK501) that targets BACE1 from the plasma membrane to endosomes (Huse et 
al., 2000). Phosphorylation at serine498 has been implicated in its trafficking between 
early endosomes and the TGN/late endosomes (Walter et al., 2001). The optimal pH of 
BACE activity is approximately 4.5, suggesting that the β-site cleavage of APP occurs 
preferentially in more acidic compartments, such as in endosomes (Vassar et al., 1999). 
It has also been suggested that BACE1 cleavage can occur in lipid rafts (Ehehalt et al., 
2003). At least one other human homologue of BACE1 has been identified, BACE2 
(Hussain et al., 2000), which interestingly is a better α- than β-secretase (Farzan et al., 
2000). Nevertheless, BACE2 is expressed at very low levels in the brain, and is mostly 
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restricted to glial cells (Laird et al., 2005); a potential role for BACE2 in AD has yet to be 
identified.
1.3.3 γ-Secretase cleavage and production of Aβ
As a result of either α-secretase or β-secretase cleavage of APP, three membrane-
bound C-terminal fragments (CTFs) are produced, C99 or C89 and C83, which all serve 
as substrates for the final cleavage event, namely γ-secretase cleavage. γ-Secretase is 
a unique aspartyl protease complex (Walsh et al., 2007), which unlike α- and β-
secretases, acts deep within the membrane and cleaves APP at multiple sites (Zhao et 
al., 2004), releasing either Aβ and intracellular C-terminal domain fragments (ICDs) or p3 
and ICDs (Figure 1-9A). However, while the two predominant forms of Aβ and p3 
terminate at valine637 (Aβ40 and p340) and alanine639 (Aβ42 and p342) (Haass et al., 1992; 
Figure 1-8C), isolated ICDs are shorter than expected and begin at sites 9-10 amino 
acid downstream of those residues (Gu et al., 2001). This inconsistency led to the 
recognition that γ-secretase-cleavage of CTFs occurs at three distinct sites. The first, 
referred to as the ε-site (Figure 1-8C), happens 9-10 residues downstream of Valine637 
and produces a 49-50 amino-acid fragment C49/C50 (Gu et al., 2001; Weidemann et 
al., 2002). The second cleavage occurs 6 residues downstream of Valine637 and is 
referred to as the ζ-site (Kakuda et al., 2006; Zhao et al., 2004). Finally, the last cut 
occurs at the γ-site to give rise to Aβ40/Aβ42 and p340/p342. In all, several Aβ species are 
generated and have been isolated, including Aβ40, Aβ42, Aβ43, Aβ45, Aβ48 and Aβ49, and 
only two species of ICDs, C49 and C50 (Kakuda et al., 2006).
Unlike its counterparts, the γ-secretase enzyme is a protein complex (Figure 1-10) 
made up of at least four individual components (reviewed by Wolfe, 2008): aph-1 
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(anterior pharyx defective-1), nicastrin, presenilin-1 (PS1) or presenilin-2 (PS2) and 
pen-2 (presenilin enhancer-2) (Edbauer et al., 2003; Francis et al., 2002; Goutte et al., 
2000; Yu et al., 2000). In humans, aph-1 exists as two isoforms, aph-1a and b --mice 
have a third isoform, aph-1c. It is thought to be a scaffolding protein that functions to 
stabilize the complex and contributes to its trafficking (Niimura et al., 2005; Takasugi et 
al., 2003). Nicastrin has recently been demonstrated to play a critical role in substrate 
recognition through its ectodomain, which binds the N-terminus of membrane-bound 
substrates (Shah et al., 2005). Upon assembly, it is believed that aph-1 and nicastrin 
first form a sub-complex (Hu and Fortini, 2003; LaVoie et al., 2003; Morais et al., 2003; 
Shirotani et al., 2004) to which PS1 or PS2 protein subsequently binds. 
PS1 and PS2 are nine-transmembrane domain proteins that are thought to possess the 
actual protease activity (Yu et al., 1998). Upon activation, full-length presenilin protein is 
cleaved in the cytoplasmic loop between the 6th and 7th transmembrane region to 
generate stable N- and C-terminal fragments (Thinakaran et al., 1996a). These 
fragments stay in close proximity in the membrane to generate the active form of the 
protein complex. It is this active form that then joins the aph-1/nicastrin sub-complex, 
before pen-2 presumably comes in to complete and perhaps to further stabilize the 
complex or to facilitate auto-cleavage of PS (LaVoie et al., 2003; Niimura et al., 2005).
The sub-cellular localization of γ-secretase and its activity remain a matter of 
controversy, as each subunit of the enzyme has been found in multiple organelle 
including the endoplasmic reticulum (ER), ER-Golgi intermediate compartments, Golgi 
apparatus, endosomes, lysosomes, phagosomes, plasma membrane, and even 
mitochondria (reviews by Marks and Berg, 2010; Tang, 2009).
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1.4		 Intracellular trafficking of APP
1.4.1	 Intracellular itinerary
The pathways of APP trafficking (reviewed by Thinakaran and Koo, 2008) are depicted 
in Figure 1-11 (Vetrivel and Thinakaran, 2010). Nascent APP molecules mature through 
the constitutive secretory pathway. As it transits from the ER through the Golgi to the 
plasma membrane, APP is post-translationally modified (reviewed in section 1.2.3). 
Interestingly, as was mentioned above, only a small fraction of nascent APP molecules 
is present at the plasma membrane (Kuentzel et al., 1993; Sambamurti et al., 1992), 
estimated to be as low as ~10%, based on APP over-expression studies in cultured 
cells. At steady state, the majority of APP localizes to the Golgi apparatus and trans-
Golgi network (TGN). In non-neuronal cells, once APP reaches the plasma membrane, it 
Figure 1-10. The γ-secretase complex
Aph-1 and nicastrin form a stable sub-complex 
early during assembly, followed by entry of the 
presenilin holoprotein to form a trimeric 
intermediate complex (Aph-1::immature 
nicastrin::presenilin holoprotein). Maturation of 
nicastrin in the Golgi/trans Golgi network and 
entry of Pen-2 into the maturing complex 
promote presenilin endoproteolysis and 
formation of active -secretase. The active 
complex contains cleaved presenilin NTF and 
CTF as well as associated cofactors. It is 
currently uncertain where some assembly steps 
occur, what is the precise composition of the 
complex at each stage, what are the specific 
interactions among various components at each stage, and whether alternative complexes with different subunit 
compositions might exist.
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is rapidly internalized (Koo et al., 1996; Sisodia, 1992) due to the presence of the 
YENPTY internalization sequence near the C-terminus of APP (residues 682-687 of 
APP695). Following endocytosis, APP is delivered to endosomes, where it can be 
trafficked through the endocytic and recycling compartments back to the cell surface or 
degraded through the lysosomal pathway. 
Several adaptor proteins have been shown to bind the NPTY sequence, regulating the 
trafficking of APP. These include X11/mint (Miller et al., 2006), Fe65 (Borg et al., 1996), 
Dab1 (Homayouni et al., 1999), JIP family of proteins (Matsuda et al., 2001) and Sortin 
nexin 17 (Lee et al., 2008a). In addition to cytosolic adaptors, several transmembrane 
proteins of the low-density lipoprotein receptor-related (LDLR) family members, 
including LRP1, LRP1B and SorLA, have been shown to interact with APP and 
modulate its trafficking and processing (Andersen et al., 2005; Cam et al., 2004; Cam et 
al., 2005). Moreover, in neurons APP is transported through the axon via the fast 
anterograde machinery (Koo et al., 1990), accounting for the observed synaptically 
released Aβ pool (Lazarov et al., 2002).
1.4.2 Endocytic sorting of APP and Aβ production
The processing of APP to Aβ is profoundly modulated by its sub-cellular localization 
(Figure 1-11), which affects not only the efficiency but also the choice of metabolic 
pathway --i.e. amyloidogenic versus non-amyloidogenic pathway (reviewed by Vetrivel 
and Thinakaran, 2010). Much of what has been learned about this topic has originated 
from studies in cultured mostly non-neuronal cell lines, such as chinese hamster ovary 
(CHO) cells and human embryonic kidney (HEK293) cells. Based on several of these 
studies, it is believed that Aβ is principally generated in the TGN and endosomes as 
APP is trafficked through both the secretory and recycling pathways (Ghribi, 2006; 
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Greenfield et al., 1999; Xu et al., 1997). This concurs with the fact that BACE1 and γ-
secretase are primarily localized to these organelles (Baulac et al., 2003; Vetrivel et al., 
2004) and with the fact that BACE1 is optimally active at pH 4.5, as mentioned earlier 
(Vassar et al., 1999). Indeed, endocytosis of APP has been found to be critical for Aβ 
production both in cultured cells and in vivo (Cirrito et al., 2008; Koo and Squazzo, 
1994). Interestingly, APP bearing mutations associated with familial early-onset AD 
(discussed later) in a swedish kindred (APP K670N/M671L; APPswe) is more readily 
cleaved by BACE1 in the secretory pathway, as early as during trafficking through the 
Golgi (Thinakaran et al., 1996b).
Figure 1-11. Schematic illustration of the intracellular itinerary of APP
Schematic illustration of intracellular itinerary of amyloid precursor protein (APP). Synthetic APP is trafficked 
through the constitutive secretory pathway to the plasma membrane (blue arrows). From the cell surface, a fraction 
of APP is internalized and trafficked through endocytic and recycling compartments (red arrows) to reach the cell 
surface, the TGN, or sorted to the lysosomes for degradation (dotted red arrows). Non-amyloidogenic processing 
occurs mainly at the cell surface, where α-secretase activity is abundant. Amyloidogenic processing likely occurs in 
the endocytic pathway as APP encounters BACE1 and γ-secretase in the endosomes and recycling organelles. γ-
secretase subunits and APP CTFs are enriched in lipid raft microdomains isolated from these compartments 
(highlighted by a circle). EE, Early endosome. For simplicity, the constitutive secretory trafficking pathway is not 
indicated by arrows. (Image adapted from Vetrivel and Thinakaran, 2010)
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1.5	 Biological functions of APP
1.5.1	 APP and APLPs loss of function studies
In order to better understand the normal biological functions of the APP family gene 
proteins, several labs have generated single APP- or APLP-knockout (KO) mice 
(reviewed by Anliker and Muller, 2006), which have largely supported the idea of 
evolutionary conserved functions. Case in point, deletion of each individual gene (e.g. 
APP-/-, APLP1-/- or APLP2-/-) yields viable and fertile mice with minor and benign 
phenotypic abnormalities, which are comparable for each of the family member. For 
example, APP-knockout mice exhibit a reduction in overall body weight and a reduction 
in grip strength (Muller et al., 1994), as well as an increased sensitivity to kainate-
induced seizures (Steinbach et al., 1998). Their brains show a decrease in the weight 
and size of forebrain commissures, reactive gliosis (Zheng et al., 1995), and an increase 
in copper levels in the cerebral cortex and liver (White et al., 1999). They also exhibit 
mild cognitive impairments and behavioral deficits (Muller et al., 1994; Zheng et al., 
1995), accompanied by impaired long-term potentiation (LTP) (Dawson et al., 1999). 
APLP1 knockout mice on the other hand show only an obvious reduction in body 
weight (Heber et al., 2000), whereas APLP2 knockout mice have no apparent 
phenotype or histological abnormalities but do have increased levels of copper in the 
cerebral cortex (White et al., 1999). The results from these studies are consistent with in 
vitro studies which have suggested that APP, APLP1 and APLP2 function to promote 
neurite outgrowth (Young-Pearse et al., 2008), neural cell migration and copper 
homeostasis (Heber et al., 2000; Herms et al., 2004; Muller et al., 1994; White et al., 
1999; Zheng et al., 1995), and suggest that the relatively mild phenotype in the KO-mice 
stems from functional redundancy between each gene family member.
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In contrast to single gene deletions, double-knockout mice APLP2-/-/APP-/- and 
APLP2-/-/APLP1-/- are perinatally (postnatal day 1, P1) lethal (von Koch et al., 1997), 
whereas APLP1-/-/APP-/- mice are viable and fertile, but otherwise relatively normal 
albeit with a slight decrease in body weight (Heber et al., 2000). The unique viability of 
the APLP1-/-/APP-/- double-knockout mice indicates that APLP2 may be the only family 
member with the key physiological role(s) necessary to compensate for the 
simultaneous loss of both of the other APP family members and provides strong genetic 
evidence for at least some unique biological functions for APLP2. Consistent with this 
idea, triple-knockout mice (APLP2−/−/APP−/−/APLP1−/−) are perinatally lethal, with 100% 
penetrance, with the majority of mice showing severe cranial defects and cortical 
dysplasia resembling human type II lissencephaly and partial loss of Cajal Retzius cells 
(Herms et al., 2004), suggesting a role for APP family genes in neuronal migration 
(Young-Pearse et al., 2007).
Although the reverse genetic studies described above have confirmed an essential role 
for APP and its family members APLP1 and APLP2 during post-natal development, the 
precise molecular nature of this function has remained difficult to pinpoint. 
Nevertheless, the numerous functional domains that have been mapped to the 
extracellular and intracellular portions of APP, as well as its metabolites have yielded 
valuable clues. 
1.5.2	 Growth promoting effects
One of the earliest evidence for APP functions was obtained by assessing the growth 
pattern of fibroblasts in which the levels of APP were depleted by an antisense 
construct (Saitoh et al., 1989). These cells grew poorly, but the growth defect could be 
reversed by either parent cell conditioned medium or by treatment with partially purified 
32
brain sAPP. The active region was subsequently mapped to a pentapeptide domain 
(RERMS; amino acids residues 403-407 of APP695) near the middle of the ectoplasmic 
region of APP (Ninomiya et al., 1993). The growth promoting properties of sAPPα have 
also been reported in a number of cells of epidermal origin, such as keratinocytes 
(Herzog et al., 2004; Siemes et al., 2006) and epidermal basal cells (Hoffmann et al., 
2000).
1.5.3	 Modulation of synaptic plasticity and memory
The activity of the pentapeptide domain of APP is not exclusive to fibroblasts. Several 
studies have demonstrated a role for APP, and especially sAPPα, in neuronal excitability 
and synaptic plasticity. For instance, it was reported that intracerebroventricular 
administration of either the pentapeptide alone or recombinant sAPP into brains of mice 
and rats lead to an increase in synaptic density as well as an improvement in learning 
and memory retention (Meziane et al., 1998; Roch et al., 1994; Taylor et al., 2008). 
Interestingly, in the latter study, they observed that this effect was accompanied by 
increased long-term potentiation (LTP) and enhanced N-methyl D-aspartate (NMDA) 
receptor-mediated current. However, this result is in conflict with the in vitro 
observations that sAPPα had a suppressive role on NMDA currents in cultured 
hippocampal neurons (Furukawa and Mattson, 1998).
Of note, while the vast majority of the literature has documented the effects of the Aβ 
peptide on learning and memory in a pathological context (discussed later), a recent 
study by Puzzo et al. suggests that its detrimental effects occur at high concentrations, 




Of all of the proposed functions of APP, its trophic properties have been perhaps the 
most consistently and arguably the best established function (reviewed by Jacobsen 
and Iverfeldt, 2009), particularly through its secreted soluble sAPPα fragment. For 
instance, the binding of APP to heparan sulphate proteoglycans (HSPG) was reported 
to stimulate neurite outgrowth in cultured chick sympathetic and mouse hippocampal 
neurons (Small et al., 1994). In addition, APP and sAPPα were shown in several studies 
to regulate neurite elongation and branching, perhaps by mediating NGF-promoted 
neurite outgrowth (Milward et al., 1992). In agreement with these results, Perez et al. 
reported shorter axonal outgrowth in hippocampal neurons from APP knock-out mice 
compared to their wild-type counterparts (Perez et al., 1997). However, this effect was 
only transient, as 3 day-old axons were longer than wild-type ones, suggesting that 
APP initially stimulates neurite outgrowth, but inhibits it over time. It has been 
suggested that this inhibitory effect is due to the interaction of full-length APP with 
integrin β1 (Young-Pearse et al., 2008). By interfering with this interaction, sAPPα is 
thought to lift the inhibitory effects of full-length APP, thereby stimulating neurite 
outgrowth. In support of this hypothesis, Young-Pearse et al. showed in the same study 
that sAPPα was unable to induce neurite outgrowth in the absence of cellular APP 
expression. The secreted form of sAPLP1 and sAPLP2 were both shown to stimulate 
neurite outgrowth in a manner similar to that of APP.
1.5.5	 Cell adhesion properties
The neurite-outgrowth-promoting functions of APP and sAPPα have led many to 
hypothesize that APP must also play a role in cell adhesion, since neuronal migration, 
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neurite outgrowth and synaptogenesis would all involve substrate adhesion (reviewed 
by Thinakaran and Koo, 2008). In line with this hypothesis, Shubert et al. reported that 
APP can modulate the adhesion of a murine pheochromocytoma cell line (PC12) to the 
substrata (Schubert et al., 1989). Moreover, a RHDS motif near the extralumenal portion 
of APP (amino acids 328-332 of APP695), within the Aβ region, has been identified and 
shown to stimulate neurite outgrowth in a variety of cell lines, by promoting cell 
adhesion (Ghiso et al., 1992; Jin et al., 1994). It is thought that this region acts in an 
integrin-like manner and can, accordingly, be blocked by RGDS peptide sequence 
derived form the fibronectin-binding domain. Fittingly, APP has been shown to 
colocalize with integrins on the surface of axons and at sites of adhesion (Storey et al., 
1996; Yamazaki et al., 1997). Evidence of its interactions with several extracellular 
matrix proteins, such as laminin, collagen and heparan sulfate proteoglycans (HSPG) 
(Beher et al., 1996; Buee et al., 1993b; Narindrasorasak et al., 1992) further strengthens 
the notion of the adhesion promoting properties of APP.
Finally, X-ray crystallography analysis has revealed that APP and APLPs can form 
antiparallel homo- and hetero-dimers (discussed in further detail below) through their 
ectodomains (Soba et al., 2005; Wang and Ha, 2004). The former study further 
demonstrated that these type of interactions may be involved in cell-cell adhesion in 
mouse embryonic fibroblasts in an APLP2-dependent manner (Soba et al., 2005). 
However, a recent study reported that although all mammalian homologues can form 
parallel (cis) interactions, antiparallel (trans) interactions were limited to APLP1 (Kaden 
et al., 2008), suggesting a specific role for APLP1 in adhesion.
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1.5.6 	 Additional functions
In addition to those functions mentioned above, several more have been reported for 
APP, including a role in neurogenesis. For example, Moya et al. showed that APP is 
developmentally regulated and its expression is increased at the time of synaptogenesis 
(Moya et al., 1994) and may play a role in the correct migration on neuronal progenitors 
into the cortical plate (Young-Pearse et al., 2007). APP has also been proposed to have 
a role in axonal outgrowth after traumatic brain injury (Leyssen et al., 2005) and a 
protective role in ischemic brain injuries (Smith-Swintosky et al., 1994). Finally, sAPPα 
has been shown to enhance long-term neuronal survival in rat cortical cell cultures 
(Araki et al., 1991) and to prevent death in human cortical cell cultures deprived of 
glucose and exposed to excitotoxins (Mattson et al., 1993), and even to Aβ-induced 
toxicity (Goodman and Mattson, 1994).
1.6 The etiology of Alzheimer’s disease (AD)
Genetically, AD is usually classified into two forms: (1) Familial cases with Mendelian 
inheritance of predominantly early-onset age (<60 years-old), usually referred to as 
early-onset familial AD (EOFAD), and (2) ostensibly called sporadic cases, with less 
apparent or no familial aggregation of usually late-onset age (>65 years-old), typically 
called late-onset AD (LOAD). It is important to stress that this traditional categorization 
is overly naive, as there are rare cases of EOFAD without evidence of strong Mendelian 
transmission, while on the other hand, LOAD is frequently observed with a strong 
familial clustering, which can mirror a Mendelian pattern.
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1.6.1 Early-onset familial Alzheimer’s disease (EOFAD)
As mentioned above, a small subset (~1% to ~5%; Maslow, 2010) of AD patients 
develop clinical symptoms (reviewed in 1.1.3) before the age of 60, sometimes as early 
as in their 30s. Positional cloning methods have led to the identification of three distinct 
genetic loci --APP on chromosome 21q, PSEN1 (presenilin-1) on chromosome 14q and 
PSEN2 (presenilin-2) on chromosome 1-- that cause AD with extremely high penetrance 
in mutation carriers (reviewed by Tanzi and Bertram, 2005). To date, a total of 32 
autosomal dominant mutations have been identified in APP, 181 in PSEN1 and 14 in 
PSEN2 (AD mutation database; reviewed in Bertram et al., 2010). The vast majority of 
these EOFAD mutations appear to confer one of two related biochemical phenotypes: 
an increased production of the Aβ peptide (Cai et al., 1993; Citron et al., 1992) or an 
increased ratio of cerebral Aβ42 relative to Aβ40 (Suzuki et al., 1994). While it remains 
unclear how these mutations alter the ratio of Aβ species generated from APP, it 
appears that they alter how APP is enzymatically processed at the γ-secretase site to 
produce Aβ (Price et al., 1998).
The identification of these mutations have lent strong support for the amyloid cascade 
hypothesis, first proposed by Glenner (Glenner and Wong, 1984), which postulates a 
central causative role for Aβ in initiating the AD pathogenic cascade and argues that the 
neurodegenerative process, including the development of NFT, is a consequence of an 
imbalance between the generation and clearance of Aβ.
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1.6.2 Late-onset Alzheimer’s disease (LOAD) and AD risk factors
Late-onset AD, sometimes referred to as sporadic AD represents by far the vast 
majority of AD cases (Maslow, 2010). Most of these individuals have no known AD-
causing mutations per se, but do have abnormally high levels of cerebral Aβ, 
particularly oligomeric Aβ, which is thought to be highly predictive of eventual AD 
changes (Lue et al., 1999). Accordingly, the fact that most currently known EOFAD 
genes cause AD through abnormal production of Aβ has led to other Aβ-centered 
hypotheses, centered around the search for genetic causes of LOAD (reviewed by 
Bertram et al., 2010) --e.g. with potential effects on Aβ production, aggregation and 
clearance.
Two such “candidate genes” evaluated for genetic association with AD were APOE 
(encoding apolipoprotein E [apoE]) on chromosome 19q13 (Strittmatter et al., 1993) and 
SORL1 (encoding the sortilin-related receptor, low-density lipoprotein receptor class A 
repeat-containing protein) on chromosome 11q23-q24 (Rogaeva et al., 2007). In the 
case of the former, the ε4 allele of a 3 allele haplotype (composed of ε2, ε3, and ε4 
alleles, which exhibit distinct biochemical properties at the protein level) leads to a 
dose-dependent increase in AD risk, by as much as ~4-fold compared to non-carriers. 
In contrast, the rarer ε2 allele seems to confer protective effects when inherited with the 
ε3 compared to homozygous ε3 carriers (Corder et al., 1994; Farrer et al., 1997; Gerdes 
et al., 2000). Functionally, apoE-dysfunction (reviewed by Kim et al., 2009; Vance and 
Hayashi, 2010) has been linked to several key aspects in the Aβ-centered AD 
hypothesis (Table 1-3; adapted from Bertram et al., 2010). As for SORL1, it was shown 
to direct trafficking of APP into recycling pathways, and that when underexpressed, 
APP is sorted into Aβ-generating compartments (reviewed in Lee et al., 2008b).
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As valuable as the “candidate gene” approach has been, it suffers from a major 
drawback in that it is centered around a preconceived functional and/or positional 
hypothesis. Fortunately, the last five years have seen the advent of microarray 
technology (Sharon et al., 2010), which has revolutionized genetic research. It allows for 
the assessment of several hundreds of thousands of single-nucleotide polymorphism 
(SNPs) in a single experiment and to perform genome-wide association studies (GWAS) 
in a largely hypothesis-free manner. A number of GWAS have been performed to date in 
AD (reviewed by Bertram et al., 2010). In addition to confirming the ε4 allele of APOE as 
an AD risk-factor in carriers, they have uncovered several new potential AD 
susceptibility genes (Table 1-3). In 2009, two large GWAS from the UK (Harold et al., 
2009) and France (Lambert et al., 2009) highlighted three novel AD genes: CLU (clustrin; 
also known as apolipoprotein J), CR1 (complement component 3b/4b receptor 1) and 
PICALM (phophatidylinositol binding clathrin assembly protein); all three currently rank 
at the very top of the Alzgene meta-analyses, directly behind APOE.
Functionally, these genes have all been implicated in a number of functions directly 
related to Aβ (Table 1.3). For example, in addition to being involved in Aβ clearance 
(DeMattos et al., 2004; Zlokovic, 1996) and aggregation (DeMattos et al., 2002; 
Thambisetty et al., 2010), clustrin has been reported to play a role in Aβ fibrillization 
(DeMattos et al., 2004; DeMattos et al., 2002), in regulating brain cholesterol and lipid 
metabolism (Gelissen et al., 1998) and in the inhibition of neuronal apoptosis (Nuutinen 
et al., 2009). CR1 is the main receptor for the complement C3b protein, a key 
inflammatory protein activated in AD (Khera and Das, 2009; Wyss-Coray et al., 2002). 
Several lines of evidence suggest that complement activation protects against Aβ-
induced neurotoxicity and may promote the clearance of Aβ (Rogers et al., 2006; Wyss-
Coray et al., 2002). Finally, PICALM is involved in clathrin-mediated endocytosis (Tebar 
et al., 1999), synaptic transmission and the removal of apoptotic cells (Harel et al., 
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2008; Yao et al., 2005). With respect to AD, brain-expressed PICALM protein is 
predominantly found in endothelial cells, where it could facilitate Aβ clearance through 
the bloodstream (Baig et al., 2010). This hypothesis is supported by recent data that, 
similar to apoE ε4, the PICALM risk allele is associated with reduced levels of Aβ in the 
cerebral spinal fluid (CSF) of AD patients and normal individuals (Schjeide et al., in 
press).
In addition to the three genes above, we should point out that other GWAS have 
identified other potential AD genes, but independent replication of these findings have 
been inconsistent. These include GAB2 (GRB2-associated binding protein 2; Reiman et 
al., 2007), ATXN1 (ataxin 1), CD33 (siglec 3) and an uncharacterized locus of 
chromosome 14 (Ionita-Laza et al., 2007), and PCDH11X (protocadherin 11 X-linked; 
Carrasquillo et al., 2009).
Table 1-3. Overview of the potential functional impact of GWAS findings and their reported or suggested 
potential involvement in a number of pathogenetic pathways of relevance to AD  
(Image adapted from Bertram et al., 2010)
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1.6.3	 Age
One notable aspect that routinely gets overlooked in AD is the age factor. As mentioned 
earlier, after the age of 65, the incidence and prevalence of AD doubles every 5 years. 
Moreover, even in carriers of risk-factor genes, the disease essentially does not occur in 
middle age. Therefore, whether or not an individual is genetically predisposed, aging 
remains an essential factor in AD (Hoyer, 1994), indicating perhaps that an age related 
component is involved in the development of the disease. Obviously, this age-related 
penetrance represents a significant risk factor in several other chronic diseases, 
including other neurodegenerative diseases, cancer, atherosclerosis among others, 
suggesting that there may exist common etiologies with diverse consequences.
1.7 Aβ aggregates and their role in AD
Aβ is widely considered to be at the heart of AD pathogenesis (reviewed by Nathalie 
and Jean-Noel, 2008). As discussed above, several Aβ species, ranging from 38 to 43 
amino acids, are produced as a result of the sequential cleavage of APP by β- and γ-
secretases. Of these Aβ species, some are considered more damaging than others, 
most notably Aβ42 due to its higher propensity to spontaneously self-aggregate into 
multiple coexisting physical forms (Burdick et al., 1992; Jarrett et al., 1993).
1.7.1 Oligomeric versus fibrillar Aβ
The ubiquitous nature of the fibrillar form of Aβ in senile plaques naturally led to the 
initial hypothesis that it caused neurodegeneration in AD (reviewed by Hardy and 
Selkoe, 2002). Indeed, over time, synthetic Aβ spontaneously aggregates into 
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neurotoxic β-rich fibrils, resembling those in plaques (reviewed by Gorman and 
Chakrabartty, 2001), further supporting the amyloid hypothesis. However, several 
studies have demonstrated that the number of SP in a particular region of the brain 
correlates poorly with the local extent of neuronal death, or synaptic loss, or with 
cognitive impairment (Dickson et al., 1995; Katzman, 1986; Terry et al., 1991). Instead, 
several recent studies have reported a robust correlation between the levels of soluble 
Aβ oligomers and the severity of the disease (reviews by Caughey and Lansbury, 2003; 
Ferreira et al., 2007; Haass and Selkoe, 2007; Klein et al., 2001).
1.7.2 Types of Aβ oligomers
The precise nature of the toxic Aβ oligomers remains contentious. They generally range 
from 2 to 6 peptides (Kayed et al., 2003; Lambert et al., 1998) but have been reported 
being as large as 12 peptides (Lesné et al., 2006) or even 24 in some cases (reviews by 
Glabe, 2008; Roychaudhuri et al., 2009). Interestingly, another form of Aβ has been 
isolated from the brains of AD patients, an N-terminally truncated Aβ (Aβ 3-40/42) 
bearing a pyroglutamate modification (Harigaya et al., 2000). Pyroglutamate-Aβ (pE-Aβ) 
as it is referred to, has been shown to have a higher propensity for oligomerization and 
aggregation than full-length Aβ, potentially seeding the accumulation of neurotoxic Aβ 
oligomers (reviewed by Gunn et al., 2010). Consistent with this idea, inhibition of 
glutaminyl cyclase was reported to reduce amyloidosis and ameliorate cognitive deficits 
in mouse models of AD (Schilling et al., 2008).
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1.7.3 Mechanism(s) of toxicity of Aβ oligomers
Regardless of the exact conformation, soluble Aβ oligomers are, as a whole, decidedly 
more neurotoxic than fibrillar Aβ, and have been shown to inhibit a host of critical 
neuronal function, including long-term potentiation (LTP), synaptic dysfunction and 
memory loss in animal models and in cell culture (Lambert et al., 1998; Lesné et al., 
2006; Shankar et al., 2008; Wang et al., 2002), through a mechanism(s) that remains 
unclear. Glabe et al. have postulated that multiple Aβ oligomer conformations may be 
produced through alternative pathways (Glabe, 2008) adding even more complexity to 
the puzzle (Figure 1-12). If that were the case, it is not inconceivable that each 
conformation acts via a specific set of neurotoxic pathways, which may account for the 
enormous diversity in the mechanisms that have been reported so far.
1.7.3.1		 Extracellular mechanisms
The idea of a putative Aβ receptor is one that has garnered a number of advocates over 
the years. Although many have been put forward (Table 1-12A), a definitive candidate 
has so far failed to gain a consensus (reviews by Chow et al., 2009; Querfurth and 
LaFerla, 2010; Sakono and Zako, 2010). We will highlight some of the notable ones 
below.
Several studies have suggested that apoptotic cell death occurs through the interaction 
of Aβ oligomers with low-affinity NGF receptor [pan neurotrophin receptor (p75NTR)] 
and the activation of downstream effectors such as c-Jun N-terminal kinase (reviewed 
by Coulson, 2006). However, this remains controversial, as other studies have shown 
that p75NTR promotes neuronal survival and differentiation, suggesting perhaps a dual 
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role both in both cell death and cell survival (reviewed by Dechant and Barde, 2002). 
Additionally, other studies have reported conflicting evidence showing that p75NTR 
exerts in fact a protective role against Aβ oligomers (Costantini et al., 2005; Zhang et 
al., 2003).
Other studies have demonstrated that Aβ-derived diffusible ligands (ADDLs) bind to 
NMDA-type glutamate receptor (NMDAR) causing abnormal calcium homeostasis, 
leading to oxidative stress and ultimately to synapse loss (De Felice et al., 2007; 
Shankar et al., 2007). ADDLs can also induce the loss of insulin receptors in neurons 
(De Felice et al., 2009; Zhao et al., 2008) and impair LTP-associated kinase activity 
(Townsend et al., 2007).
The Frizzled (Fz) receptor has also been implicated in Aβ signaling (Magdesian et al., 
2008). Inhibition of Wnt signaling by Aβ, relieves Fz-mediated inhibition of Gsk3β 
thereby increasing tau phosphorylation and neurofibrillary tangles, leading to cellular 
dysfunction. Yet another study found that Aβ oligomers can interact with synaptic 
proteins or channels and impair presynaptic P/Q-type calcium currents at both 
glutamatergic and gamma-amino butyric acid (GABA)-ergic synapses (Valincius et al., 
2008). Recently, Lauren et al. reported that cellular prion protein (PrPC) can act as an Aβ 
oligomer receptor with nanomolar affinity, mediating synaptic dysfunction (Lauren et al., 
2009). Interestingly, although misfolded prion protein (PrPSc) is thought to cause prion 
disease, the interaction with Aβ does not require the infectious conformation. Finally, Aβ 
oligomers have been shown to destabilize the cell membrane (Valincius et al., 2008) and 
form pores which allow the abnormal flow of ions such as calcium into the neurons 
(Kawahara and Kuroda, 2000).
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1.7.3.2		 Intracellular mechanisms
Although Aβ was first identified as a component of plaques, as discussed above, ample 
evidence has demonstrated that it is generated intracellularly (reviwed by LaFerla et al., 
2007). In addition to being produced intracellularly, previously secreted Aβ can be taken 
by cells and internalized through various receptors and transporters such as the 
nicotinic acetylcholine receptor, low-density lipoprotein receptor, formyl peptide 
receptor-like protein 1, NMDAR and the scavenger receptor for advanced glycation 
end-product (Figure 1-12B; reviews by LaFerla et al., 2007; Sakono and Zako, 2010). 
This has led many to propose an intracellular-mediated toxicity mechanism for Aβ 
oligomers. Unfortunately, the exact details of such a mechanism remain ambiguous.
Microinjections or over-expression of Aβ in primary neurons lead to the formation of 
low-molecular-weight Aβ oligomers accompanied by cell death (Chui et al., 2001) via 
the p53-BAX pathway (Zhang et al., 2002). A recent study by Mousnier et al. 
demonstrated a possible prefoldin (PFD)-mediated proteasomal protein-degradation 
pathway (Mousnier et al., 2007), leading to speculations that an Aβ-PFD complex could 
conceivably bind the proteasome complex and disrupt proteasomal function, causing 
eventual cell death; an idea that has received some traction in light of recent reports 
showing that proteasomal function was inhibited by interaction with Aβ oligomers, 
potentially leading to age-related accumulation of Aβ and tau protein (Tseng et al., 
2008).
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Figure 1-12. Formation and toxicity mechanisms of Aβ oligomers
(A) Formation and toxicity mechanisms of extracellular Aβ oligomers. Aβ is released extracellularly as a product of 
proteolytically cleaved, plasma membrane-localized amyloid precursor protein (APP). Extracellular Aβ oligomers 
can be formed in the presence of GM1 ganglioside on the cell membrane. GM1 induces Aβ oligomer-induced 
neuronal cell death mediated by nerve growth factor (NGF) receptors. Toxic non-fibrillar Aβ is also produced in the 
presence of αB-crystallin and ApoJ. A cellular prion protein (PrPC) acts as an Aβ oligomer receptor with nanomolar 
affinity, and mediates synaptic dysfunction. Furthermore, the membrane pore is formed by Aβ oligomers. The pores 
allow abnormal flow of ions, such as Ca2+, which causes cellular dysfunction. Binding of Aβ oligomers to the 
NMDA-type glutamate receptor (NMDAR) also causes abnormal calcium homeostasis, leading to increased 
oxidative stress and synapse loss. Binding of Aβ oligomers to the Frizzled (Fz) receptor can inhibit Wnt signaling, 
leading to cell dysfunctions such as tau phosphorylation and neurofibrillary tangles. Moreover, Aβ oligomer can 
induce insulin receptor loss from the neuronal surface and impaired kinase activity related to long-term potentiation. 
(B) Formation and toxicity mechanisms of intracellular Aβ oligomers. Aβ can be localized intracellularly by the 
uptake of extracellular Aβ or by the cleavage of APP in endosomes generated from the ER or the Golgi apparatus. 
Extracellular Aβ is internalized through various receptors and transporters, such as formyl peptide receptor-like 
protein 1 (FPRL1) or scavenger receptor for advanced glycation end-products (RAGE). These receptor–Aβ 
complexes are internalized into early endosomes. Most Aβ in the endosome is degraded by the endosome ⁄ 
lysosome system. However, Aβ in the lysosome can leak into the cytosol by destabilization of the lysosome 
membrane. Although cytosolic Aβ can be degraded by the proteasomal degradation system, inhibition of the 
proteasome function by Aβ oligomers causes cell death. Suppression of protein aggregation by interactions with 
various cellular proteins, such as prefoldin (PFD) or other molecular chaperones, may cause the formation of Ab 
oligomers. (Image adapted from Sakono and Zako, 2010)
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1.8	 Other APP metabolites and their role in AD pathology
1.8.1 sAPPα
As summarized earlier (Section 1.5.4), the beneficial properties of APP (pro-survival, 
trophic factor, memory formation, etc.) have been largely attributed to sAPPα, which is 
released after α-secretase cleavage of APP by one or more of the ADAM family of 
proteases, including ADAM9, ADAM10 and ADAM17. At the moment, it is unclear which 
of these is the relevant protease. However, over-expression of ADAM10 has been 
shown to reduce Aβ levels and plaque deposition in addition to ameliorating cognitive 
deficits in an AD mouse model (Postina et al., 2004), positioning ADAM10 as a good 
candidate for the relevant α-secretase in AD pathogenesis. Nevertheless, how sAPPα is 
related to AD remains a mystery. While sAPPα concentrations in CSF are reduced in 
carriers of the Swedish APP mutation (Lannfelt et al., 1995), those of sporadic AD cases 
have been reported unaltered (Olsson et al., 2003; Sennvik et al., 2000) or increased 
(Lewczuk et al., 2008). It is likely that the Dutch (APP E693Q) and Flemish (APP A692G) 
mutations similarly affect the α-secretase cleavage site of APP, reducing sAPPα 
(Kumar-Singh et al., 2000; Moechars et al., 1999). Interestingly, families with these 
mutations display a rather disparate clinical feature, with congophilic amyloid 
angiopathy and in the case of the Flemish mutation also AD-like dementia and 
neuropathology (Cras et al., 1998; De Jonghe et al., 1998). In these cases, both the 
altered Aβ sequence and reduced sAPPα may contribute to the clinical picture.
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1.8.2	 P3
To date, no clear biological or pathological role has been found for the P3 fragments 
(P340/P342) that are generated as a result of α- and γ-secretase cleavage of APP.
1.8.3 sAPPβ
Unlike sAPPα, sAPPβ has no demonstrable neuroprotective effect and its role in AD 
remains unclear. However, a recent report has shown that sAPPβ may serve as a 
precursor for an N-terminal fragment of APP (N-APP), which is thought to play a critical 
role in the pruning of axons (Nikolaev et al., 2009). In this study, N-APP was found to 
act as a ligand for the death receptor 6 (DR6; a member of the TNFα family), which 
upon binding, leads to activation of caspase-6. Caspase-6 activation was associated 
with degeneration of axons, but not of the cell body. The study suggests that APP and 
DR6 may be components of a neuronal self-destruction pathway, indicating that 
aberrant β-secretase cleavage of APP and production of N-APP may contribute to 
degeneration in AD. Other possible functions of sAPPβ may include suppression of 
neuronal stem cell differentiation in favor of glial differentiation (Kwak et al., 2006), but 
these have not been well characterized either from a physiological or pathological 
perspective.
1.8.4	 AICD and C31
In addition to secretases, APP is subject to cleavage at its C-terminal end by caspases 
to release a second 31-amino-acid-long neurotoxic fragment, termed C31, as well as 
membrane-bound APPΔC31. Relatively little is known about the physiological role of 
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C31 in cells. Most of its speculated functions have been inferred from studies done on 
the APP intracellular domain. Two critical sites have been identified on the C-terminus 
of APP:
The first one is a threonine residue at position 668 (APP695 numbering), which has been 
shown to be phosphorylated by several kinases, including cyclin-dependent kinase 5 
(Cdk5), c-Jun N-terminal kinase 3 (Jnk3) and glycogen synthase kinase 3β (Gsk3β) 
(Iijima et al., 2000; Kimberly et al., 2005; Muresan and Muresan, 2005a). It is not clear 
what the role of this phosphorylation event is, but it has been implicated in the 
regulation of APP to the growth cones and neurites at the nerve terminals (Ando et al., 
1999; Muresan and Muresan, 2005a, b). More importantly, it has been shown that the 
Threonine668 phosphorylated fragments are increased in AD, but not in control brains, 
and that phosphorylation may facilitate BACE1 cleavage of APP (Lee et al., 2003). How 
this phosphorylation event relates to APP cleavage at D664 and C31 production 
remains unclear. Increased levels of C31 have been detected in AD compared to control 
brains (Zhao et al., 2003), but paradoxically, a recent report showed that APP 
phosphorylated at threonine668 was less vulnerable to cytoplasmic caspase-cleavage at 
D664 (Taru et al., 2004).
The second critical site is a highly conserved domain found on all three APP family 
genes, which has been identified as the YENPTY motif. This motif has been shown to 
be required to allow interactions between the C-terminal of APP with various adaptor 
proteins, including Mint-1/X11a (and the family members Mint-2 and Mint-3), Fe65 (as 
well as Fe65-like proteins, Fe65L1 and Fe65L2) and c-Jun N-terminal kinase (JNK)-
interacting protein (JIP), through the phosphotyrosine-binding (PTB) domain (Ando et 
al., 1999; Kimberly et al., 2005; Ramelot and Nicholson, 2001). Of particular interest is 
the interaction of APP C-terminal fragments with Fe65. APP intracellular C-terminal 
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domain (AICD) fragment (C57/C59) has been demonstrated to induce transcriptional 
activation in combination with Fe65 and Tip60, a histone acetyltransferase, using a 
reporter gene system (Cao and Sudhof, 2001). Interestingly, C31 was also shown to be 
able to induce expression of genes, and one of the genes identified was Gsk3β (Kim et 
al., 2003). In addition to driving Gsk3β expression, they demonstrated that both AICD 
and C31 could not only induce cell death, but could also induce phosphorylation of Tau 
(AT8) which are two hallmarks associated with AD. Several other studies have 
confirmed the toxic effects of C31 in wide array of cells, including PC12, N2a, neuronal 
and glial cells (Galvan et al., 2006; Kim et al., 2003; Lu et al., 2000). Interestingly, there 
is some debate as to whether or not it is C31 that specifically causes these effects or 
whether they are due to the cleaved C-terminus of APP (APPΔC31). There are 
published reports that cells devoid of APP, such as the B103 mouse neuroblastoma cell 
line, are inherently resistant to C31, but succumb to its toxic effects once wild type APP 
is transfected back in, with APPΔC31 having no effect (Lu et al., 2003b). However, 
another earlier study had reported that adenovirus mediated over-expression of 
APPΔC31 was sufficient to induce apoptosis in a variety of cell lines, including NT2, 
COS-1 and HeLa cells (Nishimura et al., 2002).
The most compelling argument for the link between AD and APP cleavage at 
aspartate664 (D664) however, comes from studies performed on a modified transgenic 
APP mouse line (J20). These mice express a mutated form of APP, which, in addition to 
the Swedish and Indiana mutations, also carry a mutated C-terminus (D664A). 
Surprisingly, these mice exhibit none of the effects seen in their J20 counterparts and 
perform just as well as their wild-type littermates: LTP impairments are completely 
blocked, cognitive and behavioral deficiencies are completely absent, and astrogliosis 
and more importantly dendritic spine loss are significantly abrogated. Interestingly, all of 
these effects are prevented in spite of unaltered levels of secreted Aβ, Aβ deposition 
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and plaque load (Galvan et al., 2006; Saganich et al., 2006). These results suggest that 
D664 cleavage of APP may be, at least in part, responsible for disrupting cellular signals 
controlling synaptic integrity. Concordantly, a recent report from the Bredesen 
laboratory has revealed a significant increase in nuclear p21-activated kinase (isoforms 
1,2 and 3; PAK1/2/3) activation in the hippocampus of 3 month old J20 mice, compared 
to non-transgenic littermates, an effect that is completely prevented in the modified J20 
D664A mice. In contrast, 13 month old J20 mice displayed a significant decrease in 
PAK1/2/3 activity, which was not observed in the J20 D664A mice (Nguyen et al., 2007). 
These findings are consistent with the hypothesis that dysregulation of certain signaling 
pathways observed in AD, may in fact require caspase-mediated cleavage of APP at 
D664, specifically in the case of PAK signaling, which interestingly is an important 
modulator of dendritic spine maintenance, downstream of the Rho GTPase, Rac1.
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CHAPTER 2: PERSPECTIVES AND OBJECTIVES OF THE PRESENT STUDY
2.1	 Is APP a receptor?
When the amyloid precursor protein (APP) was cloned in 1987 (Kang et al., 1987), it was 
originally observed that APP possessed many of the characteristics of a typical 
transmembrane receptor (discussed earlier), which raised the possibility that APP could 
initiate a signal transduction cascade through an unidentified ligand. To date, the 
evidence to support this idea remains scarce, as no clear and definitive candidate has 
emerged as the major ligand responsible for triggering an APP-mediated signaling 
cascade. Nevertheless, several molecules have been found to bind the ectodomain of 
APP; these include metal ions such as copper and zinc (Bush et al., 1993; Hesse et al., 
1994), as well as several components of the extracellular matrix, such as collagen 
(types I and IV), heparan sulfate proteoglycan, heparin, laminin and glypican (Beher et 
al., 1996; Caceres and Brandan, 1997; Williamson et al., 1996), among several others. 
As we summarized earlier, the discovery of these binding partners lend support to many 
of the proposed physiological functions for APP --e.g. to facilitate the transport of metal 
ions or to promote cell to cell adhesion (reviewed by Thinakaran and Koo, 2008). 
Interestingly, it was discovered that the cell-adhesion-promoting functions of APP were 
mediated through intercellular (trans-configuration, Figure 2-1B) homo- and hetero-
complexes of the APP family proteins (Soba et al., 2005). Furthermore, in addition to the 
intercellular interactions, it was found that the APP and APLP2 proteins could also 
interact in an intracellular manner (cis-configuration, Figure 2-1A). 
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The physiological significance of this latter type of interaction has so far remained 
elusive. However, it has been well described that in mammalian cells, the most common 
mechanism of signal transduction activation for single-pass transmembrane proteins 
occurs through a ligand-mediated shift in the monomer/dimer equilibrium (reviewed by 
Ullrich and Schlessinger, 1990). Indeed, in addition to monomeric proteins, dimeric and 
tetrameric forms have been isolated for both isolated and full length APP (Gralle et al., 
2006; Scheuermann et al., 2001; Wang and Ha, 2004). This has led many to 
hypothesize that the receptor function of APP and its ability to trigger a signal 
transduction cascade may be linked to its oligomerization state. More importantly, 
several pieces of data have suggested that disruption of the oligomerization state of 
APP could play a role in the pathology of AD (Gralle et al., 2009; reviewed by Khalifa et 
al., 2010; Soba et al., 2005). Indeed, evidence of dimerization of proteins as a 
pathological mechanism in neurodegenerative processes has been demonstrated in 
current models of the prion protein’s (PrP) role in scrapie pathogenesis, where 
Figure 2-1. Schematic illustration of cis- and trans-interaction 
of APP family proteins
The N-terminal E1 domain is linked to a highly flexible acidic region, 
followed by the alternatively spliced Kunitz-type protease inhibitor 
(KPI) domain (for APP and APLP2), the E2 domain, the 
juxtamembrane/TM region, and the cytosolic domain. Based on our 
results, we suggest that APP family proteins are capable of forming 
lateral and adhesive dimers in homo- and heterotypic fashions. The 
E1 domain is crucial for both cis- (A) and trans-interactions (B), 
while the TM region could additionally contribute to lateral 
dimerization. (Adapted from Soba et al., 2005)
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oligomeric forms of PrP are believed to facilitate a more rapid conversion of PrPc to 
PrPsc (Priola et al., 1995; Turk et al., 1988). Could a similar mechanism be in play in AD 
pathogenesis as well? Is APP at the center of a pathogenic loop?
2.2 Why does Aβ increase with aging and is APP signaling a factor?
It is generally believed that both EOFAD and LOAD share a common pathological 
mechanism, with the Aβ peptide being at the center of it all. With the discovery of the 
many autosomal dominant mutations in APP and presenilins, we have a fairly detailed 
understanding of why Aβ levels are elevated in EOFAD. However, in LOAD, in spite of 
considerable advances in understanding the pathogenesis of AD, one critical question 
continues to pose a significant challenge: why do Aβ levels, especially oligomeric Aβ, 
increase in the brains of AD patients that have no mutations in the APP or secretase 
genes? As we have discussed above (Section 1.7.2), the discovery of several risk-factor 
genes has shed some light on the matter, illustrating several potential pathways leading 
to an imbalance in the levels of Aβ. However, as we have also pointed out, since age 
remains by far the highest risk factor for AD, what is the link between these two factors, 
i.e. aging and Aβ levels? 
It is often argued, supported by a wealth of evidence (reviewed in Zhang and Xu, 2007), 
that the elevated levels of Aβ in AD are due to increased processing by either or both of 
the secretases, notably β- and γ-secretases. Yet, maintaining physiological levels of Aβ 
requires a finely tuned equilibrium between two seemingly independent processes: 
production and clearance (reviewed in De Felice and Ferreira, 2002). This is the basis 
for many alternative suggestions that the abnormal increases in cerebral Aβ may be 
completely independent of the direct metabolism of APP itself. For example many have 
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hypothesized that increases in Aβ levels represent rather a deficiency in the proteases 
that physiologically degrade Aβ, such as neprilysin and insulin-degrading enzyme (IDE), 
allowing the accumulation of the peptide (Farris et al., 2007; Selkoe, 2001).
Alternatively, the tight relationship between trafficking and processing of APP have 
raised the possibility of a link between cholesterol levels and LOAD, supported by the 
discovery of the lipid transport protein apoE as a risk factor for AD (allele ε4). As an 
illustration of that idea, lowering plasma cholesterol levels with statins was reported to 
contribute to decreasing the risk of dementia (Jick et al., 2000). Cholesterol could affect 
the trafficking and the affinity of APP for the secretases, thereby influencing the release 
of Aβ (Kojro et al., 2001). Cerebral trauma is also a known risk factor for dementia 
(Jellinger, 2004), raising the possibility that short-term post-injury regenerative 
processes could lead to long-term neurodegeneration. In this regard, a relevant 
observation is that traumatic brain injuries in mice directly lead to increased --perhaps 
adaptive-- expression of APP and to the deposition of Aβ (Blasko et al., 2004; Roberts 
et al., 1991; Roberts et al., 1994). Finally, in different mouse models, deficiencies in 
trophic factors, such as nerve growth factor (NGF) have been reported to cause 
neuronal degeneration and increase production of Aβ as a secondary consequence 
(reviewed in Isacson et al., 2002).
Ultimately, whether it is driven by cholesterol imbalance or by traumatic brain injuries, it 
is clear that several factors directly or indirectly affect APP processing and Aβ 
production. Moreover, the evidence strongly suggests that the increased Aβ burden 
plays a causative role in dementia, specifically AD. This raises an important question: 
does APP signaling affect APP processing and Aβ production?
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2.3	 Aims of the current study
In the chapters that will follow, we will describe a series of experiments which were 
designed to investigate whether APP signaling plays a pathogenic role in Alzheimer’s 
disease. We will present evidence suggesting that aberrant signaling through 
dimerization of cell-surface APP may play an important role in the pathogenesis of 
Alzheimer’s disease (AD). Our data will show that dimerization of APP is sufficient to 
affect survivability and to alter normal synaptic functions in hippocampal neurons. 
Additionally, we will demonstrate that dimerization of APP may be an important factor in 
how the processing of APP itself is regulated. We will show that dimerization of APP in 
hippocampal neurons is sufficient to initiate amyloidogenic processing of APP, resulting 
in increased production of the β-amyloid peptide.
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CHAPTER 3: MATERIALS AND METHODS
3.1	 SDS-PAGE and Western blotting
After treatments, cells were rinsed twice with ice-cold PBS and harvested in 1x RIPA buffer 
(Pierce; Rockford, IL), supplemented with HaltTM Protease and Phosphatase Inhibitor Cocktails 
(Pierce; Rockford, IL). Samples were incubated on a shaker for 20 minutes at 4°C and then 
briefly sonicated on ice before being centrifuged for 20 minutes at 14K rpm at 4°C. Protein 
concentrations were determined using the BCA Protein Assay Reagent kit (Pierce; Rockford, IL) 
according to the manufacturer’s protocol. 
For SDS-PAGE, cell lysates containing 20-50 μg of total protein were boiled for 5 minutes and 
loaded on pre-cast NuPAGE® Novex 4-12% Bis-Tris gels (Invitrogen; Carlsbad, CA). Proteins 
were transferred onto PVDF or nitrocellulose membranes (Millipore Corporation; Bedford, MA). 
Primary antibodies were diluted in SuperBlock® blocking buffer in TBS (Pierce; Rockford, IL) 
containing 0.1% (v/v) Tween® 20 (Sigma; St Louis, MO). Horseradish peroxidase (HRP)-
conjugated secondary antibodies [goat anti-mouse-HRP, goat anti-rabbit-HRP (1:3000; Cell 
Signaling Technology; Beverly, MA) and donkey anti-goat-HRP (1:2000; Santa Cruz 
Biotechnology, Inc; Santa Cruz, CA)] were diluted in TBS-T [50 mM Tris, pH 8.0; 150 mM NaCl 
and 0.1% (v/v) Tween® 20] containing 5% (w/v) non-fat dry milk (Bio-Rad Laboratories; Hercules, 
CA). Chemiluminescence was detected using ImmobilonTM Western chemiluminescent HRP 
substrate (Millipore Corporation; Bedford, MA). Autoradiography was carried out using BiomaxTM 
MR films (Eastman Kodak; Rochester, NY).
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3.2 	 Densitometry and statistics
All Western blot scans and DNA gel images were quantified using the free image processing and 
analysis software Image J (National Institute of Health; Bethesda, MD). Statistical analysis was 
performed using the statistics package GraphPad Prism®.
3.3 	 Antibodies
Anti-APP N-terminal mouse antibody (mAb) 22C11 (1:4000; Millipore Corporation; Bedford, MA); 
anti-Aβ mAb 4G8 (1:4000; Millipore Corporation; Bedford, MA); anti-APP C-terminal mAb 
(1:1000; Millipore Corporation; Bedford, MA); anti-Aβ mAb 6E10 (1:2000; Millipore Corporation; 
Bedford, MA); anti-APPΔC31 rabbit antibody (rAb) [1:2500; a gift from E. Koo at the Scripps 
Institute in La Jolla, CA (Galvan et al., 2002)]; anti-PSD-95 rAb (1:1000; Cell Signaling 
Technology; Beverly, MA); anti-Drebrin A rAb (1:1000; Sigma; St Louis, MO); anti-BACE1 rAb 
(1:1000; Abcam; Cambridge, MA); anti-GGA3 rAb (1:1000; Cell Signaling Technology; Beverly, 
MA); anti-caspase-3 rAb (1:1000; Cell Signaling Technology; Beverly, MA); anti-cleaved-
caspase-3 rAb (1:1000; Cell Signaling Technology; Beverly, MA); anti-sAPPβ mAb (1:4000; 
Millipore Corporation; Bedford, MA); anti-IDE rAb (1:1000; Abcam; Cambridge, MA); anti-
neprilysin rAb (1:1000; Millipore Corporation; Bedford, MA); anti-ERK1 rAb (1:1000; Santa Cruz 
Biotechnology, Inc; Santa Cruz, CA); anti-GAPDH mAb (1:1000; Abcam; Cambridge, MA); anti-
dendra2 rAb (1:1000; Evrogen; Moscow, Russia); anti-cleaved-Notch rAb (1:1000; Cell Signaling 
Technology; Beverly, MA); anti-Aph-1 rAb (1:1000; Santa Cruz Biotechnology, Inc; Santa Cruz, 
CA); anti-HA-tag rAb (1:1000; Cell Signaling Technology; Beverly, MA); anti-EEA1 mAb (1:1000; 
Abcam; Cambridge, MA); anti-PS1 mAb (1:1000; Abgent; San Diego, CA); anti-βIII-tubulin mAb 
TUJ1 (1:1000; Covance; Princeton, NJ).
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3.4	 Hippocampal neuron cultures
Hippocampal neuron cultures were prepared following a slightly modified version of the 
previously described Brewer method (Brewer et al., 1993). Briefly, fetuses at embryonic day 18 
(E18) from timed pregnant Sprague-Dawley rats (Taconic Farms; Hudson, NY) were sacrificed 
and the hippocampi removed and collected in room temperature Hank’s balance salt solution 
(HBSS-; Invitrogen; Carlsbad, CA), supplemented with 0.6% (w/v) glucose (HBSS+).  The 
hippocampi were then incubated in 0.25% trypsin (Invitrogen; Invitrogen; Carlsbad, CA) for 15 
minutes at 37°C and washed (10 minutes, x3) with HBSS+. Finally, the neurons were dissociated 
in Neurobasal® medium (Invitrogen; Carlsbad, CA) supplemented with B27 supplements and 
GlutamaxTM-1 (Invitrogen; Carlsbad, CA), and plated at a density of 2.5x105 cell/ml on dishes 
coated with poly-L-lysine (Sigma; St. Louis, MO). The resulting neuronal cultures consists of a 
population enriched in large pyramidal neurons that constitute the main initial target in AD 
pathogenesis. For our experiments, neurons were used after approximately 14-21 days in vitro 
(DIV).
3.5	 Cell-line cultures
Human embryonic kidney 293 (HEK 293) and murine neuroblastoma B103 cells were cultured 
and maintained in Dulbecco’s Modified Eagle Medium (DMEM; I Invitrogen; Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS; Invitrogen; Carlsbad, CA) and 10% FBS + 5% 
horse serum (HS; Invitrogen; Carlsbad, CA) respectively. For stably transfected B103 cells 
expressing APP, the media was supplemented with 50 μg/ml Geneticin (Invitrogen, Invitrogen; 
Carlsbad, CA).
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3.6 Preparation of Aβ oligomers
Aβ oligomers were prepared as previously described by Barghorn (Barghorn et al., 2005). Briefly, 
lyophilized synthetic Aβ42 peptide (American Peptide; Sunnyvale, CA) was allowed to equilibrate 
to room temperature for 30 minutes and resuspended in 1,1,1,3,3,3-hexafluoro-2-propanol 
(HFIP; Sigma; St. Louis, MO) to 1.0 mM using a glass gas-tight Hamilton syringe with a Teflon 
plunger. After evaporating the HFIP in the hood, the resulting clear peptide film was dried under 
vacuum in a SpeedVac® for about 1 hour. The peptide was then resuspended to 5.0 mM in 
anhydrous dimethylsulfoxide (DMSO; Sigma; St. Louis, MO) by pipette mixing followed by bath 
sonication for 10 minutes and aliquoted. Each 5.0 mM Aβ42 aliquot in DMSO was diluted with 
cold Neurobasal medium to a final concentration of 100 μM and incubated at 4°C for 24 hours. 
The preparation was centrifuged at 3000g for 20 minutes at 4°C before using.
3.7	 Peptide and oligonucleotide delivery into cells
Peptides were synthesized and purified at the Stanford University Proteins and Nucleic Acid 
(PAN) Facility. Oligonucleotide sequences were custom ordered (Dharmacon; Lafayette, CO) with 
a thiol functionality at the 5’-end. Peptide and ologonucleotide stocks were solubilized in water 
at 1.0 or 10 mM concentration. The delivery peptide derived from the Drosophila Antennapedia 
homeodomain (CRQIKIWFQNRRMKWKK), also called penetratin-1TM (MP Biomedicals; Irvine, CA), was 
cross-linked via a Cys-Cys bond to the desired peptide or the oligonucleotide as previously 
described (Davidson et al., 2004).
3.8	 Peptide and oligonucleotide sequences
C31 sequences: AAVTPEERHLSKMQQNGYENPTYKFFEQMQNC [C31]; AAVTPEERHLSKMQQNGAENATYKFFEQMQNC 
[ G 6 8 1 / P 6 8 5 ; C 3 1 m ] ; A P P s i R N A : 5 ’ - U U G G C C A A G A C A U C G U C G G d A d G - 3 ’ [ s i 1 ] ; 5 ’ -
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UGCAUUUGCUCAAAGAACUTdG-3’ [si2]; 5’-UGCAGUUGCGCAACGAACUTdG-3’ [APP mis-match]. Caspase-3 
siRNA: 
3.9	 Generation of Fab fragments of 22C11
Fab fragments of 22C11 were prepared using the Pierce Fab micro preparation kit (Pierce; 
Rockford, IL) following the manufacturers instructions.
3.10 Quantification of Aβ by ELISA
Media and lysates were collected from treated and control hippocampal neurons and 
centrifuged for clarification at 14K rpm for 2 minutes at 4°C prior to analysis. Levels of Aβ were 
determined using an ELISA kit (Covance; Princeton, NJ) according to the manufacturer’s 
protocol.
3.11	 DiOlistic labeling of neurons
3.11.1	 Preparation of gene gun bullets
This protocol was adapted from Gan and Grutzendler (Gan et al., 2000). Briefly, 100 mg of 
tungsten particles (1.1 µm diameter; Bio-Rad Laboratories; Hercules, CA) were thoroughly 
precipitated with 5.0 mg of lipophilic dye (DiI, DiO or DiD; Invitrogen; Carlsbad, CA), and 
dissolved in 100 µl of methylene chloride. For single labeling of neurons, only DiO was used. 
After drying on the glass slide, the particles were collected in a test tube with 3 ml dH2O and 
subsequently placed in a sonicating water bath for 20 minutes. The solution was vortexed for a 
few seconds and injected into Tefzel tubing (Bio-Rad Laboratories; Hercules, CA) previously 
treated with 10 ml polyvinylpyrrolidone (PVP360; Sigma; St. Louis, MO) to improve particle 
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attachment to the tubing. The tube was then inserted into a tubing preparation station (Bio-Rad 
Laboratories; Hercules, CA) and after a 30-minute rotation period, the solution was slowly 
withdrawn. The particle-coated tube was then rotated and air-dried under a constant nitrogen 
flow (0.4 liter/min) for a further 30 minutes or until the tubing was dry. The tube was cut into 
small bullets (13 mm) and stored in a desiccated container at room temperature for up to one 
month. 
3.11.2	 Delivery of dye-coated particles
Dye-coated particles were shot into the cells using the Helios gene gun system (165-2431; 
BioRad Laboratories; Hercules, CA). To aid dye dispersion and prevent large particles from 
landing on the cells, a custom fabricated filter holder using a membrane with 3 µm diameter 
holes (TSTP04700; Millipore; Corporation; Bedford, MA) was placed between the gun and the 
cells. The cells were shot 2 to 3 times, depending on their density at a constant pressure of 150 
psi, and left in 0.1 M PBS overnight to allow dye diffusion along neuronal processes. Cells were 
post fixed with 4% paraformaldehyde (PFA; Pierce; Rockford, IL) for 1 hour to preserve staining 
then mounted onto glass slides using Gel MountTM (Biomeda Corporation; Forster City, CA) and 
stored at 4°C in the dark.
3.11.3	 Spine imaging
Labeled neurons were imaged using the Laser Scanning Microscope (LSM) 510 Meta confocal 
microscope (Zeiss), equipped with 40X 1.3 NA and a 100X 1.4 NA oil immersion objectives. 
Scanning used three excitation lines of the argon laser (488 nm for DiO, 568 nm for DiI and 647 
nm for DiD) with three separate barrier filter sets (522 ± 35 nm for DiO, 580 ± 32 nm for DiI, and 
680 ± 32 nm for DiD). Z stacks were collected at 1 µm intervals to cover the full depth of the 
neuronal dendritic trees (20, 30 µm) and then compressed into a single image. 
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3.11.4	 Spine analysis, quantification and statistics
The NIH image software program Image J was used the quantify DiO labeled cultured neurons. 
An average of 8 compressed images (20 µm thick) consisting of pyramidal neurons in the 
hippocampus were quantified for each treatment. The NIH image software program gave two 
parameters: Number of puncta per 100 µm of dendrite and total dendrite area. Puncta included 
both spines and boutons along and around the dendritic trees of neurons. Cell bodies were 
blocked out so that only spines and dendrites were quantified. Statistical analysis was 
performed using the statistics package GraphPad Prism®.
3.12	 Assessment of cell death
Cell death was assayed using the LIVE/DEAD® Cell Viability Assay kit (Invitrogen, Carlsbad, CA) 
following the manufacturer’s protocol. After the appropriate treatments, cells were treated with a 
solution containing 2.0 µM calcein AM and 4.0 µM Ethidium homodimer 1 (EthD-1) in PBS for 30 
minutes. After washing off the solution, cells were directly analyzed without fixing. Live cells are 
distinguished by the presence of ubiquitous intracellular esterase activity, determined by the 
enzymatic conversion of the virtually non-fluorescent cell-permeant calcein AM to the intensely 
fluorescent calcein. The polyanionic dye calcein is well retained within live cells, producing an 
intense uniform green fluorescence in live cells (ex/em ~495 nm/~515 nm). EthD-1 enters cells 
with damaged membranes and undergoes a 40-fold enhancement of fluorescence upon binding 
to nucleic acids, thereby producing a bright red fluorescence in dead cells (ex/em ~495 nm/~635 
nm). EthD-1 is excluded by the intact plasma membrane of live cells.
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3.13 γ-Secretase activity assay
γ-Secretase activity was assayed adapting the previously described protocols (Hansson et al., 
2006). Briefly, γ-secretase activity in hippocampal neurons was detected as AICD-myc formation 
using as substrate C99-myc derived from HEK293 cells transfected with a C99-myc plasmid 
(Appendix A). CHAPS-solubilized (20 mM HEPES, pH 7.0; 150 mM KCl; 2.0 mM EGTA; 1.0% 
CHAPS and 2x protease inhibitor cocktail) HEK293 cells were incubated together with 
solubilized 22C11-treated and untreated hippocampal neuron membranes (1:1 ratio) at -20°C or 
37°C with or without the γ-secretase inhibitor (DAPT; 1.0 μM) for 2 hours. AICD fragments were 
detected by Western blot analysis using an anti-myc rAb (Cell Signaling Technology; Beverly, 
MA).
3.14	 NucView caspase-3 activity assay
Caspase-3 activity in hippocampal neurons was assessed with the NucViewTM 488 Caspase 
Detection kit (Biotium Inc.; Hayward, CA) following the manufacturer’s protocol. Briefly, 
hippocampal neurons cultured in chamber slides were treated with a 5.0 μM solution of the 
NucView caspase-3 substrate for 30 minutes. Cells were then fixed with 4.0% paraformaldehyde 
(Pierce, Rockford, IL), mounted and observed under a fluorescence microscope using a 
fluorescein isothiocyanate (FITC) filter.
3.15	 Immunocytochemistry
Hippocampal neurons grown in chamber slides were treated with 22C11 (100 ng/ml) only or 
22C11 (100 ng/ml) and Penetratin-1-linked-siCasp3 (80 nM) for 8 hours. After fixing with 4.0% 
paraformaldehyde (Pierce, Rockford, IL) cells were permeabilized with 0.5% Triton® X-100 
(Sigma; St. Louis, MO) in PBS and incubated the anti-BACE1 rAb (1:1000; Abcam; Cambridge, 
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MA) and anti-EEA1 mAb (1:1000; Abcam; Cambridge, MA) overnight. Anti-mouse and anti-rabbit 
secondary antibodies conjugated with Alexa® Fluor dyes (1:1000; Invitrogen; Carlsbad, CA) 
were used. Labeled neurons were imaged using the Laser Scanning Microscope (LSM) 510 Meta 
confocal microscope (Zeiss), equipped with 40X 1.3 NA and a 100X 1.4 NA oil immersion 
objectives. Scanning used two excitation lines of the argon laser (488 nm for Alexa Fluor-488, 
568 nm for Alexa Fluor-568). Z stacks were collected at 1.0 µm intervals and then compressed 
into a single image for analysis using the Volocity® Imaging software (Volocity® Acquisition and 
Volocity® Visualization; Perkin-Elmer; Waltham, MA).
3.16	 Isolation of cell-surface proteins
Cell surface proteins were biotinylated using the EZ-Link® NHS-PEO4 reagent (500 μg; Pierce; 
Rockford, IL) according to the manufacturer’s protocol. Biotinylated proteins were precipitated 
using Dynabeads® M-280 Streptavidin beads (Invitrogen; Carlsbad, CA). Biotinylated proteins 
were resolved by SDS-PAGE and immuno-blotted with the appropriate antibodies.
3.17	 Cross-linking of cell-surface APP with 22C11
HEK293 cells (6-well dish; ~106 cells) were transiently transfected with 4.0 μg of APP-dendra2 
plasmid (Appendix A) with LipofactamineTM 2000 reagent (Invitrogen; Carlsbad, CA). 48 hours 
after transfections, the culture medium was removed and replaced with a 5.0 μg/ml solution of 
22C11 and incubated at 4°C. After 2 hours, the solution was removed, the cells washed with ice-
cold PBS and incubated with the cross-linker DTSSP (25 mM; Pierce; Rockford, IL) for 1 hour at 
4°C. After quenching the reaction with 1 M Tris-HCl, cells were washed with ice-cold PBS (x3) 
and harvested in RIPA buffer (2-wells were pooled for each set of conditions). Cross-linked APP 
was immunoprecipitated and immuno-blotted with anti-dendra2 rAb. 
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3.18	 Cycloheximide degradation time-course assay
Hippocampal neurons were treated with cycloheximide (CHX; 150 μM) only or with 22C11 (100 
ng/ml) and CHX (150 μM) over an 18-hour time course. Lysates from each time time were 
immuno-blotted with the specific antibody for BACE1 (1:1000; Abcam; Cambridge, MA).
3.19	 qRT-PCR
To quantify mRNA levels, mRNA from 22C11-treated and untreated cells was isolated using the 
TRIzol® plus reagent (Invitrogen; Carlsbad, CA). Reverse transcription was carried out using 
SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen; Carlsbad, CA). Real-time 
PCR was done using the SYBR Green method. The following primer pair for BACE1 were used F: 
5’-CAGCTCTGTGGCGCTGGCTT-3’ R: 5’-CCAGCACACCAGCTGCTCCC-3’.
3.20	 Transfections and plasmids
Plasmids (sequences in Appendix A) used in these studies include the following: pcDNA3.1-
dendra2 was a kind gift from Jordi Magrane at Cornell Universiry; pSG5L-Flag-HA-GGA3 
(11185; Addgene; Cambridge, MA) was originally cloned by the Sellers Laboratory (Harvard 
university; Boston, MA). Wild-type C99 cDNA was cloned into pcDNA3.1 (Invitrogen; Carlsbad, 
CA) with a Myc-tag fused at the C-terminal end of C99 (Appendix A).
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CHAPTER 4: NEUROTOXIC AND SYNAPTOTOXIC EFFECTS OF THE 
DIMERIZATION OF CELL-SURFACE APP IN HIPPOCAMPAL NEURONS
4.1	 Introduction
In spite of the wealth of evidence pointing towards the existence of naturally occurring 
multimeric forms of APP on the cell surface (Gralle et al., 2006; Scheuermann et al., 
2001; Wang and Ha, 2004), their physiological function(s) remain unclear. So far, the 
aggregation of cell-surface APP and APLPs has only been implicated in cell-cell binding 
(Soba et al., 2005) but, being a type I trans-membrane protein, APP has also been 
postulated to be involved in signal transduction (reviewed by Ullrich and Schlessinger, 
1990). Unfortunately, while many molecules and proteins have been shown to bind to 
APP (Section 2-1), it is not known whether or not they influence the monomer/multimer 
equilibrium of cell-surface APP nor the pathways that are activated either in a 
physiological or a pathological context, such as in AD. Interestingly, soluble and 
insoluble aggregated forms of the Aβ peptide itself have been proposed as a potential 
ligand for APP in a pathologic context, able to induce apoptosis in cells upon their 
interaction at the cell surface (Lorenzo et al., 2000; Lu et al., 2003a; Shaked et al., 
2006). While the exact mechanism is not known, it has been proposed that APP-
dependent Aβ toxicity involves the facilitation of APP multimerization at the cell surface 
by aggregated Aβ. Indeed, cells lacking APP are resistant to the neurotoxic effects of 
Aβ (Lu et al., 2003b; White et al., 1998). In this proposed mechanism, aggregated Aβ 
interacts directly with cell-surface APP to facilitate APP homo-oligomerization by 
binding to its homologous sequence (amino acids 597-624 of APP695; Figure 1-8C) on 
the extracellular domain of APP (Lu et al., 2003a; Shaked et al., 2006). However, the 
specificity of Aβ binding to APP remains a controversial subject. As we reviewed earlier, 
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a wide variety of cell-surface proteins have been identified as not only binding partners 
for Aβ, but as being required for its neurotoxic effects (reviewed in section 1.7.3.1).The 
promiscuous nature of Aβ binding has made isolating the specific signaling pathway(s) 
triggered by Aβ binding to APP a challenging endeavor.
In order to bypass the absence of a known ligand for APP and to overcome the high 
propensity of Aβ to bind other receptors, we opted for an antibody-mediated approach 
to study APP signaling in neurons. The bivalent nature of most antibodies (Figure 4-1A) 
makes them ideal candidates to facilitate multimerization of receptors at the cell-
surface, such as APP (Figure 4-1B). This approach afforded us two key advantages. 
First, no chemical modifications of APP were required, allowing us to study the effects 
of endogenous APP in its intact native form. Second, using an APP antibody allowed us 
to target a specific region of the APP molecule, notably the E1 domain, which has been 
shown to be important for its dimerization (Soba et al., 2005). In the present chapter, we 
show the effectiveness of the commercially available mouse monoclonal antibody 
directed against amino acids 66-81 of the E1 domain of the N-terminus of APP (clone 
22C11; Hilbich et al., 1993) to alter the state of surface APP multimers in cultured cells. 
We demonstrate that this antibody triggers apoptotic death at high concentrations and 
synaptic alterations at low concentrations in hippocampal neurons, in an APP 
dependent manner. Our data suggests that dimerization of cell-surface is sufficient to 
trigger one or more signaling pathways ending in cell death and synaptic dysfunction in 
hippocampal neurons, indicating that APP signaling may play an important role in AD 
pathogenesis.
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Figure 4-1. Strategy for inducing dimerization of APP in cultured cells
(A) Schematic representation of the general structure of divalent antibodies, with two antigen-binding sites. (B) 
Illustration showing the dimerization of APP at the cell surface by the divalent antibody directed at amino acids 
66-81 in the E1 domain of the N-terminal end of APP.
4.2 	 Results
4.2.1	 Divalent APP antibody 22C11 increases the sub-population of dimeric and 
tetrameric APP expressed on the cell surface
Our first objective was to examine whether the APP N-terminal antibody 22C11 could 
alter multimerization of APP at the cell surface. Low levels of surface APP in neurons 
forced us to employ an APP over-expressing model for those studies. B103 cells were 
transiently transfected with an APP construct, fused at its C-terminus with the 
fluorescent protein dendra2 (Gurskaya et al., 2006) to facilitate immunoprecipitation of 
the APP complexes with an anti-dendra2 antibody. Two days after transfection (Figure 
4-2C), the cells were incubated with 22C11 (5.0 μg) for two hours, followed by 
incubation with the homobifunctional, thiol-cleavable and membrane impermeable 
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cross-linker 3,3’-Dithiobis(sulfosuccinimidylpropionate) (DTSSP) in order to cross-link 
and stabilize any APP multimers within 8 Å of each other. Isolation of cross-linked APP 
by immoprecipitation followed by Western blotting analysis (Figure 4-2A) with the same 
dendra2 antibody, revealed an increase not only in dimeric but in tetrameric complexes 
of APP in cells incubated with 22C11 compared to control cells incubated with PBS 
(Figure 4-2B). Consistent with previous reports (Gralle et al., 2009; Scheuermann et al., 
2001), control cells also contained isolatable APP complexes in dimeric and tetrameric 
forms, suggesting that at least a sub-population of APP may exists as dimer and 
tetramers. To ascertain the identity of these higher molecular weight species, the 
immunoprecipitated complexes were treated with the reducing agent dithiothreitol (DTT) 
to cleave the cross-linker and release the cross-linked molecules. DTT treatment 
resulted in the disappearance of both upper bands, ~250 kDa and ~400 kDa (Figure 
4-2A), corresponding to dimeric and tetrameric APP respectively.
These results suggest that the N-terminal antibody 22C11 is capable of increasing 
oligomerization of cell surface APP in vivo in cultured cells. We could not test the 
antibody in cultured hippocampal neurons, but given the previously published reports of 
antibody-mediated dimerization of cell-surface receptors (Gralle et al., 2009; Mbebi et 
al., 2002), we felt confident that 22C11 was a viable means of increasing 
oligomerization of cell-surface APP in cultured neurons as well.
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Figure 4-2. Increased oligomerization of surface APP by the N-terminal antibody 22C11
B103 cells over-expressing APP-dendra2 were treated with N-terminal APP antibody 22C11 (5.0 μg) for 2 hours, 
followed by cross-linking with the dithiol cleavable cross-linker DTSSP. Immunoprecipitation of cross-linked APP 
complexes showed in enrichment in not only APP dimers, but of APP tetramers as well compared to control cells 
that were treated with PBS. (A) Representative Western blot showing increased APP dimers (~250 kDa) and 
tetramers (~400 kDa) after 22C11 incubation. The corresponding bands disappear after a 10 minute treatment with 
DTT prior to loading the gel (*non-specific band). (B) Densitometric analysis of the data was quantified from at least 
3 independent experiments and expressed as the mean+/-SEM (p=0.06 for APP dimers, **p=0.035 for APP 
tetramers) band intensity. (C) Representative Western blot showing the expression levels of APP-dendra2 in 
transfected B103 cells. 
4.2.2 Aβ42 induces dose-dependent neuronal death and synaptic dysfunction in 
hippocampal neurons
Recent evidence has suggested that Aβ oligomers are perhaps the main culprits in the 
pathology of AD (reviews by Caughey and Lansbury, 2003; Ferreira et al., 2007; Haass 
and Selkoe, 2007; Klein et al., 2001). Oligomeric preparations of synthetic Aβ42 (Figure 
4-3A) are highly toxic to hippocampal neurons at high concentrations (10 μM), reducing 
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the number of viable cells by ~50% after 24 hours of treatment (Figure 4-3B) and 
triggering marked neuritic dystrophy (Figure 4-3C). At low sub-apoptotic concentrations 
(300 nM), oligomeric Aβ42 triggers synaptic alterations after 24 hours in hippocampal 
neurons, characterized by a significant decrease by as much as ~55% in the density of 
dendritic spine (Figure 4-4A, B), as well as a reduction in the protein levels of the post-
synaptic markers PSD-95 (Figure 4-4C, D) and Drebrin A (Figure 4-4E, F), by ~30% and 
~40% respectively, both of which have been shown to be critical for proper dendritic 
spine maintenance and synaptic function (Ehrlich et al., 2007; Ivanov et al., 2009; Mizui 
et al., 2005; Takahashi et al., 2006).
Figure 4-3. Neurotoxic effects of Aβ oligomers on hippocampal neurons
(A) Representative Western blot showing the different Aβ species present in the oligomeric preparation described in 
the Materials and Methods section. (B) Treatment of hippocampal neurons for 24 hours with 10 μM of oligomeric 
Aβ resulted in a significant amount of cell death compared to control cells, treated with fresh Neurobasal medium. 
Cell death was quantified from at least 3 independent experiments and expressed as the mean+/-SEM (*p=0.012) 
number of viable cells per field. (C) Representative image showing significant neuritic dystrophy in neurons treated 
with 10 μM Aβ for 24 hours. 
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Figure 4-4. Effects of oligomeric Aβ on dendritic spines
Treatment of hippocampal neurons for 24 hours with a 300 nM solution of oligomeric Aβ resulted in a significant 
decrease in dendritic spine density, compared to control cells that were treated with fresh Neurobasal medium. 
Spine effects were measured by direct count of dendritic spines (A, B) and by measuring the levels of two dendritic 
spine markers, PSD95 (C, D) and Drebrin A (E, F). (A) Dendritic spines were quantified from an average of 12 
neurons from at least 3 independent experiments, and expressed as the mean+/-SEM (*p=0.023) number of spines/
μM. (B) Representative image showing a decrease in dendritic spines in Aβ-treated neurons compared to control 
neurons. (C, E) Representative Western blots showing a decrease in the synaptic markers PSD-95 and Drebrin A in 
Aβ-treated neurons. (D, F) Densitometric analysis of data was quantified from 3 independent experiments and 
expressed as the mean+/-SEM (*p=0.034 for PSD95; *p=0.013 for Drebrin A) band intensity.
The exact mechanism(s) by which Aβ initiates these effects remains unclear. Several 
lines of evidence have shown that dimerization of APP by Aβ may play a key role in Aβ-
induced toxicity (Lorenzo et al., 2000; Lu et al., 2003a; Shaked et al., 2006). We 
wondered whether the observed toxic effects were intrinsic properties of Aβ, or whether 
signaling through APP alone was a sufficient trigger. To address this question we tested 
73
whether oligomerization of APP by 22C11 could recapitulate the neurotoxic effects of 
oligomeric Aβ. Previous reports have demonstrated that 22C11 is highly toxic to 
cultured cortical neurons (Rohn et al., 2000). Nevertheless, we had two objectives. First, 
we wanted to confirm the neurotoxic effects of 22C11 on cultured hippocampal 
neurons. Second, we set out to establish a dose-response curve to identify a 
concentration at which the neurotoxic effects of 22C11 were minimized while still 
triggering synaptic alterations in these neurons. Synaptic dysfunction is thought to be 
one of the earlier events in the progression of AD, with neuronal death occurring at a 
later stage (Delaere et al., 1989; Terry et al., 1991). Our results are presented below.
4.2.3	 Hippocampal neurons treated with 22C11 undergo apoptosis
To establish a dose-response curve for the neurotoxic effects of 22C11, we treated 
cultured hippocampal neurons with various concentrations of 22C11 (100 pg/ml, 100 
ng/ml and 1.0 μg/ml) for 24 hours. A count for cell viability showed that 22C11 triggered 
neuronal death (~20%) starting at a concentration of 1.0 μg/ml. Lower concentrations of 
22C11 (i.e. 100 pg/ml and 100 ng/ml) did significantly not affect neuronal viability after 
24 hours (Figure 4-5A). The possibility remains however that these lower concentrations 
of 22C11 could be toxic after a longer exposure. As was previously reported (Rohn et 
al., 2000), we observed a significant amount of neuritic dystrophy in neurons exposed 
to toxic concentrations of 22C11 (Figure 4-5B), which was not apparent at the sub-
apoptotic concentrations (data not shown).
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Figure 4-5. Neurotoxic effects of 22C11 in hippocampal neurons
(A) Dose-response curve for hippocampal neurons over 24 hours with various concentrations of 22C11 showed a 
significant amount of cell death at 1.0 μg.ml compared to control cells, which were treated with PBS. Lower 
concentrations of 100 pg/ml and 100 ng/ml had no significant neurotoxic effects after 24 hours. Cell death was 
assessed with the LIVD/DEAD cell viability assay kit and quantified the from at least 3 independent experiments 
and expressed as the mean+/-SEM (*p<0.05) number of viable cells per field. (B) Representative image showing a 
significant amount of neuritic dystrophy in cells treated with 1.0 μg/ml of 22C11 for 24 hours.
4.2.4	 22C11-induced cell death is dependent on APP
To confirm that the effects of 22C11 were triggered by binding APP, we treated a murine 
neuroblastoma cell line B103, previously characterized (Schubert and Behl, 1993) as 
being devoid of APP and APLPs, with 22C11 (5.0 μg) for 24 hours. We found that these 
cells were completely resistant to the toxic effects of 22C11 (Figure 4-6A). One the 
other hand, B103 cells that stably expressed APP were found to be vulnerable to the 
effects of 22C11 after 24 hours (Figure 4-6A), confirming that APP is required for the 
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toxic effects of 22C11. These results suggest that 22C11 induces its toxic effects by 
specifically interacting with APP at the cell surface. We did not test whether APLP1 or 
APLP2 could restore the neurotoxic effects of 22C11 on B103 cells. While 22C11 is 
highly specific for APP, it has been shown to cross-react, albeit weakly with both APLP1 
and APLP2 (Wang et al., 2006). Therefore, it is possible that they may contribute as well 
to the toxic effects of 22C11 in neurons, which express APLPs.
4.2.5	 22C11-induced toxicity is dependent on its ability to dimerize cell surface 
APP
While the experiments described above suggest that APP is required for the toxic 
effects of 22C11, they do not address whether oligomerization of APP is also required. 
To tackle this question, we treated hippocampal neurons with isolated monovalent Fab 
fragments of 22C11 (5.0 μg/ml), which retain the ability to bind cell surface APP without 
being able to dimerize it. As expected, 22C11 Fab fragments had almost no effects on 
the treated neurons after 24 hours (Figure 4-6B), consistent with the idea that APP 
dimerization is essential for triggering the signaling pathway leading to observed 
toxicity.
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Figure 4-6. Neurotoxic effects of 22C11 require APP and are dependent on its ability to dimerize surface APP
(A) Treatment of B103 cells with a 5 μg/ml solution of 22C11 had no significant neurotoxic effects compared to 
control cells treated with PBS. Alternatively, similar treatment of B103 stably expressing APP resulted in a 
significant decreased in cell viability when compared to control cells treated with either PBS. Cell death was 
quantified from at least 3 independent experiments and expressed as the mean+/-SEM (***p<0.001 for B103APP 
cells) number of viable cells per field. (B) Treatment of hippocampal neurons with 2.5 μg of Fab fragments of 22C11 
did show any significant toxicity compared to the same concentration of the intact antibody. Cell death was 
quantified from at least 3 independent experiments and expressed as the mean+/-SEM (***p<0.001 for 22C11; 
**p=0.002 for 22C11-Fab) number of viable cells per field.
4.2.6	 Sub-apoptotic concentrations of 22C11 induce synaptic dysfunction in 
hippocampal neurons
Having confirmed that 22C11 is toxic to hippocampal neurons and having established a 
dose-response curve for it, we next set out to investigate whether a low concentration 
of 22C11 could mimic the synaptotoxic effects of sub-lethal levels of oligomeric Aβ42. 
To investigate this, hippocampal neurons were treated with a sub-apoptotic 
concentration of 22C11 (100 ng/ml) for 24 hours. A direct count of the number of 
dendritic spines revealed a significant decrease in their density, by as much as ~40%, in 
neurons treated with 22C11 compared to control neurons treated with PBS (Figure 
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4-7A, B). As was the case with Aβ (300 nM), the observed decline in overall spine 
numbers was accompanied by a corresponding reduction in the protein levels of the 
dendritic spine markers PSD-95 (Figure 4-7C, D) and Drebrin A (Figure 4-7E, F) after the 
24 hour period.
Figure 4-7. Effects of 22C11 on dendritic spines in hippocampal neurons
Treatment of hippocampal neurons for 24 hours with a 100 ng/ml solution of 22C11 resulted in a significant 
decrease in dendritic spine density, compared to control cells that were treated with PBS. Spine effects were 
measured by direct count of dendritic spines (A, B) and by measuring the levels of two dendritic spine markers, 
PSD95 (C, D) and Drebrin A (E, F). (B) Dendritic spines were quantified from an average of 12 neurons taken from at 
least 3 independent experiments, and expressed as the mean+/-SEM (**p=0.009) number of spines/μM. (C, E) 
Representative Western blots showing a decrease in the synaptic markers, PSD95 and Drebrin A in 22C11-treated 
neurons. (D, F) Densitometric analysis of the data was quantified from 3 independent experiments and expressed 
as the mean+/-SEM (**p=0.005 for PSD95; ***p<0.001 for Drebrin A) band intensity.
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4.2.7	 22C11-induced loss of dendritic spines is dependent on oligomerization of 
cell-surface APP
The fact that the monovalent Fab fragments of 22C11 had no demonstrable toxicity, 
suggests that dimerization of APP is necessary for the neurotoxic effects of 22C11. We 
set out to evaluate whether the effects of 22C11 on synaptic function were also 
dependent on the dimerization of APP. Again, hippocampal neurons were treated with 
the isolated Fab fragments of 22C11 (100 ng/ml) for 24 hours. As expected, we found 
no significant changes in dendritic spine density in neurons treated with the Fab 
fragments, whereas intact 22C11 reduced dendritic spine density by ~50%. Control cell 
treated with PBS had no adverse effects (Figure 4-8).
Figure 4-8. The effects of 22C11 on 
dendritic spines in hippocampal 
neurons are dependent on its ability 
to oligomerize cell-surface APP
Treatment of hippocampal neurons for 
24 hours with the Fab fragment of 
22C11 (100 ng/ml) showed no 
significant effects in dendritic spine 
density compared to the same 
concentration of the intact antibody. 
Dendritic spines were quantified from 
an average of 12 neurons taken from at least 3 independent experiments, and expressed as the mean+/-SEM 
(***p<0.001) number of spines/μM.
4.3	 Discussion
Much has been learned about APP since its discovery over 20 years ago (Kang et al., 
1987). However, many more questions have remained unanswered, particularly with 
regard to the role of the intact, full-length form of APP in AD pathology and in neuronal 
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plasticity. In fact, while the vast majority of synthesized APP is metabolized in various 
cell compartments, with the fragments being secreted or degraded (reviewed by Chow 
et al., 2009), a small proportion of transmembrane APP remains stably localized to the 
plasma membrane (Storey et al., 1999). Different lines of evidence have suggested a 
growth promoting (references) or cell-adhesion promoting (references) role for 
transmembrane APP due to its propensity to dimerize, reminiscent of tyrosine kinase 
receptors. This has led many to wonder whether perturbation of the APP monomer/
dimer equilibrium could play a role in AD. To investigate this problem, we employed an 
artificial system, making use of the divalent mouse monoclonal antibody (clone 22C11) 
to dimerize APP. This technique had previously been utilized to study similar effects in 
cortical neurons (Mbebi et al., 2002; Rohn et al., 2000); however in our studies we 
focused primarily on hippocampal neurons, since the hippocampus is one of the region 
that is most affected in AD (reviewed by Burger, 2010).
The usage of an antibody can be used to facilitate oligomerization of surface APP. 
Interestingly, similar to other published data (Gralle et al., 2009; Scheuermann et al., 
2001), we found that a large proportion of cell-surface APP could be isolated as dimers 
and tetramers under normal conditions, albeit in APP over-expressing cells. These APP 
complexes were isolated in larger quantities (especially tetrameric APP) in cells that had 
been treated with the antibody 22C11, suggesting that the antibody acts to stabilize 
preformed cell-surface APP oligomers, rather than inducing oligomerization per se of 
APP. Based on our results and other published data, we concluded that 22C11 is a 
viable method for artificially shifting the APP monomer/multimer equilibrium towards the 
higher APP aggregates.
Additionally, our results demonstrate that 22C11 can induce apoptosis in hippocampal 
neurons, as well as the previously reported cortical neurons (Rohn et al., 2000), 
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suggesting that shifting the APP oligomerization equilibrium was sufficient to activate 
one or more pathways leading to neuronal death. In contrast, we found no neurotoxic 
effects in neurons treated with the isolated Fab fragment of 22C11, supporting our 
hypothesis that oligomerization of APP by 22C11 is necessary for the observed 
neurotoxicity. Complementary evidence corroborating this model came from the work of 
Gralle et al., who showed that the neuroprotective effects of sAPPα were due to its 
ability to destabilize APP dimers (Gralle et al., 2009). Moreover, a significant amount of 
neuritic dystrophy (not quantified) was observed in the treated neurons, which was 
apparent as early as 8 hours, when the majority of neurons appeared to be otherwise 
viable, suggesting that neurite degeneration precedes apoptosis. Whether this 
accompanying neuritic dystrophy is a result of a process affecting the whole cell or due 
to 22C11 inducing a local, deleterious effect on neuritic processes remains unclear.
We found that these effects required the presence of APP, as B103 cells lacking APP 
were resistant to the effects of 22C11. Because these cells also lack APLP1 and 
APLP2, we cannot rule out the possibility that they also contribute to the neurotoxic 
effects of 22C11 in our model. Indeed, most of the functional domains and structural 
motifs found in APP are also present in APLPs, particularly APLP2 (White et al., 1998), 
suggesting that they may share common biological functions in neurons. In support of 
this possibility, cortical neurons taken from APP-knockout mice were shown to retain 
their vulnerability in an antibody-mediated death model (Mbebi et al., 2002) and the fact 
that 22C11 can cross-react weakly with APLP2 (Wang et al., 2006). However, since 
B103 cells lack APLP2, our studies demonstrate that APP alone is sufficient for the 
neurotoxic effects of 22C11.
Finally, while neuronal death is a common occurrence in AD, there is ample evidence 
suggesting that synaptic dysfunction correlates very well with memory impairments and 
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may precede not only amyloid plaques, but neuronal apoptosis as well in mouse 
models of AD (Chapman et al., 1999; Cleary et al., 2005; Hsia et al., 1999; Lesné et al., 
2006; Rowan et al., 2007; Selkoe, 2002). Synaptic transmission and plasticity were 
shown to be altered in neurons over-expressing APP (Kamenetz et al., 2003) or exposed 
to elevated levels of Aβ (Freir et al., 2001; Hartley et al., 1999; Vitolo et al., 2002), which 
also resulted in a significant decrease in dendritic spine numbers (Shrestha et al., 2006). 
Interestingly, both of these paradigms lead to an increase in dimerized APP (Lu et al., 
2003a; Scheuermann et al., 2001; Shaked et al., 2006), which led us to examine the 
effects of sub-apoptotic concentrations of 22C11 on synaptic functions in hippocampal 
neurons. Our results showed a significant reduction in dendritic spine numbers, as well 
as a decrease in the synaptic markers PSD-95 and Drebrin A in 22C11-treated neurons, 
suggesting that increased dimerization of APP can exert localized effects on synaptic 
function without affecting neuronal viability. Whether or not apoptotic and sub-
apoptotic concentrations of 22C11 modulate the same signaling pathway remains 
uncertain. It is possible that 22C11 affects synaptic contacts by shifting the APP dimer 
equilibrium from an intercellular trans-configuration to a intracellular cis-configuration. 
The evidence suggests that increased dimerization of APP may affect one or more 
pathways, perhaps through caspase-3 activation (Rohn et al., 2000) or by disrupting 
Ca2+ entry in the cells (Bouron et al., 2004) or by stimulating pro-inflammatory cytokine 
release (Sondag and Combs, 2004; Sondag and Combs, 2006) or perhaps by 
simulating the production and release of Aβ (Kaden et al., 2008; Kaden et al., 2009; 
Kienlen-Campard et al., 2008; Munter et al., 2010; Munter et al., 2007; Scheuermann et 
al., 2001; Sondag and Combs, 2006). In the following chapter, we will explore the latter 
hypothesis that dimerization of APP regulates the production of Aβ in hippocampal 
neurons.
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CHAPTER 5: ABERRANT DIMERIZATION OF APP TRIGGERS THE 
AMYLOIDOGENIC PATHWAY AND INCREASES Aβ LEVELS IN 
HIPPOCAMPAL NEURONS
5.1	 Introduction
The progressive accumulation and deposition of the β-amyloid peptide (Aβ) leading to 
the formation of senile plaques (SP) is an invariant feature of Alzheimer’s disease. The 
amyloidogenic processing of the amyloid precursor protein (APP; Kang et al., 1987) by 
the β- and γ-secretases leading to the production of Aβ is a well characterized process 
(reviewed by Walsh et al., 2007). APP and APLPs were conventionally thought to exist 
and function as monomers. However, biochemical and structural data obtained over the 
past years have indicated that APP and APLPs may in fact exist as functional dimers or 
even present in higher oligomeric complexes (Chen et al., 2006; Gralle et al., 2009; 
Kaden et al., 2008; Rossjohn et al., 1999; Scheuermann et al., 2001; Wang and Ha, 
2004). Many studies have implicated the APP and APLP homo- and heterotypic 
interactions in cellular adhesion (Soba et al., 2005). Among other proposed 
mechanisms, the strength and degree of APP dimerization has been reported to 
influence APP processing (Kaden et al., 2008; Scheuermann et al., 2001) and many 
have suggested that aberrant dimerization of APP may play a critical factor in the 
pathogenesis of late-onset Alzheimer’s disease (LOAD). The identification of hereditary 
early-onset familial Alzheimer’s disease (EOFAD) mutations in PS1 and particularly in 
APP have provided ample support for this view. 
Most EOFAD mutations are known to increase Aβ. It has been proposed that this 
increase may be driven by abnormal dimerization of APP through its transmembrane 
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sequence (TMS). APP contains three GxxxG motifs at the junction between the 
juxtamembrane and the TMS regions (Liu et al., 2005; Marchesi, 2005; Munter et al., 
2007; Sato et al., 2006). GxxxG motifs were originally identified in the sequence of the 
glycophorin A (GpA) protein where they mediate sequence-specific dimerization 
between transmembrane helices by direct glycine-glycine contacts (Bormann et al., 
1989; Lemmon et al., 1994; Smith et al., 2001). Since their discovery, GxxxG motifs 
have been shown to play a generic role to facilitate oligomerization of TM domains of 
many transmembrane proteins (Russ and Engelman, 2000), including APP. The 
presence of these three GxxxG motifs have led to the suggestions that the glycine face 
of the TMS helix of APP may mediate APP homo- and hetero-oligomerization (Kienlen-
Campard et al., 2008; Munter et al., 2007). Interestingly, one of the identified mutations 
in EOFAD, the Flemish mutations, involves the substitution of an alanine residue to a 
glycine residue resulting in the creation of a fourth GxxxG motif in APP (Hendriks et al., 
1992). Moreover, mutations of the glycine residues of the GxxxG motifs to alanine 
residues attenuate TM dimerization and result in a marked reduction in the processing 
of APP and the production of Aβ (Munter et al., 2010). Similarly, compounds that 
directly interfere with APP TMS dimerization were recently demonstrated to lower Aβ 
levels (Richter et al., 2010).
The evidence presented above supports the view that APP dimerization plays a role in 
its processing and enhances Aβ production. However, the precise mechanism(s) by 
which homo-dimerization of APP affects its proteolytic cleavage remains largely 
unresolved. In this study we show that enhanced dimerization of APP triggers 
amyloidogenic processing of APP in hippocampal neurons, resulting an increased Aβ 
production. Moreover, we demonstrate that increased Aβ production is due to an 
increase in the protein levels and activity of the β-secretase BACE1. We demonstrate 
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that elevated levels of BACE1 stem from decreased lysosomal degradation through a 
caspase-3 dependent mechanism, leading to an accumulation of BACE1 in endosomal 
compartments.
5.2	 Results
5.2.1 22C11 treatment increases Aβ levels in cultured hippocampal neurons 
without affecting cell viability
To investigate whether dimerization of APP played a direct role in increasing the levels 
of Aβ in neurons, cultured hippocampal neurons were treated with a sub-lethal 
concentration of the N-terminal APP antibody 22C11 (100 ng/ml; Figure 4-7) as 
previously described. After treatment, cells were harvested and the levels of 
intraneuronal Aβ were measured using two independent techniques. First, Aβ was 
immunoprecipitated from the neuronal lysates with the monoclonal anti-Aβ antibody 
4G8. We detected a significant increase in Aβ production (~2-fold) in 22C11-treated 
neurons compared PBS-treated control neurons (Figure 5-1A). Additionally, we did not 
detect any significant changes in the levels of full-length APP either in 22C11- nor PBS-
treated neurons (Figure 5-1), suggesting that 22C11 treatment increases Aβ levels by 
directly affecting its production or clearance.
In a second approach, the levels of Aβ in the lysates were measured using a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit, which 
measures the levels of Aβ(x-42). Consistent with our immunoprecipitation results, we 
found a significant increase in the levels of intraneuronal Aβ(x-42) in the 22C11-treated 
cells compared to PBS-treated control cells (Figure 5-1B). Interestingly, we did not 
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detect a significant change in the levels of secreted Aβ in the culture medium of either 
22C11-treated neurons nor PBS-treated control cells, as measured by ELISA or 
immunoprecipitation (data not shown).
Figure 5-1. 22C11 treatment increases Aβ levels in hippocampal neurons
Treatment of hippocampal neurons for 24 hours with a 100 ng/ml solution of 22C11 resulted in a significant 
increase in Aβ production compared to control cells that were treated with PBS. Aβ levels were assessed by 
immunoprecipitation with the anti-Aβ antibody 4G8, from cell lysates (A) and by measuring secreted Aβ in the 
culture medium by ELISA (C). (A) Representative Western blot showing an increase in Aβ levels in 22C11-treated 
neurons. Data was quantified from at least 3 independent experiments and expressed as the mean+/-SEM 
(**p=0.039) band intensity. (B) Densitometric analysis of the data was quantified from 3 independent experiments 
and expressed as the mean+/-SEM (**p=0.005 for PSD95; ***p<0.001 for Drebrin A) band intensity. (C) 
Quantification of Aβ(x-42) from culture medium by ELISA from 4 independent experiments was expressed as the 
mean+/-SEM (*p=0.033) signal intensity in arbitrary units (AU).
5.2.2 Increased Aβ levels by 22C11 correlates with increased BACE1 levels and 
activity but not with increased γ-secretase activity
Our next objective was to determine the mechanism by which Aβ levels were increased 
in 22C11-treated neurons. Since the levels of APP remained unchanged in the treated 
cells, we hypothesized that the changes in Aβ levels might be due to a perturbation in 
the equilibrium between its clearance and production rates. As we discussed earlier 
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(Section 1.9.2), several studies have implicated the metalloproteases neprilysin and IDE 
in the degradation of Aβ (Figure 5-2A; reviewed in Miners et al., 2008). The levels of 
those two proteins have also been shown to be reduced in several AD mouse models 
and in AD patients (Apelt et al., 2003; Cook et al., 2003; Kurochkin and Goto, 1994; 
Yasojima et al., 2001). To test whether a deficiency in clearance correlated with the 
increased Aβ levels in our system, we measured the protein levels of IDE and neprilysin 
by Western blot, using commercially available polyclonal antibodies. We did not detect 
any significant changes in the protein levels of either IDE nor neprilysin (Figure 5-2B) in 
the 22C11-treated neurons after 8 hours, indicating that increased β- and/or γ-
secretase processing of APP (Figure 5-2B) was the likely cause of the elevated Aβ 
levels.
Figure 5-2. 22C11 does not affect Aβ 
degradation in neurons
(A) Aβ is degraded by insulin degrading 
enzyme (IDE) and Neprilysin (Farris et al., 
2007; Selkoe, 2001). (B) Western blot 
analysis of lysates from neurons treated 
with 100 ng/ml of 22C11 for 8 hours did 
not show any significantly changes in the 
protein levels IDE or Neprilysin compared 
to control neurons treated with vehicle.
To evaluate γ-secretase processing of APP, we used two different approaches. Active 
endogenous presenilin (PS) exists mainly as a heterodimeric complex formed from the 
endoproteolytically processed N- and C-terminal fragments of PS (Figure 5-3A; 
Thinakaran et al., 1996a). Therefore, we measured the levels of N-terminal fragments 
(~28 kDa) by Western blot, using a commercially available N-terminal antibody for 
presenilin-1. There was no statistical difference in the levels of cleaved PS1 N-terminal 
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fragments between neurons that were treated with 22C11 and vehicle (PBS)-treated 
control neurons (Figure 5-3B). As a potential read-out of γ-secretase activity, we 
evaluated cleavage of the γ-secretase substrate Notch1 (Ray et al., 1999; Steiner et al., 
1999), by Western blot using a polyclonal antibody which recognizes endogenous levels 
of the cytosolic domain of Notch1 only when cleaved between Glycine1743 and Valine1744 
(Ray et al., 1999). Interestingly, we detected a modest, albeit statistically insignificant 
increase in Notch1 cleavage (Figure 5-3B) in 22C11 treated neurons.
Figure 5-3. 22C11 treatment does not affect cleavage of presenilin-1 protein
(A) Topology and proteolytic processing of presenilins. Presenilins are cleaved within the hydrophobic region of the 
large cytosolic loop between TM6 and TM7, resulting in the formation of a heterodimeric complex composed of the 
N-terminal fragment (NTF) and the C-terminal fragment (CTF). (B) Western blot analysis of lysates prepared from 
hippocampal neurons treated with 22C11 (100 ng/ml) for 8 hours. No significant increases in the levels of N-
terminal fragments of presenilin-1 nor in the levels of the γ-secretase substrate Notch were observed in treated 
neurons compared to PBS-treated control.
Because of the modest increase in Notch1 cleavage in 22C11-treated cells, we could 
not rule out the possibility that γ-secretase activity was enhanced by 22C11 through a 
mechanism distinct from increasing PS1 cleavage. Therefore, we decided to directly 
measure cleavage of CTFβ (C99) by γ-secretase using a previously described cell-free 
assay (Hansson et al., 2006; Sastre et al., 2001) as depicted in Figure 5-4A. Briefly, 
HEK293 cells were transiently transfected with a C99-myc construct and membrane 
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fractions were prepared from these cells 48 hours post-transfection. These membrane 
fractions, enriched with APP C99-myc fragments (Figure 5-S3), were combined with 
solubilized hippocampal neurons (γ-secretase complex source) from 22C11-treated and 
PBS-treated cells and incubated for 2 hours at 37°C to allow γ-secretase cleavage of 
C99-myc. The generated AICD-myc fragments were then analyzed by Western blot 
using a polyclonal anti-myc antibody and were detected in both control and 22C11-
treated samples (Figure 5-4B. We did not observe a significant difference across the 
samples (Figure 5-4C). γ-Secretase-mediated cleavage of C99-myc, was confirmed by 
the addition of the γ-secretase inhibitor DAPT (Dovey et al., 2001), which completely 
abolished generation of AICD-myc fragments (Figure 5-4B).
Figure 5-4. 22C11 treatment does not increase γ-secretase activity
(A) Complexed N- and C-terminal fragments of cleaved presenilin-1 (Psn-1) are stabilized by binding to Aph-1 and 
nicastrin, although the complex still remains inactive. Binding of Pen-2 elicits the final step of maturation of the γ-
secretase complex, facilitating endoproteolysis of PS1 and conderring γ-secretase activity. (B, C) In vitro γ-
secretase activity assay with hippocampal neurons treated with 22C11 for 8 hours. Solubilized membranes from 
C100-myc expressing HEK293 cells were mixed with solubilized 22C11-treated (100 ng/ml; 8 hours) or vehicle-
treated (PBS) hippocampal neurons. Samples were incubated for 2 hours in the absence or presence of the γ-
secretase inhibitor (DAPT). (B) AICD-myc formation at 37°C was detected by Western blot with a myc-specific 
antibody. No AICD was formed at -20°C or in the presence of DAPT at 37°C. (C) No observable increase in AICD 
production was observed in 22C11-treated compared to vehicle-treated neurons. Quantification of AICD-myc from 
3 independent experiments, expressed as the relative mean+/-SEM (p=0.231) signal intensity.
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To assess β-secretase cleavage of APP, we first measured the total levels of cellular 
BACE1 protein in hippocampal neurons following an 8-hour treatment with a sub-lethal 
concentration of 22C11. BACE1 levels were determined by Western blot using a 
commercially available polyclonal anti-BACE1 antibody (Figure 5-5B). We detected a 
significant increase in total BACE1 protein levels, normalized against GAPDH, in 22C11-
treated neurons compared to PBS-treated control cells (Figure 5-2C). To correlate 
increased BACE1 levels with increased activity, we measured the levels of sAPPβ 
(Figure 5-5A) in the culture medium by Western blot, using a commercially available 
monoclonal sAPPβ-specific antibody (Figure 5-5B). Concomitant with the increase in 
BACE1, sAPPβ levels were significantly higher in the culture medium from 22C11-
treated neurons compared to that of control cells (Figure 5-2C), consistent with the idea 
that increased BACE1 protein leads to increased β-secretase processing of APP.
Figure 5-5. BACE1 protein level and activity are increased in 22C11-treated hippocampal neurons
(A) Schematic illustration of of APP by BACE1, generating the soluble sAPPβ fragment as well as the membrane 
bound C100 fragment. (B-D) Treatment of primary hippocampal neurons with 22C11 (100 ng/ml) for 8 hours 
resulted in Increased BACE1 protein levels with a concomitant increase in secreted APPβ fragments as measured 
by (B) Western blot analysis. (C, D) Densitometric analysis of the data was quantified at least 3 independent 
experiments and expressed as the mean+/-SEM (***p<0.001 for BACE1; *p=0.05 for sAPPβ) band intensity.
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Taken together, these results suggest that the observed increase in the levels of 
intracellular Aβ in 22C11-treated hippocampal neurons, is unlikely caused by a 
deficiency in the clearance mechanism of Aβ, supported by the unchanged levels of 
IDE and nepriplysin in 22C11-treated neurons. Instead, our results led us to propose 
that increased processing of APP, specifically by BACE1 at the β-secretase cleavage 
site of APP was responsible for driving the elevated Aβ levels.
5.2.3	 Increases in BACE1 protein levels are not caused by increased 
transcription or translation but are due to increases in protein stability
Having demonstrated that levels of BACE1 protein were elevated in 22C11-treated 
hippocampal neurons, our next objective was to investigate potential mechanisms to 
explain this observation. Several factors might be in play, including transcriptional, 
post-transcriptional, translational and/or post-translational modifications (reviewed in 
Tabaton et al., 2010).
We first investigated the possibility that 22C11 could activate transcription of BACE1 in 
hippocampal neurons. qRT-PCR analysis of BACE1 mRNA levels in 22C11 treated-
neurons did not reveal any significant changes over control neurons after 8 hours 
(Figure 5-6A). Since BACE1 protein levels was already shown to be elevated at this time 
point (Figure 5-5B, C), we ruled out the possibility that 22C11 could affect 
transcriptional control of BACE1. This is in line with several findings that have failed to 
show a significant increase in BACE1 mRNA levels in AD brains and in AD mouse 
models, in spite of elevated BACE1 protein levels (Hébert et al., 2008; Holsinger et al., 
2002; Zhao et al., 2007).
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An alternative explanation for the increase in BACE1 protein levels is the perturbation of 
one or more of its post-transcriptional regulatory mechanisms. Regulatory noncoding 
RNAs (ncRNA) are widely recognized today for their potent roles in regulating gene 
expression in many key developmental processes (reviewed by Brosnan and Voinnet, 
2009). The neuronal functions of ncRNAs have only begun to be explored and are for 
the most part unknown. However, specific ncRNAs have been shown to regulate 
dendritic spine development, neuronal fate specification and differentiation and 
synaptic protein synthesis (reviewed in Satterlee et al., 2007). Additionally, ncRNAs have 
been implicated in a number of neuronal diseases, including Tourette’s syndrome and 
Fragile X syndrome (reviews by Iacoangeli et al., 2010; Mehler and Mattick, 2007). 
Recently, a potential role for ncRNAs was proposed in AD with two the discovery of 
several novel ncRNAs, namely a naturally occurring BACE1-antisense transcript 
(BACE1-AS; Faghihi et al., 2008) and its binding competitor (miR-485-5p; Faghihi et al., 
2010), and a microRNA cluster (miR-29a/b-1; Hébert et al., 2008). They have all been 
implicated in regulating the stability of BACE1 mRNA and their misexpression have 
been shown to correlate with increased Aβ production.
To test the hypothesis that BACE1 was elevated due to increased synthesis from stabler 
mRNAs, we performed a cycloheximide degradation assay to directly study changes in 
the turnover rate of BACE1. Hippocampal neurons were treated with cycloheximide to 
prohibit protein synthesis and BACE1 protein levels were evaluated by Western blot 
over the course of 18 hours. At that time point, BACE1 protein levels were almost 
completely depleted in control cells (Figure 5-6B). Alternatively, in 22C11-treated 
neurons, BACE1 protein levels were elevated after 3 hours and fell only to control levels 
over the course of 18 hours (Figure 5-6B). Comparing neurons at the 18 hour mark 
showed a significantly higher amount of endogenous BACE1 protein in 22C11-treated 
neurons (Figure 5-6C). This suggests that 22C11 affects the turnover rate of BACE1, 
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increasing the half-life of endogenous BACE1 protein. These results rules out increased 
translation as the cause of elevated BACE1 levels.
Figure 5-6. 22C11-treatment leads to accumulation of BACE1 through post-translational stabilization, not 
through increased synthesis
(A) qRT-PCR assay for BACE1 mRNA: primary hippocampal neurons were treated with 22C11 (100 ng/ml) for 8 
hours prior to analysis. No significant changes in BACE1 mRNA levels were observed between 22C11- and vehicle 
(PBS)-treated neurons. The data was quantified from 3 independent experiments and is expressed as the relative 
mean+/-SEM (p=0.193) signal intensity. (B, C) Cycloheximide (CHX) degradation time course: BACE1 protein was 
detected by Western blot at various times (3, 6 and 18 hours) after addition of CHX (150 μM) only or 22C11 (100 ng/
ml) + CHX in hippocampal neurons. The degradation of BACE1 in control neurons after 18 hours was blocked by 
the addition of 22C11.
Collectively, the above data suggests that 22C11 drives Aβ production by altering the 
steady-state levels of BACE1, the rate-limiting enzyme in the biogenesis of Aβ. They 
also indicate that the increase in BACE1 levels is, at least in part, the result of post-
transcriptional stabilization of BACE1.
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5.2.4	 The lysosomal pathway is the predominant route for degradation of 
endogenous BACE1 in hippocampal neurons
At least three different mechanisms have been reported to control the degradation of 
BACE1: (1) endoproteolysis within its catalytic domain (Huse et al., 2003), (2) the 
lysosomal pathway (Koh et al., 2005), and (3) the ubiquitin-proteasomal pathway (Qing 
et al., 2004). The discrepancy between the last two studies is puzzling, but can be 
reconciled. The latter study by Qing et al. was largely based on over-expression of 
BACE1 in several cell lines. Hence, it remains unclear whether endogenous BACE1 
would normally be degraded through the proteasomal pathway. In addition, since the 
effects of lysosomal inhibitors were not studied, any potential contribution from 
lysosomal degradation to the degradation of BACE1 is unknown. Moreover, the 
interpretation of experiments involving proteasome inhibitors can be problematic since 
many proteasome inhibitors can also inhibit lysosomal cathepsins (Kisselev and 
Goldberg, 2001; Kozlowski et al., 2001).
In order to overcome these shortcomings, we decided to evaluate the respective 
contributions of proteasomal and lysosomal degradative pathways in regulating the 
levels of endogenous BACE1 in our model system, namely hippocampal neurons. To 
assess lysosomal degradation of endogenous BACE1, hippocampal neurons were 
treated for 8 hours with ammonium chloride (NH4Cl; 500 μM) and chloroquine (100 μM), 
weak bases known to inhibit lysosomal hydrolases by reducing the acidification of the 
endosomal/lysosomal compartments (Ohkuma and Poole, 1978). After treatments, 
neurons were harvested and the levels of BACE1 protein were evaluated by Western 
blot analysis (Figure 5-7A). Both chloroquine and NH4Cl treatments induced a marked 
increase in endogenous BACE1 protein levels after 8 hours (Figure 5-7B). Increasing the 
concentrations each inhibitor did not appear to significantly affect the build-up of 
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BACE1. However, longer treatments did lead to higher BACE1 levels (data not shown). 
These results are in line with previous studies that demonstrated a similar effect in 
several cell lines, including CHO and SY5Y cells and in cortical neurons (Koh et al., 
2005). To assess proteasomal degradation, a similar protocol was followed and cultured 
hippocampal neurons were treated with the proteasomal inhibitor MG132 (1.0 μM) for 8 
hours. Western blot analysis (Figure 5-7C) showed no significant increase in BACE1 
levels after 8 hours (Figure 5-7D). Increasing the concentration of MG132 or extending 
the treatment over a longer time frame proved problematic due to toxicity. Comparable 
results were also obtained with another proteasomal inhibitor, lactacystin (data not 
shown).
Figure 5-7. Inhibition of lysosomal hydrolase leads to increased levels of endogenous BACE1 in 
hippocampal neurons
Primary hippocampal neurons were treated with various protease inhibitors for 8 hours (A-D). (A) Western blot 
analysis of lysates prepared from neurons treated with the lysosomal inhibitors Chloroquine (100 μM) and NH4Cl 
(500 μM) resulted in a significant increase in BACE1 levels with a concomitant increase in the levels of the C100 
fragment resulting from BACE1 cleavage of APP. (B) Densitometric analysis of the data was quantified from 3 
independent experiments and expressed as the mean+/-SEM (**p=0.002 for chloroquine; **p=0.004 for NH4Cl) 
band intensity. (C, D) Western blot analysis of lysates from neurons treated with the proteasomal inhibitor MG132 
(1.0 μM) did not significantly affect BACE1 protein levels after 8 hours. (D) Densitometric analysis of the data was 
quantified from 3 independent experiments and expressed as the mean+/-SEM (p=0.099) band intensity.
These results, taken collectively, indicate that endogenous BACE1 degradation in 
hippocampal neurons is primarily determined by the activity of lysosomal hydrolases. 
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Any contribution from proteasomal degradation appears to be minimal, at least within 
the time frame of our experiments.
5.2.5	 22C11 treatment interferes with the sorting properties of BACE1 by GGA3
The dileucine (DXXLL) motif of BACE1 (discussed in Section 1.3.2) is believed to play a 
critical role in its degradation, as mutating the leucine residues to alanine residues 
increases the levels of BACE1 protein (Pastorino et al., 2002). Mutagenesis of the 
dileucine motif has been shown to interfere with the lysosomal degradation of BACE1 
by blocking its transport from endosomes to lysosomes (Koh et al., 2005). This 
trafficking pathway is mediated by the Vps-27, Hrs and STAM (VHS) domain of the 
Golgi-localized gamma-ear-containing ARF-binding (GGA) proteins (GGA1, 2, and 3), 
which binds the dileucine motif of BACE1 (reviewed in Bonifacino, 2004). Depletion of 
GGA proteins by RNAi increases accumulation of BACE1 in early endosomes (He et al., 
2005; Tesco et al., 2007; Wahle et al., 2005) and increases Aβ secretion in neurons 
(Wahle et al., 2006). Alternatively, over-expression of GGA proteins or dominant-
negative variants reduce CTFβ generation and Aβ production (Wahle et al., 2006). 
Interestingly, of the three GGA family member proteins, GGA3 has been highlighted in a 
recent report by Tesco et al. for its potential role in AD pathology. GGA3 protein levels 
were found to be significantly decreased in AD brains and inversely correlated with 
increased levels of BACE1 (Tesco et al., 2007).
Given our earlier results confirming that endogenous BACE1 is predominantly degraded 
through the lysosomal pathway in hippocampal neurons, we set out out to investigate 
the fate of GGA3 in hippocampal neurons in response to 22C11 treatment.
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5.2.5.1		 22C11 treatment increases caspase-3 activity in hippocampal neurons
The Tesco et al. study referenced above demonstrated that GGA3 was a substrate for 
caspase-3 (Tesco et al., 2007). Additionally, it has previously been demonstrated in 
many instances that apoptosis-inducing levels of Aβ (Figure 5-S2) and 22C11 activates 
caspase-3 in a variety of cell lines and primary neurons (Harada and Sugimoto, 1999; 
Marin et al., 2000). With those results in mind, we wanted to determine whether sub-
apoptotic levels of 22C11 could also lead to activation of caspase-3 in hippocampal 
neurons. To that end, we first analyzed the levels of cleaved caspase-3 in hippocampal 
neurons that were treated with a sub-lethal concentration of 22C11 (100 ng/ml) for 1 
and 8 hours. After treatment, cells were harvested and cleaved caspase-3 levels were 
assessed by Western blot using an antibody which recognizes endogenous levels of the 
large fragment (17/19 kDa) of cleaved caspase-3 resulting from cleavage adjacent to 
Asp175. A significant increase in cleaved caspase-3 levels was apparent after 8 hours of 
treatment with 22C11 compared to control cells (Figure 5-8A).
It is often assumed that increased caspase-3 cleavage equates to increased caspase-3 
activity. However, IAPs such as xIAP, c-IAP1/2 and Survivin can bind processed 
caspase-3 and block its activity (reviewed in Liston et al., 2003). To overcome this issue, 
we directly measured activity of caspase-3 in live cells using a commercially available 
fluorescent caspase-3 substrate, DEVD-NucView. The DEVD peptide is attached to a 
DNA-binding dye, which is unable to produce fluorescence in the absence of DNA. 
Upon entering the cell cytoplasm, it is cleaved by active caspase-3 to release the high-
affinity DNA dye. The released dye migrates to the nucleus and brightly stains it. 
Consistent with the observed increased in cleaved caspase-3 levels, we found that 
hippocampal neurons treated with 22C11 showed a notable increase in fluorescence 
compared to control neurons (Figure 5-8B), indicative of increased DEVD cleavage by 
97
active caspase-3. Fluorescence was significantly attenuated by pre-treating the neurons 
for 1 hour with the competing non-fluorescent caspase-3 inhibitor Z-DEVD-FMK (25 
μM; Figure 5-8B).
Figure 5-8. 22C11 treatment results in increased cleavage and activity of caspase-3 in hippocampal neurons
Primary hippocampal neurons were treated with with 22C11 (100 ng/ml) for various time points (1 and 8 hours) 
before lysates were analyzed by (A) Western blot using an cleaved-caspase-3-specific antibody. Treatment with 
22C11 resulted in increased cleavage of caspase-3 compared to vehicle (PBS)-treated neurons. (B) NucView assay 
for in vivo caspase-3 activity: primary hippocampal neurons cultured in chamber slides were treated with 22C11 
(100 ng/ml) for 8 hours before incubating with the DEVD-NucView caspase-substrate. Upon cleavage of this 
substrate by caspase-3, the NucView moiety enters the nucleus and fluoresces upon binding DNA. Treated neurons 
showed a marked increase in fluorescence compared to vehicle (PBS)-treated neurons indicative of increased 
caspase-3 activity. Pre-treatment for 1 hour with the caspase inhibitor z-DEVD-FMK blocked increased NucView 
fluorescence, confirming that fluorescence was a result of caspase activity.
5.2.5.2		 22C11 treatment increases caspase-3 dependent cleavage of GGA3
Our data above indicated increased caspase-3 activity in 22C11-treated hippocampal 
neurons. Since GGA3 was shown to be a caspase-3 substrate (Tesco et al., 2007), we 
decided to look at the state of endogenous GGA3 protein in 22C11-treated neurons. 
Cleavage of full-length GGA3 by active caspase-3 was shown to occur at three major 
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sites within its hinge domain, generating three C-terminal fragments of ~50 kDa, ~48 
kDa and ~37 kDa, as well as an N-terminal fragment, which also function as a dominant 
negative form of GGA3 (Figure 6-9A; Tesco et al., 2007). As in our earlier experiments, 
hippocampal neurons were treated with a sub-apoptotic concentration of 22C11 for 8 
hours. Cells were harvested and cleavage of endogenous GGA3 in hippocampal 
neurons, was assessed by Western blot using a commercially available antibody 
against the C-terminus of GGA3, which recognizes the full-length protein as well as the 
three C-terminal fragments (Figure 5-9B). Cells that were treated with 22C11 had 
increased levels of cleaved GGA3 (~37 kDa fragment) compared to control neurons 
(Figure 5-8C). However, we could not detect the larger ~50 kDa fragment of GGA3. One 
possible explanation is that the levels were below the limit of detection. This is 
consistent with previous reports, where the authors were also unsuccessful at detecting 
endogenous levels of the larger fragment in lysates from the human glioblastoma cell 
line, H4. Interestingly, no significant change in the levels of the ~48 kDa fragment was 
observed in 22C11-treated cells, suggesting a possible preference for the third 
cleavage site to produce the smaller fragment.
Our next objective was to confirm the role of caspase-3 in the cleavage of GGA3 in 
neurons. The demonstrated lack of specificity of many of the available chemical 
caspase inhibitors (McStay et al., 2008), persuaded us to use an siRNA to deplete the 
levels of endogenous caspase-3 (siCasp3). The siRNA was delivered to the neurons by 
linking it to the cell-penetrating peptide Penetratin-1TM, which has previously been used 
as an effective method for delivering siRNA sequences to primary neurons (Davidson et 
al., 2004). We achieved about 40% knockdown of endogenous caspase-3 protein in 
hippocampal neurons after 8 hours Figure 5-S1). Nevertheless, this was sufficient to 
significantly abrogate cleavage of GGA3, as demonstrated by the reduced levels of the 
~37 kDa fragment in 22C11 neurons (Figure 5-9B, C). Interestingly, basal levels of 
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cleaved GGA3 were not affected by treatment with siRNA alone suggesting that 
perhaps that other factors may play a role in regulating basal levels of GGA3.
Figure 5-9. 22C11 treatment triggers caspase-3-dependent cleavage of GGA3 in hippocampal neurons
(A) Schematic representation of GGA3 caspase cleavage. Caspase-cleavage of GGA3 generates three C-terminal 
fragments (~50, ~48 and ~37 kDa). (B, C) Treatment of primary hippocampal neurons with 22C11 (100 ng/ml) for 8 
hours resulted in increased cleavage of GGA3 compared to vehicle-treated neurons. Downregulation of caspase-3 
by siRNA significantly abrogated cleavage of GGA3 (B) Western blot analysis with a C-terminal-specific GGA3 
antibody showing increased production of the ~37 kDa fragment in 22C11-treated neurons, which is blocked by 
downregulation of caspase-3. (C) Densitometric analysis of the data was quantified from 3 independent 
experiments and expressed as the mean+/-SEM (**p=0.001 for Control vs. 22C11; *p=0.014 for 22C11 vs. 22C11 + 
siCaspase3) band intensity. 
5.2.5.3 22C11-induced BACE1 and Aβ increase are caspase-3 dependent
The above results suggest a mechanism whereby 22C11 increases caspase-3 activity in 
hippocampal neurons, followed by increased cleavage of GGA3. Our hypothesis 
predicts then that depletion of caspase-3 by siRNA as above should reverse the effects 
of 22C11 on both BACE1 and Aβ levels. To test this prediction, we treated hippocampal 
neurons with a sub-apoptotic concentration of 22C11, in the presence and absence of 
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the caspase-3 siRNA. As in our earlier results, 22C11 treatment led to a significant 
increase in BACE1 and Aβ levels in hippocampal neurons (Figure 5-10A, B). The effects 
of 22C11 were markedly blocked in neurons with partially depleted caspase-3 levels, as 
indicated by a reduction in the levels of BACE1 and Aβ to near control (Figure 5-10A, 
B).
Figure 5-10. 22C11-induced BACE1 
and Aβ increase in hippocampal 
neurons is caspase-3-dependent
(A, B) Primary hippocampal neurons 
were treated with 22C11 (100 ng/ml) 
only or with 22C11 + siCaspase-3 for 
8 hours. (A) Western blot and 
immunoprecipitation analysis showing 
increased levels of BACE1 and Aβ 
production in 22C11-treated neurons 
compared to vehicle (PBS)-treated 
n e u r o n s . D o w n r e g u l a t i o n o f 
caspase-3 blocked both BACE1 
increase and Aβ production. (B) Densitometric analysis of BACE1 was quantified from 3 independent experiments 
and expressed as the mean+/-SEM (*p=0.013 for Control vs. 22C11; *p=0.052 for 22C11 vs. 22C11 + siCaspase3) 
band intensity. showing increased Aβ production in 22C11-treated neurons, which is blocked by downregulation of 
caspase-3.
Taken collectively, these results lend support for a mechanism in which 22C11 
promotes BACE1 accumulation in hippocampal neurons by interfering with its normal 
degradation process. Activation of caspase-3 by 22C11 leads to increased cleavage of 
GGA3, generating its N-terminal dominant negative fragment. This process is 
dependent on caspase-3 as its depletion by siRNA reverses the effects of 22C11 both 
on BACE1 levels and Aβ production.
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5.2.6	 22C11 treatment leads to accumulation of BACE1 in endosomes
As mentioned above, depletion of GGA3 by siRNA impairs its normal function of 
targeting BACE1 to lysosomes for degradation. This leads to the accumulation of 
BACE1 in early endosomes (He et al., 2005; Tesco et al., 2007; Wahle et al., 2005). 
Since 22C11 treatment promotes GGA3 cleavage, our model would predict a similar 
effect. Namely, 22C11 treatment should lead to an increase of BACE1 in the endosomal 
compartments of treated hippocampal neurons. To test this prediction, hippocampal 
neurons were treated as described above with 22C11 for 8 hours. After treatment, the 
neurons were fixed with paraformaldehyde and stained with a monoclonal antibody 
against the early endosome marker EEA1 (Figure 5-11B, F, J; Mu et al., 1995) as well as 
a polyclonal antibody against endogenous BACE1 (Figure 5-11A, E, I). Confocal 
analysis of the obtained images (Figure 5-11C, G, K) revealed a marked increase in the 
colocalization of BACE1 and EEA1 in 22C11-treated compared to control neurons 
(Figure 5-11D, H). This would indicate that BACE1 is accumulating in early endosomal 
compartments of 22C11-treated neurons, in support of our proposed model.
We demonstrated above that the effects of 22C11 on the levels of GGA3 were 
dependent on caspase-3 function. Therefore, similarly, we predicted that 
downregulation of caspase-3 would also reverse the observed the 22C11-induced 
accumulation of BACE1 in endosomes. This prediction was tested in hippocampal 
neurons treated with 22C11 and the caspase-3 siRNA. Consistent with our model, 
downregulation of caspase-3 resulted in a notable reduction in the colocalization of 
BACE1 with EEA1 (Figure 5-11H, L), suggesting that BACE1 is prevented from 
accumulating in early endosomes.
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Taken together, these results provide additional evidence in support of our model. 
22C11 treatment blocks lysosomal degradation of BACE1, allowing it to accumulate in 
early endosomes. Depletion of caspase-3 in treated cells prevents this accumulation by 
presumably restoring normal trafficking of BACE1 to lysosomes. We wanted to test the 
latter prediction by attempting to detect a shift in the accumulation of BACE1 from 
endosomes to lysosomes using the the lysosomal markers LAMP1 and LAMP2 (Fukuda 
et al., 1988). However, unlike the reports by Koh et al. (Koh et al., 2005) we were 
unsuccessful at detecting any significant colocalization of endogenous BACE1 with 
either marker in both control and treated neurons (data not shown). One possible 
explanation could be due to low levels of non-degraded endogenous BACE1 in 
neuronal lysosomes, below the detection limit of our experiment.
Figure 5-11. Treatment with 22C11 induces accumulation of BACE1 in early endosomal compartments
Primary hippocampal neurons cultured in chamber slides were treated with 22C11 (100 ng/ml) for 8 hours. 
Following fixation and permeabilization, neurons were stained with antibodies for BACE1 (A, E, I) and the sub-
cellular early endosome marker EEA1 (B, F, J) and imaged and analyzed by confocal microscopy (C, G, K). (D) 
Colocalization of BACE1 with EEA1 in control vehicle (PBS)-treated neurons was markedly increased in (H) neurons treated 
with 22C11 consistent with an endosome to lysosome trafficking defect. (I-L) Downregulation of caspase-3 by siRNA 
completely blocked (L) colocalization of BACE1 with EEA1.
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5.2.7 Over-expression of human GGA3 blocks 22C11-induced Aβ increase
Since downregulation of GGA3 leads to increased BACE1 levels, our next objective was 
to determine whether over-expression of GGA3 could block the increase in BACE1 and 
Aβ production triggered by 22C11. Initially, we had wanted to test this in primary 
hippocampal neurons. However, because of the low transfection efficiency in primary 
cultures, we decided to use the previously described neuroblastoma cell line B103, 
stably expressing APP. These cells were treated with a sub-apoptotic concentration of 
22C11 (100 ng/ml) for 8 hours and the levels of intracellular Aβ were determined by 
immunoprecipitation as described earlier. Similar to hippocampal neurons, B103 cells 
treated with 22C11 show a significant increase in both BACE1 levels and Aβ production 
(Figure 5-12A, B). To test GGA3 function, B103 cells were transfected with a plasmid 
expressing full-length human GGA3. After 48 hours, these cells were treated with the 
same concentration of 22C11 as above. Consistent with our proposed model, cells 
over-expressing GGA3 did not exhibit an increase in BACE1 levels nor Aβ production in 
response to 22C11 treatment.
Figure 5-12. Over-expression of 
human GGA3 restores normal 
degradation of BACE1 and 
blocks Aβ increase in 22C11-
treated B103 cells
B103 cells stably expressing APP 
(B103APP) were transfected with 
4.0 μg GGA3 plasmid or 4.0 μg 
emplty vector and treated with 500 
ng/ml of 22C11 after 48 hours. (A) 
Representative Western blots 
showing increased BACE1 levels in mock-transfected cells, as well as increased Aβ production. Overexpression of 
human GGA3 in the cells blocked both BACE1 increase and Aβ production. (B) Aβ levels were determined by 




Much progress has been accomplished towards deciphering some of the biological 
functions of APP, particularly for its role in facilitating cell-cell adhesion through homo- 
and hetero-dimerization with the other APP family protein, namely APLP1 and APLP2. 
However, the focus has remained mostly on its pathogenic role in the context of 
Alzheimer’s disease, due to it being the source of the Aβ peptide. The identification and 
characterization of APP-cleaving enzymes, such as secretases (BACE1 and the γ-
secretase complex) and caspases have provided great insight into the complex steps 
involved in the proteolytic processing of APP and the production of Aβ. Whether the Aβ 
peptide itself is the cause of AD remains a subject for debate. The identification of 
several mutations in the APP and presenilin (PS) genes in early-onset familial AD seem 
to support this view, as these mutations have been shown promote the production of 
Aβ. In late-onset AD however, the picture becomes a little more nebulous. While many 
risk factor genes have been identified, age remains the greatest risk factor for AD. This 
raises several important questions: does the cleavage process of APP change with 
aging or in AD, and if so what triggers these changes? Do elevated BACE1 levels in the 
brain play a role in AD pathogenesis, and if so what causes BACE1 to become 
elevated? Could dimerization of APP provide some of these answers?
The exact consequences of homo-dimerization of APP on the processing of APP is not 
fully understood and remains a contentious topic. Introduction of a cysteine mutation in 
the juxtamembrane (JM) region of APP has been reported to enhance Aβ production 
through the formation of stable disulfide-linked APP dimers (Scheuermann et al., 2001), 
consistent with the observation that stable Aβ dimers can be found intracellularly in 
vitro and in vivo in brains (Walsh et al., 2000). However, other laboratories have reported 
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the opposite effect, where enhanced dimerization of APP led to decreased APP 
processing and decreased Aβ levels (Eggert et al., 2009; Struhl and Adachi, 2000). 
Reconciling this dichotomy remains difficult, but could simply be explained by 
differences in the manner through which APP dimerization is promoted in each model 
systems. 
Here we show that enhanced oligomerization of endogenous APP through the use of a 
divalent antibody triggers the amyloidogenic pathway in cultured hippocampal neurons, 
resulting in a rise in the levels of intracellular Aβ. This increase in Aβ was observed 
under non-apoptotic conditions, at least within 48 hours of treatment. Synaptic 
dysfunction, as indicated by a significant reduction in synaptic markers and spine 
density, is observed however at these concentrations. This is an important 
consideration since neuronal and non-neuronal cells undergoing apoptosis have been 
shown to overproduce and secrete Aβ, whether triggered by staurosporine or by trophic 
factor withdrawal (Barnes et al., 1998; Galli et al., 1998; Gervais et al., 1999; Guo et al., 
2001; LeBlanc, 1995; Matrone et al., 2008a; Sodhi et al., 2004; Tesco et al., 2003). This 
wide array of conditions and cell types raises questions as to whether the observed Aβ 
overproduction is a specific process or simply a general response to apoptotic stimuli. 
Our result supports the former view, but it is possible that both APP signaling and 
apoptosis stimuli share common pathways.
Whether driven by apoptosis or by APP signaling, enhanced Aβ production seems to 
correlate with high levels of BACE1. We show that the observed Aβ overproduction in 
treated neurons is due primarily to increased processing of APP by BACE1, but not by 
γ-secretase. This was reflected by a significant increase in the production of sAPPβ 
fragments correlating with elevated BACE1 protein levels. BACE1 levels rise in response 
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to physiological stress or injury, such as oxidative stress (Tamagno et al., 2002), 
traumatic brain injury (Blasko et al., 2004), ischemia (Wen et al., 2004), hypoxia (Zhang 
et al., 2007) and energy impairment (Velliquette et al., 2005). BACE1 is also increased in 
brains from LOAD and EOFAD patients compared to cognitively normal individuals 
(Fukumoto et al., 2002; Holsinger et al., 2002; Li et al., 2004; Tyler et al., 2002; Yang et 
al., 2003). Our results imply that in addition to age-related stress, aberrant signaling 
triggered by APP oligomerization may enhance levels of BACE1 and Aβ in the brain, 
and drive AD pathogenesis. 
The exact mechanism of this up-regulation is not fully understood and hypotheses vary 
from transcriptional, post-transcriptional, translational and post-translational 
modifications of BACE1 (Faghihi et al., 2008; Hébert et al., 2008; Holsinger et al., 2002; 
Wen et al., 2008; Zhao et al., 2007). Our results indicate that BACE1 increase may be 
due, at least in part, to enhanced protein stabilization and accumulation. This is 
reflected by the fact that no significant changes were observed in BACE1 mRNA in 
treated hippocampal neurons. Alternatively, BACE1 half-life was significantly prolonged 
in treated neurons, persisting to near control levels after 18 hours of cycloheximide 
treatment. These results suggest that oligomerization of APP may trigger a signaling 
cascade that directly interferes with the normal degradation of BACE1 protein, thus 
allows BACE1 to accumulate in treated neurons. Our data shows that activation of this 
pathway may lead to the loss of function of the GGA3 protein. GGA family proteins are 
known to be involved in the trafficking of proteins, such as BACE1, which contain the 
DXXLL signal between different compartments, e.g. Golgi complex, endosomes and 
lysosomes (reviewed in Bonifacino, 2004). We demonstrated that activation of 
caspase-3 in treated neurons promotes cleavage of GGA3, likely generating increased 
amounts of the dominant negative N-terminal fragment (Tesco et al., 2007), although 
this was not directly established in our study. The accumulation of BACE1 in early 
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endosomal compartments in treated neurons was consistent with a loss of function of 
the GGA3 protein. Furthermore, downregulation of caspase-3 by siRNA prevented the 
accumulation of BACE1 in endosomes as well as an increase in intracellular Aβ. A 
similar effect was observed in cells over-expressing human GGA3, which did not exhibit 
an accumulation of BACE1 nor overproduction of Aβ.
The mechanism by which GGA3 targets some cargo to lysosomes has been shown to 
be ubiquitin-dependent (Puertollano and Bonifacino, 2004). While there is some 
evidence that BACE1 is ubiquitinated (Qing et al., 2004), future studies will be required 
to determine whether GGA3-dependent degradation of BACE1 requires ubiquitination 
or whether is occurs via an alternate mechanism --e.g. binding the VHS domain of 
GGA3. Additionally, RNAi silencing of GGA1 and GGA2 has also been shown to lead to 
the accumulation of BACE1 in endosomes. However, unlike GGA3, which shuttles 
BACE1 from endosomes to lysosomes, GGA1 and GGA2 appear to regulate retrograde 
transport of BACE1 from endosomes to the TGN (Wahle et al., 2005). Further studies 
will be required to determine whether loss of function or depletion of GGA1 and GGA2 
contribute to BACE1 accumulation in our model. Finally, phosphorylation of BACE1 at 
Serine498 facilitates its binding to GGA proteins (He et al., 2002; He et al., 2003; Shiba et 
al., 2004; von Arnim et al., 2004). However, we did not observe any changes in the 
phosphorylation status of BACE1 in treated neurons (data not shown).
In summary, taken collectively our results argue for a well-defined mechanism through 
which aberrant APP signaling can trigger amyloidogenic processing of APP, without 
affecting neuronal survival, as depicted in Figure 5-13.
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Figure 5-13 Schematic illustration of 22C11-induced BACE1 accumulation and Aβ production in neurons
Following synthesis in the endoplasmic reticulum, pro-BACE1 traffics through the trans-Golgi network (TGN) where 
it matures before localizing to the plasma membrane. (A) Under normal conditions, surface BACE1 is re-internalized 
through the endosomal pathway and may be recycled from endosomes to the TGN back to the plasma membrane. 
Alternatively, BACE1 can interact with GGA3, which targets BACE1 to lysosomes for degradation. (B) Dimerization 
of APP and activation of caspase-3 results in the cleavage of GGA3, preventing it from shuttling BACE1 to 
lysosomes. This allows BACE1 to accumulate in endosomes, resulting in increased cleavage of APP and Aβ 
production.
As we discussed earlier, alterations in synaptic density occur early in AD and strongly 
correlate with the cognitive decline observed in the disease (reviewed by Scheff and 
Price, 2006). Our results suggest that aberrant signaling through APP oligomerization is 
sufficient to drive synaptic dysfunction as well as promote Aβ production in 
hippocampal neurons. Whether, these effects are dependent on each other remains 
unclear. However, it raises the interesting possibility that abnormal oligomerization of 
APP initiates a positive feedback loop in an affected neuronal population, resulting in 
local synaptic dysfunction and local increases in Aβ production.
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Supplemental Figure 5-S1. siRNA-mediated 
down-regulation of caspase-3 in hippocampal 
neurons after 8 hours
Primary hippocampal neurons were treated with 80 nM 
Penetratin-1-linked Caspase-3 siRNA (siCasp3) for 8 
hours. (A) Representative Western blot showing a 
decrease in caspase-3 protein levels. (B) Densitometric 
analysis of the data was quantified from 3 
independent experiments and expressed as the 
mean+/-SEM (**p=0.01) band intensity.
Supplemental Figure 5-S2. Aβ treatment 
increases cleavage of caspase-3 in 
hippocampal neurons
Primary hippocampal neurons were 
treated with various stimuli, including 
oligimeric Aβ (1.0 μM), Penetratin-1linked 
C31 (C31-P; 100 nM), and Camptothecin 
(Cto; 1.0 μM) for 8 hours. Western blot 
analysis with a cleaved-caspase-specific antibody showing increased caspase cleavage in Aβ and Cto-treated 
neurons. C31 did not induce cleavage of caspase-3.
Supplemental Figure 5-S3. Expression of C99-myc 
fragments in HEK293 cells
HEK293 cells were transfected with increasing 
concentrations of pcDNA3.1-C199-myc (2.0, 4.0, 8.0, 10 
and 12 μg) with lipofectamine 2000 resulting in robust 
expression of C99-myc fragments after 24 hours as 
determined by Western blot analysis using a myc-specific 
antibody.
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CHAPTER 6: MECHANISTIC STUDIES INTO HOW APP DIMERIZATION 
LEADS TO SYNAPTIC DYSFUNCTION
6.1 Is the synaptotoxicity of 22C11 tied to the production of Aβ
The data presented above indicates that increasing dimerization of cell-surface APP in 
primary hippocampal neurons has two important consequences. First, it triggers the 
amyloidogenic route with consequent intracellular accumulation of Aβ, and its partial 
release into the culture medium (Section 5.2). Second, it triggers a significant degree of 
synaptic dysfunction in hippocampal neurons, as indicated by a significant loss in 
dendritic spine density, as well as a marked decrease in the levels of the post-synaptic 
markers, PSD-95 and Drebrin A (Section 4.2). Strikingly, both of these outcomes were 
observed in the absence of any significant cell death, which has been shown in many 
instances to trigger the amyloidogenic pathway (Galli et al., 1998; LeBlanc, 1995). 
Because Aβ is neurotoxic and contributes to apoptosis in a variety of cultured cells, it 
has been proposed that increased Aβ secretion causes increased cell death in 
susceptible neurons. This initiates a cycle in which dying neurons in turn release more 
Aβ, which causes additional cell death.
However, at low concentrations (nM), Aβ does not cause any significant cell death in 
neurons, but does significantly affect normal synaptic functions, including long-term 
potential (LTP) and dendritic spine maintenance. The extensive similarities between the 
synaptotoxic of synthetic Aβ42 oligomers and the effects of 22C11 on hippocampal 
neurons led us to wonder whether these two outcomes were interdependent, 
specifically whether the loss of synapses triggered by 22C11 required the production of 
Aβ.
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Previous studies have demonstrated that interruption of NGF and BDNF signaling in 
PC12 cells and in hippocampal neurons result in the activation of the amyloidogenic 
pathway and subsequence apoptotic death (Matrone et al., 2008a; Matrone et al., 
2008b). In hippocampal neurons, cell death was found to be dependent on Aβ 
production, as it was blocked by β- and γ-secretase inhibitors as well as by an antibody 
directed at against the Aβ peptide (Matrone et al., 2008a).
6.1.1 The synaptotoxic effects of 22C11 in hippocampal neurons are blocked by 
the anti-Aβ antibody 4G8
Our first approach was to investigate whether an antibody-directed approach could 
protect the neurons against the effects of 22C11. Hippocampal neurons were pre-
incubated for 1 hour with a monoclonal antibody directed at amino acids (aa) 17-24 of 
Aβ (clone 4G8, 2.0 μg/ml; Figure 6-1A) prior to treating with 22C11 (100 ng/ml) for 24 
hours. The addition of the Aβ antibody 4G8 completely reversed the synaptotoxic 
effects of 22C11, as these neurons did not incur any significant loss of dendritic spines 
(Figure 6-1B). Protection against 22C11 was also achieved by pre-treatment with an 
alternative Aβ antibody directed at aa 1-16 of Aβ, but not with a C-terminal antibody 
directed at the C-terminal region of full-length APP (data not shown), consistent with 
the idea that binding Aβ blocks the synaptotoxic effects of 22C11.
112
Figure 6-1. 22C11-induced spine loss in hippocampal neurons is blocked by the Aβ antibody 4G8
(A) Schematic illustration of the relative binding site for several APP-targeting antibodies [6E10: amino acids (aa) 
1-16 of Aβ; 4G8: aa 17-24 of Aβ; APP-CT: aa 643-695 of APP]. (B) Primary hippocampal neurons were treated for 
24 hours with 22C11 (100 ng/ml) alone, or after pre-treating for 1 hour with the Aβ-specific antibody 4G8. The 
synaptotoxic effects of 22C11 on dendritic spines were completely blocked by the addition of 4G8. Treatment with 
4G8 alone did not significantly affect dendritic spines. Dendritic spines were quantified from an average of 12 
neurons from at least 3 independent experiments, and expressed as the mean+/-SEM (*p=0.038 for Control vs. 
22C11; *p=0.036 for 22C11 vs. 22C11 + 4G8) number of spines/μM. (C) Representative image of dendrites and 
spines showing the neuroprotective effects of 4G8 against 22C11.
6.1.2	 The synaptotoxic effects of 22C11 in hippocampal neurons are 
independent of caspase-3
Our earlier data suggests that increased Aβ production in neurons treated with 22C11 
results from the accumulation of BACE1 in endosomes, through a mechanism that is 
caspase-3 dependent (Figure 5-13). Since siRNA-mediated downregulation of 
caspase-3 in neurons results in attenuated Aβ production, we argued that 
downregulation of caspase-3 should also block the synaptotoxic effects of 22C11. To 
test this idea, primary hippocampal neurons, were pre-treated with a Penetratin-1-
linked siRNA against caspase-3 (siCasp3) for 1 hour prior to treating with 22C11 (100 
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ng/ml). 24 hours after treatment, neurons were harvested and the state of the synapses 
was evaluated by measuring post-synaptic marker PSD-95 levels by Western blot 
analysis. Contrary to our hypothesis, we found that downregulation of caspase-3 did 
not protect neurons against 22C11 (Figure 6-2A).
6.1.3 The synaptotoxic effects of 22C11 are not blocked by inhibiting production 
of Aβ
Since the two results above, conflicted with each other, we decided to test whether 
blocking production of Aβ by inhibiting γ-secretase or β-secretase activity could protect 
neurons against 22C11. To that end, hippocampal neurons, were pre-incubated with 
several inhibitors of APP secretases, including β-secretase inhibitors IV (5.0 μM) and 
OM99-2 (2.5 μM) as well as γ-secretase inhibitor IX (25 μM) for 1 hour prior to treating 
with 22C11 (100 ng/ml) for 24 hour. Once again, paradoxically, neither inhibitor 
protected neurons against the synaptotoxic effects of 22C11, as determined by 
measuring the levels of the post-synaptic protein PSD-95 (Figure 6-2B).
On the surface, these three results appear to be incompatible with each other. If Aβ 
production was required for the effects of 22C11, the blocking its production should 
have blocked the effects of 22C11. Yet, neither downregulation of caspase-3 nor 
secretase inhibitors demonstrated any protection. In light of these results, how do we 
then account for the protection conferred by the Aβ antibodies? One possibility is that 
the antibodies protect neurons through a different mechanism.
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Figure 6-2. 22C11-induced loss of PSD-95 in hippocampal neurons is independent of caspase-3 and Aβ 
production
Primary hippocampal neurons were treated over the course of 24 hours with 22C11 (100 ng/ml) alone or with 
22C11 + siRNA against caspase-3 (80 nM), or with 22C11 + γ-secretase inhibitor IX (25 μM) and β-secretase 
inhibitors IV (10 μM) and OM99-2 (5,0 μM). (A) Western blots showing the lack of protection against the 
synaptotoxic effects of 22C11 by (B) siRNA-mediated downregulation of caspase-3 or by (C) the inhibitors of γ-
secretase and β-secretase. (data not quantified; N=2)
6.1.4 Treatment with anti-Aβ antibodies decrease the expression of cell-surface 
APP in hippocampal neurons
Tampellini et al. recently demonstrated that Aβ antibodies protect against synaptic 
alterations by reducing intracellular Aβ (Tampellini et al., 2007). They propose that the 
antibodies get internalized after binding the extracellular portion of APP. It is likely 4G8 
protects against 22C11 through a similar mechanism. To test this hypothesis, we 
measured the levels of APP expressed at the cell surface of primary hippocampal 
neurons that had been incubated with several Aβ antibodies [4G8 and 6E10 (2.0 μg); 
APP-CT: 2.0 μg/ml)] for 2 hours prior to analysis. Cell surface proteins were biotinylated 
and precipitated by incubating streptavidin coated beads. Western blot analysis of the 
precipitated protein with the APP antibody 22C11 (Figure 6-3A) revealed a significant 
reduction in the levels of surface-expressed APP in neurons incubated with the Aβ 
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antibodies 4G8 and 6E10 (Figure 6-3B). The monoclonal antibody directed against the 
C-terminal portion of APP (APP-CT) did not affect cell-surface APP, consistent with the 
idea that Aβ antibodies may become endocytosed together with APP upon binding it. 
However, this remains to be demonstrated as we do not have any evidence confirming 
any internalization of the Aβ antibodies.
Figure 6-3. Treatment with Aβ antibodies decreases cell-surface APP in hippocampal neurons
Primary hippocampal neurons were incubated for 1 hour with various antibodies against several epitopes on APP 
[6E10: amino acids (aa) 1-16 of Aβ; 4G8: aa 17-24 of Aβ; APP-CT: aa 643-695 of APP]. Cell surface proteins were 
biotinylated and immunoprecipitated with streptavidin-coated beads. (A) Western blot analysis of isolated cell-
surface proteins with APP-antibody 22C11 showed a significant decrease in cell-surface APP in neurons treated 
with 4G8 and 6E10. No significant changes were observed in neurons treated with the APP C-terminal antibody 
APP-CT. (B) Densitometric analysis of the images was quantified from 3 independent experiments (N=2 for 6E10) 
and expressed as the relative mean+/-SEM (**p=0.003 for 4G8) band intensity. 
6.2	 Alternative mechanism of 22C11-induced synaptotoxicity
If endogenous rat Aβ is not the sole cause of the synaptotoxic effects of 22C11, what 
then is the intracellular mechanism? In addition to amyloidogenic and non-
amyloidogenic processing, APP can be cleaved by caspases in its C-terminal region 
(Aspartate664 of APP695) to produce an intracellular cytotoxic fragment termed C31 
(Section 1.8.4; Pellegrini et al., 1999). Several caspases have been implicated in the 
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cleavage of APP, including caspase-3, -6, -8 and -9 (Galvan et al., 2002; Lu et al., 2000; 
Lu et al., 2003b; Pellegrini et al., 1999). This suggests that C31 could be generated by a 
host of stimuli that activate one or more of these caspases. One such insult is the Aβ 
peptide, which has been shown to promote C-terminal cleavage of APP and production 
of C31 (Lu et al., 2003b). Since dimerization of APP by Aβ is a key mediator of this 
cleavage event (Shaked et al., 2006), we postulated that 22C11 could also induce APP 
cleavage and C31 production.
6.2.1	 22C11 treatment promotes caspase-dependent C-terminal cleavage of APP 
at Asp664
To test this hypothesis, cultured hippocampal neurons were treated with 22C11 (100 
ng/ml) for 24 hours. After treatment, the cells were then harvested, lysed and analyzed 
by Western blot using an antibody directed at the newly generated APP C-terminal 
fragment (APP-neo; Figure 6-4A). Neurons that were treated with 22C11 showed 
increased cleavage of APP as indicated by the higher levels of APP-neo in treated 
neurons compared to those treated with vehicle (PBS) (Figure 6-4B). This increase in 
APP-neo was comparable to that seen in neurons that were treated with oligomeric Aβ 
(300 nM; Figure 6-4B). 22C11-induced cleavage of APP was abrogated by the addition 
of pan-caspase inhibitor z-VAD-FMK (Figure 6-4B) confirming that APP is cleaved by 
caspases to produce the C31 fragment.
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Figure 6-4. 22C11 treatment triggers 
caspase-dependent cleavage of APP at 
Asp664 in hippocampal neurons
(A) Schematic illustration of caspase-
mediated cleavage of APP and generation of 
C31 fragments as well as the newly 
g e n e r a t e d A P P - n e o e p i t o p e . ( B ) 
Hippocampal neurons were treated with 
oligomeric Aβ (1.0 nM) and with 22C11 (100 
ng/ml) alone or with 22C11 + caspase-
inhibitor z-VAD-FMK (zVAD; 25 μM) for 24 hours. Western blot analysis with an antibody directed against the APP-
neo epitope revealed an increase in cleavage of APP. Co-treatment with the general caspase inhibitor zVAD blocked 
cleavage of APP.
This result indicates that in addition to stimulating Aβ production in hippocampal 
neurons, 22C11 also drives caspase-mediated cleavage of APP and presumably 
generation of the C31 fragment. Unfortunately, our efforts to isolate or directly detect 
the C31 fragment in vitro or in vivo have yielded mixed results at best. One possible 
explanation is that the newly generated C31 fragment is rapidly degraded before it can 
be observed. This would suggest that cleaved APP is somehow inducing the observed 
toxicity (Nishimura et al., 2002) and not C31 directly. However, the evidence for this 
alternative mechanism remains scarce.
6.2.2 C31 mimics the effects of Aβ and 22C11 on hippocampal neurons 
6.2.2.1		 Intracellular C31 induces apoptotic death in a dose-dependent manner 
in hippocampal neurons
An alternative explanation is that C31 undergoes a rapid post-cleavage modification, 
such as phosphorylation (Ando et al., 1999), or further cleavage (Bertrand et al., 2001), 
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which precludes us from detecting it using the C-terminal APP antibodies at our 
disposal. This is supported by the fact intracellular C31 in itself is sufficient to trigger 
apoptotic death in a wide variety of neuronal and non-neuronal cells (Galvan et al., 
2002; Kim et al., 2003; Lu et al., 2000; Lu et al., 2003a; Lu et al., 2003b). When we 
tested the neurotoxicity of C31 on hippocampal neurons, our results were consistent 
with the referenced reports.
To deliver the C31 peptide to the neurons, a synthetic C31 fragment containing an extra 
C-terminal cysteine residue was linked to the cell-penetrating peptide Penetratin-1TM 
(Pen1; Galvan et al., 2002). After 24 hours, Pen1-linked C31 (C31-P) revealed to be 
toxic to hippocampal neurons in a dose-dependent manner (Figure 6-5A). Neither 
unlinked C31 nor Pen1 had any observable affect on the viability of the neurons, even 
after 48 hours of exposure (data not shown). Additionally, C31-P-induced cell death was 
blocked by the pan-caspase inhibitor z-VAD-FMK (25 μM), but interestingly not by z-
DEVD-FMK (10 μM) suggesting that one or more caspases other than caspase-3 may 
be required for C31-induced death (Figure 6-5B). In fact, when we looked at caspase-3 
in hippocampal neurons in response to C31-P (100 nM), we did not detect any 
increased cleavage of caspase-3 after 8 hours, as determined by Western blot analysis 
(Figure 6-S1A), nor any increased DEVD cleavage indicated by the NucView assay. 
Robust caspase-3 cleavage and activity was observed at that time point with both 
oligomeric Aβ (1.0 μM) and camptothecin (1.0 μM).
119
Figure 6-5. Intracellular C31 induces apoptotic death in hippocampal neurons
(A) Dose-response curve for hippocampal neurons over 24 hours with various concentrations of Penetratin-1-linked 
C31 (C31-P) showing a significant amount of cell death starting at 1.0 μM, and exacerbated at 5.0 μM, compared 
to control cells, which were treated with vehicle (H2O). Lower concentrations of 100 nM had no significant 
neurotoxic effects after 24 hours. Cell death was assessed with the LIVD/DEAD cell viability assay kit and quantified 
the from at least 3 independent experiments and expressed as the mean+/-SEM (*p=0.026 for 1.0 μM; **p=0.009 
for 2.5 μM; ***p=0.001 for 5.0 μM) number of viable cells per field. (B) Primary hippocampal neurons were treated 
with C31-P (2.5 μM) only or with C31-P + z-VAD-FMK (zVAD; 25 μM) or with 22C11 + z-DEVD-FMK (zDEVD; 10 
μM) for 24 hours. Co-treatment with the pan-caspase inhibitor zVAD completely blocked the neurotoxic effects of 
22C11, whereas zDEVD had no effect.
6.2.2.2		 Sub-apoptotic concentration of intracellular C31 induces synaptic 
dysfunction in hippocampal neurons
Having established a dose-response curve for C31 in hippocampal neurons, we 
proceeded to investigate whether a sub-apoptotic concentration of C31-P could induce 
synaptic alterations in hippocampal neurons. To test this hypothesis, primary 
hippocampal neurons were treated with C31-P (100 nM) for 24 hours, after which they 
were fixed and stained with diOlistic dye as described earlier for dendritic spine 
analysis. Similar to Aβ and 22C11, we found a significant decrease in dendritic spine 
density in C31-P-treated neurons compared to vehicle (H2O)-treated ones (Figure 6-6A, 
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B). Western blot analysis of lysates from treated neurons revealed a concomitant 
decrease in the levels of both dendritic spine markers PSD-95 and Drebrin A (Figure 
6-6C-E).
Figure 6-6. Intracellular C31 induces loss of dendritic spines in hippocampal neurons
Treatment of hippocampal neurons for 24 hours with Penetratin-1-linked C31 (C31-P, 100 nM) resulted in a 
significant decrease in dendritic spine density, compared to vehicle (H2O)-treated control neurons. Spine loss were 
measured by direct count of dendritic spines (A, B) and by measuring the levels of two dendritic spine markers, 
PSD-95 (C, E) and Drebrin A (C, D). (A) Dendritic spines were quantified from an average of 12 neurons taken from 
at least 3 independent experiments, and expressed as the mean+/-SEM (***p<0.001) number of spines/μM. (B) 
Representative image showing a decrease in dendritic spines in C31-P-treated neurons compared to control 
neurons. (C) Representative Western blots showing a decrease in the synaptic markers, PSD95 and Drebrin A in 
C31-P-treated neurons. (D, E) Densitometric analysis of the data was quantified from 3 independent experiments 
and expressed as the mean+/-SEM (*p=0.026 for Drebrin A; **p=0.008 for PSD-95) band intensity.
6.2.3	 The synaptotoxic effects of intracellular C31 are caspase-2 dependent
Our earlier results suggested C31-P-induced death was independent of caspase-3. 
Interestingly, work from our lab had pointed at caspase-2 as the critical caspase 
responsible for mediating cell death and synaptic dysfunction in hippocampal neurons 
by oligomeric Aβ (Troy et al., 2000). This prompted us to also test whether the effects of 
C31 were also dependent on caspase-2. We first tested whether C31 could activate 
caspase-2 in hippocampal neurons. We used the previously described in situ trapping 
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of active caspase technique to assess caspase-2 activity (Tu et al., 2006). Primary 
hippocampal neurons were pre-incubated for 2 hour with a biotinylated irreversible 
caspase inhibitor (b-VAD-FMK; 80 nM). Neurons were then treated with the required 
stimuli [oligomeric Aβ (300 nM); C31-P (100 nM); 22C11 (100 ng/ml) for 1 hour before 
harvesting. Active caspases bind b-VAD-FMK in an irreversible manner, allowing the 
whole complex (bVAD/caspase) to be precipitated out using streptavidin coated beads 
and analyzed by Western blot with the appropriate antibody for the caspase of interest. 
In our case, immunoblotting with caspase-2 specific antibody revealed a strong 
activation of caspase-2 in hippocampal neurons treated with all three stimuli, namely 
oligomeric Aβ, C31-P and 22C11 (Figure 6-7A).
Next, we focused on addressing whether the effects of C31 were dependent of 
caspase-2. To test this hypothesis, we once again opted to downregulate caspase-2 
through the use of siRNA in order to avoid possible specificity issues with chemical 
caspase inhibitors. Treatment of primary hippocampal neurons with Penetratin-1-linked 
caspase-2 siRNA (siCasp2, 80 nM; Troy et al., 2000) resulted in robust downregulation 
of caspase-2 after 24 hours, which persisted up to 48 hours after the start of treatment 
(Figure 6-S2). Neurons were treated with C31-P (100 nM) at the 24 time point after 
addition of Casp2 for an additional 24 hours. DiOlistic labeling of neurons allowed us to 
directly count dendritic spines, which showed that neurons with depleted levels of 
caspase-2 were completely resistant to effects of C31 (Figure 6-7B; Pozueta, 2010, 
personal communications) compared to control neurons, which suffered a significant 
amount of spine loss in response to C31-P. Downregulation of caspase-2 did not 
otherwise affect dendritic spines in control neurons. Similarly, we saw a significant 
degree of protection against 22C11 (100 ng/ml) by caspase-2 downregulation (Figure 
6-7C).
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Figure 6-7. C31- and 22C11-induced dendritic spine loss is caspase-2 dependent
(A) In situ trapping of active caspase-2: Primary hippocampal neurons were pre-incubated with a biotinylated non-
reversible pan caspase-inhibitor b-VAD-FMK (bVAD; 50 nM) for 1 hour before being treated for 1 hour with various 
stimuli, including oligomeric Aβ (1.0 μM), Penetratin-1-linked C31 (C31-P; 100 nM) and 22C11 (100 ng/ml). Lysates 
from each sample were incubated with streptavidin coated beads to precipitate the caspase/inhibitor complex. 
Western blot analysis with a caspase-2 antibody showed increased caspase-2 levels, indicative of increased 
caspase-2 activation in treated compared to control neurons. (B,C) siRNA-mediated downregulation of caspase-2 
blocks the synaptotoxic effects of C31-P and 22C11 in hippocampal neurons: primary hippocampal neurons were 
pre-incubated with a Penetratin-1-linked siRNA against caspase-2 (siCasp2; 80 nM) for 24 hours before being 
treated with C31-P (100 nM) or 22C11 (100 ng/ml) for 24 hours. (B) Primary hippocampal cultures pretreated for 24 
hrs with siRNA against caspase-2 showed no decrease in spine density after treatment with C31-P. Represented as 
the mean+/-SEM. [(3 independent experiments measuring 150 dendrites per point, *P <0.01; Pozueta; 2010 
personal communications)]. (C) Similarly, primary hippocampal cultures pre-treated for 24 hrs with siRNA against 
caspase-2 showed no decrease in spine density after treatment with 22C11. Dendritic spines were quantified from 
an average of 12 neurons taken from at least 3 independent experiments, and expressed as the mean+/-SEM 
(**p=0.006 for 22C11; **p=0.008 for 22C11 + siCasp2) number of spines/μM.
6.3		 Discussion
6.3.1 Rat versus human Aβ
Whether Aβ antibodies protect by downregulating cell-surface APP or by binding up 
intracellular Aβ remain a difficult question to answer in system other than human 
neurons, specifically in rat and murine neurons One very important distinction between 
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human APP and murine and rat APP is in the amino acid sequence of the Aβ peptide: 
rodent Aβ42 contains three amino acid variations of the human peptide sequence: Arg5, 
Tyr10 and His13 are substituted by Gly, Phe and Arg respectively (Figure 6-S3A; Kowalik-
Jankowska et al., 2002). This histidine residue in the human sequence has been shown 
to be critical for the aggregation of Aβ, especially in the presence of metal ions such as 
copper (Liu et al., 1999). In fact, it has been shown that rodent Aβ does not form fibrillar 
aggregates in the brain due to its lower tendency to form β-sheet structures in vivo 
(Dyrks et al., 1993; Otvos et al., 1993). Because of these differences, it is widely 
believed that rodent Aβ does not possess the same toxic properties as human Aβ42. 
Interestingly, using synthetic rat Aβ in our standard preparation of oligomeric Aβ yields 
noticeably different species (Figure 6-S3B). However, the results from Matrone and 
colleagues suggest that rodent Aβ may be at least a contributor to apoptotic death 
(Matrone et al., 2008a; Matrone et al., 2008b). Nevertheless, in our system, it is possible 
that since apoptosis is avoided, endogenous rat Aβ does not reach sufficiently high 
levels to correctly aggregate to contribute to the synaptotoxic effects of 22C11.
6.3.2 C31 as intracellular messenger for 22C11/Aβ signaling
Whether induced by 22C11 or Aβ, one important aspect is to understand the signaling 
pathway that are activated by dimerization of APP. We have provided some evidence to 
suggest that caspase-mediated cleavage of APP and production of C31 may play a 
critical role in relaying the signal from an extracellular stimulus -- dimerization of the 
extracellular region of APP -- to an intracellular messenger -- C31. We showed that 
introduction of this fragment is sufficient to trigger a wide variety of effects, ranging 
from apoptotic cell death at high concentrations (1.0 μM) to synaptic dysfunction at 
lower concentrations (100 nM). Furthermore, we showed that caspase-2 is essential for 
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the effects of C31 and both 22C11 and Aβ, consistent with a model in which C31 acts 
downstream to those two stimuli. Unfortunately, as we alluded to earlier, the exact 
caspase responsible for cleaving APP remains a mystery. Caspases -8 and -9 have 
been posited as potential candidates, but our results suggest otherwise. 
Downregulation of caspase-8 and -9 where either one can cleave APP in the absence of 
other. Whether downregulation of both can protect against Aβ and 22C11 remains to be 
seen. Another potential candidate to cleave APP is caspase-6 (Pellegrini et al., 1999), 
but it has not been evaluated yet in our studies.
Finally, there is the question of the mechanism of C31 itself. The most commonly 
assigned mechanism is a transcriptional one. The YENPTY motif contained within C31 
allows it to interact with various adaptor proteins, including Mint-1/X11a (and the family 
members Mint-2 and Mint-3), Fe65 (as well as Fe65-like proteins, Fe65L1 and Fe65L2) 
and c-Jun N-terminal kinase (JNK)-interacting protein (JIP), through the 
phosphotyrosine-binding (PTB) domain (Ando et al., 1999; Kimberly et al., 2005; 
Ramelot and Nicholson, 2001). Of particular interest is the interaction of APP C-terminal 
fragments with Fe65. APP intracellular C-terminal domain (AICD) fragment (C57/C59) 
has been demonstrated to induce transcriptional activation in combination with Fe65 
and Tip60, a histone acetyltransferase, using a reporter gene system (Cao and Sudhof, 
2001). Interestingly, C31 was also shown to be able to induce expression of genes, and 
one of the genes identified was Gsk3β (Kim et al., 2003). In addition to driving Gsk3β 
expression, they demonstrated that both AICD and C31 could not only induce cell 
death but could also induce phosphorylation of Tau (AT8), which are two hallmarks 
associated with AD. Further studies will be needed to clarify C31-mediated signaling.
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Figure 6-S1. C31 does not trigger the 
cleavage or activation of caspase-3 
in hippocampal neurons
(A) Primary hippocampal neurons were 
treated with various stimuli, including 
o l i g i m e r i c Aβ ( 1 . 0 μM ) , 
Penetratin-1linked C31 (C31-P; 100 
nM), and Camptothecin (Cto; 1.0 μM) 
for 8 hours. Western blot analysis with a 
cleaved-caspase-specific antibody 
showing increased caspase cleavage in 
Aβ and Cto-treated neurons. C31 did 
not induce cleavage of caspase-3. (B-
D) NucView assay for in vivo caspase-3 
activity: primary hippocampal neurons cultured in chamber slides were treated with Penetratin-1linked C31 (C31-P; 
100 nM), and Camptothecin (Cto; 1.0 μM) for 8 hour before incubating with the DEVD-NucView caspase substrate. 
(C) C31-P-treated neurons did not exhibit any increased fluorescence compared to (B) vehicle (H2O)-treated 
neurons, whereas (D) Cto-treated neurons exhibited robust fluorescence indicative of caspase activity.
Figure 6-S2. Time-course of siRNA-mediated caspase-2 down-
regulation in hippocampal neurons
(A) Rat hippocampal primary cultures treated with 80 nM Penetratin 
linked siRNA against Casp2 show a time dependent decrease in 
Casp2 levels. Representative immunoblot for Casp2 levels. (B) 
Densitometric analysis of Casp2 levels shows a 60% reduction of 
Casp2 by 12h. During the following 24 hours Casp2 levels are 
maintain below 40% (Basal levels of Casp2 are indicated as 100%, 
n=3 independent experiments). [Pozueta et al.,(submitted)]
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Figure 6-S3. Human and rat Aβ aggregate into different oligomeric species
(A) Amino acid sequences for rodent and human Aβ42. rodent Aβ42 contains three amino acid variations of the 
human peptide sequence: Arg5, Tyr10 and His13 are substituted by Gly, Phe and Arg respectively. (B) Representative 
Western blot comparing the different Aβ species present in the oligomeric preparation using synthetic human Aβ 
and rodent Aβ: only three predominant bands can be seen for rodent Aβ, whereas human Aβ oligomerizes into 
many more forms. Note the prominent absence of dimeric Aβ in the rodent preparation.
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CHAPTER 7: PERSPECTIVES AND FUTURE AIMS
7.1 Aβ production in Alzheimer’s disease (AD)
Over the past few decades, extensive research efforts have been undertaken to 
understand the processing of the amyloid precursor protein (APP). Secretases, such as 
BACE1 and the γ-secretase complex have been identified and characterized, as well as 
novel caspase-cleavage site (i.e. Asp664). However, while the “cutters” are known, we 
still do not fully understand the mechanisms that regulate these different cleavage 
processes, let alone how they might be dysregulated in neurodegenerative diseases, 
such as Alzheimer’s disease (AD). Indeed, a widely accepted assumption is that AD 
begins with abnormal processing of APP, which leads to excess production or reduced 
clearance of Aβ in the brain (Hardy and Selkoe, 2002). This view is supported by the 
fact that all known form of autosomal-dominant AD to date involve genes that either 
encode for APP itself, or for the γ-secretase subunits (PS1 and PS2) directly lead to 
increased Aβ production. It has been speculated that it is the Aβ oligomers (Klein et al., 
2004), through yet unclear mechanisms, that initiate a pathogenetic cascade 
characterized by abnormal tau aggregation, synaptic function failure and neuronal death 
(Oddo et al., 2006). 
This raises an important question: if aberrant APP processing is the cause of early-
onset familial AD (EOFAD), could aberrant APP processing also cause late-onset AD 
(LOAD)? Many factors that directly influence APP processing have been proposed to 
play a role in LOAD, including risk factor genes (e.g. PICALM; Harold et al., 2009), 
environmental factors (e.g. metal ions; Maynard et al., 2005; Walton and Wang, 2009), 
epigenetics (reviewed in Chouliaras et al., 2010). While there is ample evidence to 
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suggest that these may play an important role in AD pathogenesis, it remains that aging 
represents the highest risk factor for LOAD. This raises the possibility that APP 
processing may be altered and dysregulated over time with aging. Recent imaging 
studies have suggested a temporal ordering of biomarker abnormalities, reflective of the 
disease progression (Ingelsson et al., 2004; Jack et al., 2010). This has lead to a 
hypothetical model (Figure 7-1) in which biomarkers of Aβ deposition become abnormal 
early, before the onset of neurodegeneration and clinical symptoms, consistent with the 
idea of gradual altered APP processing. Biomarkers of neuronal injury, dysfunction, and 
neuronal degeneration become abnormal later in the disease.
Figure 7-1 Dynamic bio-
markers of the Alzheimer’s 
pathological cascade 
Aβ is identified by CSF Aβ42 or 
PET amyloid imaging. Tau-
mediated neuronal injury and 
dysfunction is identified by CSF 
tau or fluorodeoxyglucose-PET. 
Brain structure is measured by 
use of structural MRI. Aβ=β-
amyloid. MCI=mild cognitive 
impairment. (Jack et al., 2010)
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highly abnormal PiB study. Calculated rates from serial 
PiB imaging studies indicate that Aβ-plaque accumulation 
in individuals destined to become demented might begin 
as much as two decades before the manifestation of clinical 
symptoms.62 We note that both Aβ deposition and NFTs 
can be present in individuals with no symptoms. However, 
the presence of NFTs in asymptomatic individuals tends to 
be confi ned to the entorhinal cortex, Braak stage I–II, 
whereas NFTs in symptomatic individuals are far more 
widespread.3–5,72 By contrast, Aβ-plaque deposition can be 
widespread in clinically asymptomatic individuals.
There is strong evidence that MRI, FDG-PET, and CSF 
tau biomarkers are already abnormal in patients who are 
in the MCI phase of AD.37,51,73–75 Abnormalities in neuro-
degenerative AD biomarkers also precede the appearance 
of the fi rst cognitive symptoms. Of the three 
neurodegenerative biomarkers, evidence that FDG-PET 
abnormalities precede any cognitive symptoms in 
individual  who la er prog ess to AD is probably the 
strongest.76,77 However, rates of atrophy on MRI do 
become abnormal in cognitively normal individuals who 
later progress to AD.78–80 Thus, the available data strongly 
support the conclusion that abnormalities in both Aβ 
and neurodegenerative biomarkers precede clinical 
symptoms.
Aβ biomarker abnormalities precede neurodegenerative 
biomarker abnormalities
The rate of MRI atrophy on serial imaging studies is 
greatest in patients with a clinical diagnosis of AD, least 
in cognitively normal i dividuals, nd intermediate in 
those with a clinical diagnosis of MCI. By contrast, rates 
of change in PiB retention over time are just slightly 
greater than zero for all these three clinical groups, and 
do not diﬀ er by clinical group.62 Thus, in patients who are 
rapidly declining clinically (ie, patients with AD) MRI 
rates map well onto simultaneous cognitive deterioration, 
whereas rates of change in PiB do not.62,81 Similarly, CSF 
Aβ does not change signifi cantly over time in patients 
with AD. Rates of brain atrophy correlate well with 
pathological indices of NFTs and other neurodegenerative 
changes, but do not correlate with severity of Aβ 
deposition at autopsy.82 Cognitively normal individuals 
with positive Aβ imaging studies might have normal 
structural MRI studies, implying that a substantial Aβ 
load can accumulate with no immediate eﬀ ect on gross 
brain structure or cognition (fi gure 1).83 In a modelling 
study inferring cause and eﬀ ect, Mormino and 
colleagues84 found that the direct substrate of memory 
impairment was hippocampal atrophy on MRI, and not 
Aβ deposition as measured by PiB imaging. Frisoni and 
colleagues85 also placed amyloid deposition before MRI 
changes in the sequence of events. These fi ndings 
support the conclusion that an abnormality in biomarkers 
of Aβ-plaque deposition is an early event that nears a 
plateau before the appearance of both atrophy on MRI 
and cognitive symptoms, and remains relatively 
static thereafter. By contrast, abnormalities in neuro-
degenerative biomarkers on MRI accelerate as symptoms 
appear, and then parallel cognitive decline. 
Neurodegenerative biomarkers are temporally ordered
Available evidence suggests that FDG-PET changes 
might precede MRI changes.77,86,87 Up to this point, we 
have discussed the temporal ordering of AD biomarkers 
from the perspective of which biomarker becomes 
abnormal earlier during the progression of AD. However, 
the order in which the dynamic range of biomarkers 
approaches its maximum is also relevant to the discussion 
of biomarker ordering. MRI and CSF tau correlate well 
with cognition if individuals who span the entire cognitive 
spectrum (controls, MCI, and AD) are combined. 
However, among patients with MCI or AD alone, 
correlations with measures of general cognition are 
strong with structural MRI, but are not signifi cant with 
CSF tau.88 These data are consistent with studies 
indicating that CSF tau does not change appreciably over 
time in cognitively impaired patients.89,90 Furthermore, 
although both MRI and CSF tau are predictive of future 
conversion from MCI to AD, the predictive power of 
structural MRI is greater.91 These fi ndings imply that the 
correlations between cognition and CSF tau weaken as 
patients progress into the mid and late stages of the 
clinical AD spectrum. Conversely, structural MRI 
measures of atrophy retain a highly signifi cant correlation 
with observe  clinical impairment in both the MCI and 
dementia phases of AD. Moreover, rates of atrophy on 
MRI are signifi cantly greater in patients with AD than in 
cognitively normal elderly individuals.92 This body of 
literature implies that MRI atrophy is a later event in AD 
progression, preceded by abnormalities in CSF tau and 
FDG-PET, and that MRI retains a closer correlation with 





















Figure 2: Dynamic biomarkers of the Alzheimer’s pathological cascade 
Aβ is identifi ed by CSF Aβ42 or PET amyloid imaging. Tau-mediated neuronal injury and dysfunction is identifi ed by 
CSF tau or fl uorodeoxyglucose-PET. Brain structure is measured by use of structural MRI. Aβ=β-amyloid. MCI=mild 
cognitive impairment. 
7.2. APP dimerization and Aβ production - Implications for AD
Recently, a new picture has started to emerge, which underscores the importance of 
APP dimerization, whether it is in a physiological context, as in promoting cell-cell-
adhesion, or in a pathological context, as in influencing APP cleavage and the release 
of Aβ. APP homo-dimerization is driven by motifs present in the extracellular domain, as 
well as in the juxtamembrane (JM) and transmembrane (TM) domains of the molecule. 
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Strikingly, one of the structural motifs involved in the dimerization of APP is also 
responsible for the aggregation of Aβ peptides into proto-fibrillar structures, namely the 
GxxxG motif (Sato et al., 2006). Glycine residues within this motif not only allow for 
protein-protein interactions in the α-helical TM domain, but facilitate the formation of 
globular toxic forms of Aβ aggregates. Could homo-dimerization of APP play a critical 
role in the pathogenesis of AD? Our results along with several others (Kaden et al., 
2008; Kaden et al., 2009; Munter et al., 2010; Munter et al., 2007) suggest that it may 
be the case. 
We found that inducing APP multimerization through an antibody-mediated approach 
perfectly mimicked the dose-dependent neurotoxic effects of oligomeric Aβ in 
hippocampal neurons. At high concentrations, the antibody induced apoptotic death in 
neurons, whereas low sub-apoptotic concentrations triggered significant synaptic 
dysfunction, as reflected by a marked loss of dendritic spines. The exact mechanism 
through which this occurs remains unclear, however several lines of evidence (Galvan et 
al., 2002; Lu et al., 2000; Lu et al., 2003a; Lu et al., 2003b) including ours suggest that 
dimerization of APP initiates a caspase-mediated cleavage of the C-terminal end of 
APP to release a cytotoxic fragment termed C31. Our results also showed that this 
fragment recapitulates the effects oligomeric Aβ on hippocampal neurons. Moreover, in 
addition to adversely affecting the viability and synaptic functions of hippocampal 
neurons, our results suggest that multimerization of APP can also drive the processing 
of APP and the production of Aβ. Taken together, our data hints at the occurrence of a 
positive feedback loop involving Aβ and APP. According to this hypothetical model, as 
an individual ages, small local variations in the extent of APP multimers could not only 
adversely affect synaptic functions in a few neurons, but also drive the production of 
intraneuronal Aβ. As this Aβ is secreted, it spreads to nearby neurons thereby 
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perpetuating the pathogenic cycle. Over time, these small changes could continue to 
snowball until the advent of noticeable cognitive impairment. It is not yet known 
whether APP dimerization is increased in AD patients. Future fluorescent probes 
designed to measure APP oligomerization could provide a useful means to evaluate the 
aggregation state of cell-surface APP in a patient’s brain and may eventually serve as a 
biomarker for early detection.
7.3	 What factors influences APP dimerization in the brain?
In a more general perspective, one is led to wonder whether any type of molecule 
capable of promoting the pathogenic dimerization of APP could initiate this cascade 
and contribute to its amyloidogenic processing or if there are specific molecules 
involved in this process. Of the many binding partners for APP, one class of molecules 
that is of particular interest in AD are proteoglycans (PGs), more specifically heparan 
sulfate proteogylcans (HSPGs; reviewed in van Horssen et al., 2003). Interestingly, 
colocalization of carbohydrates and amyloid deposits -- hence the name amyloid -- 
were first described in the 19th century by Virchow (Virchow, 1853), but it was not until 
the 1970s that details about these molecules were studied and the relationship between 
PGs and amyloid deposits became a focus of interest. 
HSPGs can be classified into two main families: those of the extracellular matrix, 
including perlecan, agrin and collagen XVIII; and those of the cell surface, such as 
syndecans and glypicans. Snow and his colleagues were the first to report the presence 
of HSPGs in diffuse and neuritic plaques by the use of immunohistochemistry (Snow et 
al., 1988; Snow et al., 1990). Since then, it has been reported that both intact HSPG 
and the core protein bind the brain specific isoform APP695 with similar affinities 
(Narindrasorasak et al., 1991).
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The question remains whether deposition of HSPGs in AD lesions is preceded by 
accumulation of Aβ or vice versa. In the brains of adolescent patients with Down’s 
syndrome, antibodies directed against HSPGs stain diffuse primitive SP; the 
accumulation of proteoglycans seems to be an early event in the formation of SP (Snow 
et al., 1990). Additionally, accumulation of glycosaminoglycans have been shown to 
occur at about the same time and the same location as amyloid deposits in 
experimental amyloidosis (Snow and Kisilevsky, 1985). One explanation for these 
findings could be that the presence of Aβ affects the biosynthesis of HSPGs. 
Alternatively, HSPGs could promote the conversion of non-fibrillary Aβ into fibrillary Aβ, 
as is the case for perlecan and agrin (Castillo et al., 1997; Snow et al., 1994).
Another possible explanation could be that the interaction between APP and HSPGs 
might influence the generation of Aβ from APP. Dahms and colleagues recently reported 
that the isolated E1 domain of APP from tightly bound dimers upon interacting with 
another glycosaminoglycan, heparin (Dahms et al., 2010). This suggests that full-length 
APP may also dimerizes upon interacting with heparin (Gralle et al., 2006) or perhaps 
HSPGs. In support of this view, the addition of heparinase has been shown to disrupt 
cell-surface APP dimers in an APP over-expressing model (Gralle et al., 2009). Further 
studies are required to demonstrate a role for HSPGs in promoting APP dimerization. 
However, it is worth noting that glypican and an unidentified HSPG have also been 
shown to bind with high affinity the N1 domain of APP (Buee et al., 1993a; Williamson et 
al., 1996; Williamson et al., 1995).
It is our hope that the studies presented here may help shed some light into some of 
biggest unanswered questions in the field of Alzheimer’s disease, namely how the 
disease begins and how the mechanism(s) regulating Aβ production become perturbed 
over time in an individual’s brain and how this imbalance may lead to memory 
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impairments. Ultimately, a thorough understanding of APP processing may lead to novel 
therapeutic targets, designed to block dimerization of APP and to selectively lower Aβ 
levels in the brain. As a proof of concept, non-steroidal anti-inflammatory drugs 
(NSAID), such as sulindac sulfide and indomethacin, which are known to specifically 
modulate APP processing and to lower the levels of Aβ (Weggen et al., 2001), where 
recently shown to interfere with APP transmembrane dimerization (Richter et al., 2010). 
High-throughput screen to identify and develop novel APP dimer breaker may be 
promising avenue for therapy. 
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APPENDIX II: CULTURE MEDIA
Defined media for hippocampal neuron cultures
Growth Medium (G2)
NeurobasalTM medium (Invitrogen, 21103-049)	 	 	 500 ml
• B-27 supplement (Invitrogen, 17504)	 	 10 ml
• 0.5 mM L-glutamine (Invitrogen, 25030-081)		 1.27 ml (200 mM solution)
• 0.6% glucose (Sigma, G8769)	 	 	 6.7 ml (40% solution)
• 1% penicillin/streptomycin (Invitrogen, 15070)	 5.0 ml
Plating Medium (G3)
Growth medium (G2) with:
• 25 μM L-glutamate (add fresh)   63.9 μl (200 mM solution)
Minimal Substrate
Poly-D-lysine (Sigma, P6407-5MG) is generally used as minimal substrate for neurons. For 
coating plastic surfaces used for the culture of neuronal cells, it should be dissolved in boric acid 
(0.1M Na2HBO3, pH 8.1) at a minimum concentration of 10 μg/mL. Coat the plates with this 
solution for at least 1 hour or overnight at 37oC, then rinse once with distilled water and let dry 
for 1 hour under the hood to keep the dishes sterile.
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